Protein_ID,Protein_Name,Gene_Symbol,Tissue,Species,Age,Age_Unit,Abundance,Abundance_Unit,Method,Study_ID,Sample_ID,Parsing_Notes,Canonical_Gene_Symbol,Matrisome Category,Matrisome Division,Match_Level,Match_Confidence
P16112,Aggrecan core protein,ACAN,Skin dermis,Homo sapiens,2,years,8.11277006687392,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ACAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P16112,Aggrecan core protein,ACAN,Skin dermis,Homo sapiens,2,years,8.03693786304509,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ACAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P16112,Aggrecan core protein,ACAN,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ACAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P16112,Aggrecan core protein,ACAN,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ACAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P16112,Aggrecan core protein,ACAN,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ACAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P16112,Aggrecan core protein,ACAN,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ACAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P16112,Aggrecan core protein,ACAN,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ACAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P16112,Aggrecan core protein,ACAN,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ACAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
O75487,Glypican-4,GPC4,Skin dermis,Homo sapiens,2,years,6.44362009342327,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",GPC4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75487,Glypican-4,GPC4,Skin dermis,Homo sapiens,2,years,8.03279209846048,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",GPC4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75487,Glypican-4,GPC4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",GPC4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75487,Glypican-4,GPC4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",GPC4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75487,Glypican-4,GPC4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",GPC4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75487,Glypican-4,GPC4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",GPC4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75487,Glypican-4,GPC4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",GPC4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75487,Glypican-4,GPC4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",GPC4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13928,Annexin A8 {ECO:0000312|HGNC:HGNC:546},ANXA8,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA8,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13928,Annexin A8 {ECO:0000312|HGNC:HGNC:546},ANXA8,Skin dermis,Homo sapiens,2,years,6.38227553858647,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA8,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13928,Annexin A8 {ECO:0000312|HGNC:HGNC:546},ANXA8,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA8,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13928,Annexin A8 {ECO:0000312|HGNC:HGNC:546},ANXA8,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA8,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13928,Annexin A8 {ECO:0000312|HGNC:HGNC:546},ANXA8,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA8,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13928,Annexin A8 {ECO:0000312|HGNC:HGNC:546},ANXA8,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA8,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13928,Annexin A8 {ECO:0000312|HGNC:HGNC:546},ANXA8,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA8,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13928,Annexin A8 {ECO:0000312|HGNC:HGNC:546},ANXA8,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA8,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29508,Serpin B3,SERPINB3,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29508,Serpin B3,SERPINB3,Skin dermis,Homo sapiens,2,years,5.87050347804311,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29508,Serpin B3,SERPINB3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29508,Serpin B3,SERPINB3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29508,Serpin B3,SERPINB3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29508,Serpin B3,SERPINB3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29508,Serpin B3,SERPINB3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29508,Serpin B3,SERPINB3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8N6G6,ADAMTS-like protein 1,ADAMTSL1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8N6G6,ADAMTS-like protein 1,ADAMTSL1,Skin dermis,Homo sapiens,2,years,5.54601442524714,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8N6G6,ADAMTS-like protein 1,ADAMTSL1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8N6G6,ADAMTS-like protein 1,ADAMTSL1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8N6G6,ADAMTS-like protein 1,ADAMTSL1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8N6G6,ADAMTS-like protein 1,ADAMTSL1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8N6G6,ADAMTS-like protein 1,ADAMTSL1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8N6G6,ADAMTS-like protein 1,ADAMTSL1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UXI9,Nephronectin,NPNT,Skin dermis,Homo sapiens,2,years,4.41816302165228,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NPNT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI9,Nephronectin,NPNT,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NPNT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI9,Nephronectin,NPNT,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NPNT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI9,Nephronectin,NPNT,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NPNT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI9,Nephronectin,NPNT,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NPNT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI9,Nephronectin,NPNT,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NPNT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI9,Nephronectin,NPNT,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NPNT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI9,Nephronectin,NPNT,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NPNT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75094,Slit homolog 3 protein,SLIT3,Skin dermis,Homo sapiens,2,years,2.64243437244752,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLIT3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75094,Slit homolog 3 protein,SLIT3,Skin dermis,Homo sapiens,2,years,5.97583257921694,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLIT3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75094,Slit homolog 3 protein,SLIT3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLIT3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75094,Slit homolog 3 protein,SLIT3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLIT3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75094,Slit homolog 3 protein,SLIT3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLIT3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75094,Slit homolog 3 protein,SLIT3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLIT3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75094,Slit homolog 3 protein,SLIT3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLIT3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75094,Slit homolog 3 protein,SLIT3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLIT3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P13674,Prolyl 4-hydroxylase subunit alpha-1,P4HA1,Skin dermis,Homo sapiens,2,years,10.5438484315626,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13674,Prolyl 4-hydroxylase subunit alpha-1,P4HA1,Skin dermis,Homo sapiens,2,years,11.4805418675786,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13674,Prolyl 4-hydroxylase subunit alpha-1,P4HA1,Skin dermis,Homo sapiens,14,years,7.41891774553531,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13674,Prolyl 4-hydroxylase subunit alpha-1,P4HA1,Skin dermis,Homo sapiens,14,years,5.77694454745729,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13674,Prolyl 4-hydroxylase subunit alpha-1,P4HA1,Skin dermis,Homo sapiens,14,years,5.54841577764435,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13674,Prolyl 4-hydroxylase subunit alpha-1,P4HA1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13674,Prolyl 4-hydroxylase subunit alpha-1,P4HA1,Skin dermis,Homo sapiens,65,years,6.65582101615415,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P13674,Prolyl 4-hydroxylase subunit alpha-1,P4HA1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UVK1,Chondroitin sulfate proteoglycan 4,CSPG4,Skin dermis,Homo sapiens,2,years,7.76238718794765,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSPG4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UVK1,Chondroitin sulfate proteoglycan 4,CSPG4,Skin dermis,Homo sapiens,2,years,10.0995465972439,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSPG4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UVK1,Chondroitin sulfate proteoglycan 4,CSPG4,Skin dermis,Homo sapiens,14,years,5.64516346085832,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSPG4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UVK1,Chondroitin sulfate proteoglycan 4,CSPG4,Skin dermis,Homo sapiens,14,years,5.89061237330091,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSPG4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UVK1,Chondroitin sulfate proteoglycan 4,CSPG4,Skin dermis,Homo sapiens,14,years,4.82088551623721,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSPG4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UVK1,Chondroitin sulfate proteoglycan 4,CSPG4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSPG4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UVK1,Chondroitin sulfate proteoglycan 4,CSPG4,Skin dermis,Homo sapiens,65,years,5.8879598505866,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSPG4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UVK1,Chondroitin sulfate proteoglycan 4,CSPG4,Skin dermis,Homo sapiens,65,years,3.63092140717095,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSPG4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01019,Angiotensinogen {ECO:0000305},AGT,Skin dermis,Homo sapiens,2,years,11.6770747683615,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGT,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01019,Angiotensinogen {ECO:0000305},AGT,Skin dermis,Homo sapiens,2,years,11.5651928356541,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGT,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01019,Angiotensinogen {ECO:0000305},AGT,Skin dermis,Homo sapiens,14,years,9.46857318120469,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGT,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01019,Angiotensinogen {ECO:0000305},AGT,Skin dermis,Homo sapiens,14,years,7.51240598097829,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGT,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01019,Angiotensinogen {ECO:0000305},AGT,Skin dermis,Homo sapiens,14,years,9.73967492076554,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGT,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01019,Angiotensinogen {ECO:0000305},AGT,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGT,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01019,Angiotensinogen {ECO:0000305},AGT,Skin dermis,Homo sapiens,65,years,7.15498596600778,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGT,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01019,Angiotensinogen {ECO:0000305},AGT,Skin dermis,Homo sapiens,65,years,9.34027160657707,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGT,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20908,Collagen alpha-1(V) chain,COL5A1,Skin dermis,Homo sapiens,2,years,12.9099581032624,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P20908,Collagen alpha-1(V) chain,COL5A1,Skin dermis,Homo sapiens,2,years,13.7613016441948,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P20908,Collagen alpha-1(V) chain,COL5A1,Skin dermis,Homo sapiens,14,years,12.0567860591333,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P20908,Collagen alpha-1(V) chain,COL5A1,Skin dermis,Homo sapiens,14,years,12.8367946137689,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P20908,Collagen alpha-1(V) chain,COL5A1,Skin dermis,Homo sapiens,14,years,12.1564631457184,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P20908,Collagen alpha-1(V) chain,COL5A1,Skin dermis,Homo sapiens,65,years,12.5088740685404,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P20908,Collagen alpha-1(V) chain,COL5A1,Skin dermis,Homo sapiens,65,years,10.3747726656482,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P20908,Collagen alpha-1(V) chain,COL5A1,Skin dermis,Homo sapiens,65,years,13.5986655655535,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
O15460,Prolyl 4-hydroxylase subunit alpha-2,P4HA2,Skin dermis,Homo sapiens,2,years,10.444067784346,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15460,Prolyl 4-hydroxylase subunit alpha-2,P4HA2,Skin dermis,Homo sapiens,2,years,10.906183224519,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15460,Prolyl 4-hydroxylase subunit alpha-2,P4HA2,Skin dermis,Homo sapiens,14,years,7.09053803888326,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15460,Prolyl 4-hydroxylase subunit alpha-2,P4HA2,Skin dermis,Homo sapiens,14,years,7.04654694798145,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15460,Prolyl 4-hydroxylase subunit alpha-2,P4HA2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15460,Prolyl 4-hydroxylase subunit alpha-2,P4HA2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15460,Prolyl 4-hydroxylase subunit alpha-2,P4HA2,Skin dermis,Homo sapiens,65,years,5.09934654963972,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15460,Prolyl 4-hydroxylase subunit alpha-2,P4HA2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P4HA2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q07283,Trichohyalin,TCHH,Skin dermis,Homo sapiens,2,years,10.7873178429611,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TCHH,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q07283,Trichohyalin,TCHH,Skin dermis,Homo sapiens,2,years,10.0971029344572,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TCHH,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q07283,Trichohyalin,TCHH,Skin dermis,Homo sapiens,14,years,4.83488928814563,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TCHH,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q07283,Trichohyalin,TCHH,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TCHH,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q07283,Trichohyalin,TCHH,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TCHH,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q07283,Trichohyalin,TCHH,Skin dermis,Homo sapiens,65,years,8.95487245255894,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TCHH,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q07283,Trichohyalin,TCHH,Skin dermis,Homo sapiens,65,years,4.22609854744005,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TCHH,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q07283,Trichohyalin,TCHH,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TCHH,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P51610,Host cell factor 1 {ECO:0000303|PubMed:10629049},HCFC1,Skin dermis,Homo sapiens,2,years,8.47010838587616,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HCFC1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P51610,Host cell factor 1 {ECO:0000303|PubMed:10629049},HCFC1,Skin dermis,Homo sapiens,2,years,8.58425512963162,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HCFC1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P51610,Host cell factor 1 {ECO:0000303|PubMed:10629049},HCFC1,Skin dermis,Homo sapiens,14,years,6.35845690895006,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HCFC1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P51610,Host cell factor 1 {ECO:0000303|PubMed:10629049},HCFC1,Skin dermis,Homo sapiens,14,years,6.39807753682872,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HCFC1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P51610,Host cell factor 1 {ECO:0000303|PubMed:10629049},HCFC1,Skin dermis,Homo sapiens,14,years,5.94075577657373,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HCFC1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P51610,Host cell factor 1 {ECO:0000303|PubMed:10629049},HCFC1,Skin dermis,Homo sapiens,65,years,5.68546736973167,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HCFC1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P51610,Host cell factor 1 {ECO:0000303|PubMed:10629049},HCFC1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HCFC1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P51610,Host cell factor 1 {ECO:0000303|PubMed:10629049},HCFC1,Skin dermis,Homo sapiens,65,years,4.62917407053106,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HCFC1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35442,Thrombospondin-2,THBS2,Skin dermis,Homo sapiens,2,years,7.30756194563159,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35442,Thrombospondin-2,THBS2,Skin dermis,Homo sapiens,2,years,7.48861447880568,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35442,Thrombospondin-2,THBS2,Skin dermis,Homo sapiens,14,years,4.61755840843598,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35442,Thrombospondin-2,THBS2,Skin dermis,Homo sapiens,14,years,4.67473155195164,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35442,Thrombospondin-2,THBS2,Skin dermis,Homo sapiens,14,years,5.43421017568928,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35442,Thrombospondin-2,THBS2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35442,Thrombospondin-2,THBS2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35442,Thrombospondin-2,THBS2,Skin dermis,Homo sapiens,65,years,4.28800355118296,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96P44,Collagen alpha-1(XXI) chain,COL21A1,Skin dermis,Homo sapiens,2,years,10.7887546385515,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL21A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q96P44,Collagen alpha-1(XXI) chain,COL21A1,Skin dermis,Homo sapiens,2,years,11.4544443871106,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL21A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q96P44,Collagen alpha-1(XXI) chain,COL21A1,Skin dermis,Homo sapiens,14,years,8.89573599636965,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL21A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q96P44,Collagen alpha-1(XXI) chain,COL21A1,Skin dermis,Homo sapiens,14,years,8.8866490387265,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL21A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q96P44,Collagen alpha-1(XXI) chain,COL21A1,Skin dermis,Homo sapiens,14,years,8.89739695845805,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL21A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q96P44,Collagen alpha-1(XXI) chain,COL21A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL21A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q96P44,Collagen alpha-1(XXI) chain,COL21A1,Skin dermis,Homo sapiens,65,years,6.9259462147965,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL21A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q96P44,Collagen alpha-1(XXI) chain,COL21A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL21A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NT22,EMILIN-3,EMILIN3,Skin dermis,Homo sapiens,2,years,12.3279433969354,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NT22,EMILIN-3,EMILIN3,Skin dermis,Homo sapiens,2,years,12.8060609226345,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NT22,EMILIN-3,EMILIN3,Skin dermis,Homo sapiens,14,years,9.9437214973111,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NT22,EMILIN-3,EMILIN3,Skin dermis,Homo sapiens,14,years,9.50093661003293,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NT22,EMILIN-3,EMILIN3,Skin dermis,Homo sapiens,14,years,9.06352221763701,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NT22,EMILIN-3,EMILIN3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NT22,EMILIN-3,EMILIN3,Skin dermis,Homo sapiens,65,years,7.27360111960615,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NT22,EMILIN-3,EMILIN3,Skin dermis,Homo sapiens,65,years,4.84163763999854,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P13727,Bone marrow proteoglycan,PRG2,Skin dermis,Homo sapiens,2,years,10.4187300427027,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13727,Bone marrow proteoglycan,PRG2,Skin dermis,Homo sapiens,2,years,10.3798319224223,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13727,Bone marrow proteoglycan,PRG2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13727,Bone marrow proteoglycan,PRG2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13727,Bone marrow proteoglycan,PRG2,Skin dermis,Homo sapiens,14,years,5.31286246604611,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13727,Bone marrow proteoglycan,PRG2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13727,Bone marrow proteoglycan,PRG2,Skin dermis,Homo sapiens,65,years,7.90152284046574,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13727,Bone marrow proteoglycan,PRG2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q99715,Collagen alpha-1(XII) chain,COL12A1,Skin dermis,Homo sapiens,2,years,13.1478003272834,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL12A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q99715,Collagen alpha-1(XII) chain,COL12A1,Skin dermis,Homo sapiens,2,years,14.6144967317204,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL12A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q99715,Collagen alpha-1(XII) chain,COL12A1,Skin dermis,Homo sapiens,14,years,12.3880747668466,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL12A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q99715,Collagen alpha-1(XII) chain,COL12A1,Skin dermis,Homo sapiens,14,years,12.202230026848,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL12A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q99715,Collagen alpha-1(XII) chain,COL12A1,Skin dermis,Homo sapiens,14,years,12.7460192932967,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL12A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q99715,Collagen alpha-1(XII) chain,COL12A1,Skin dermis,Homo sapiens,65,years,11.394779234467,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL12A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q99715,Collagen alpha-1(XII) chain,COL12A1,Skin dermis,Homo sapiens,65,years,10.324732863165,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL12A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q99715,Collagen alpha-1(XII) chain,COL12A1,Skin dermis,Homo sapiens,65,years,11.6302706035967,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL12A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39059,Collagen alpha-1(XV) chain,COL15A1,Skin dermis,Homo sapiens,2,years,10.0631170501868,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL15A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39059,Collagen alpha-1(XV) chain,COL15A1,Skin dermis,Homo sapiens,2,years,10.2900536967019,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL15A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39059,Collagen alpha-1(XV) chain,COL15A1,Skin dermis,Homo sapiens,14,years,9.42823107719667,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL15A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39059,Collagen alpha-1(XV) chain,COL15A1,Skin dermis,Homo sapiens,14,years,8.99714857999205,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL15A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39059,Collagen alpha-1(XV) chain,COL15A1,Skin dermis,Homo sapiens,14,years,8.52848494224753,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL15A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39059,Collagen alpha-1(XV) chain,COL15A1,Skin dermis,Homo sapiens,65,years,7.86698944214513,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL15A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39059,Collagen alpha-1(XV) chain,COL15A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL15A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39059,Collagen alpha-1(XV) chain,COL15A1,Skin dermis,Homo sapiens,65,years,9.80349324840795,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL15A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P07942,Laminin subunit beta-1,LAMB1,Skin dermis,Homo sapiens,2,years,10.1279511924154,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P07942,Laminin subunit beta-1,LAMB1,Skin dermis,Homo sapiens,2,years,10.3220416029329,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P07942,Laminin subunit beta-1,LAMB1,Skin dermis,Homo sapiens,14,years,9.39061148993495,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P07942,Laminin subunit beta-1,LAMB1,Skin dermis,Homo sapiens,14,years,9.32118696407135,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P07942,Laminin subunit beta-1,LAMB1,Skin dermis,Homo sapiens,14,years,9.17274005624983,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P07942,Laminin subunit beta-1,LAMB1,Skin dermis,Homo sapiens,65,years,8.42257793566237,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P07942,Laminin subunit beta-1,LAMB1,Skin dermis,Homo sapiens,65,years,7.77315334217032,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P07942,Laminin subunit beta-1,LAMB1,Skin dermis,Homo sapiens,65,years,9.63820712682323,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8N2S1,Latent-transforming growth factor beta-binding protein 4,LTBP4,Skin dermis,Homo sapiens,2,years,8.43294500468738,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8N2S1,Latent-transforming growth factor beta-binding protein 4,LTBP4,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8N2S1,Latent-transforming growth factor beta-binding protein 4,LTBP4,Skin dermis,Homo sapiens,14,years,7.84326857647551,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8N2S1,Latent-transforming growth factor beta-binding protein 4,LTBP4,Skin dermis,Homo sapiens,14,years,7.30544985867338,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8N2S1,Latent-transforming growth factor beta-binding protein 4,LTBP4,Skin dermis,Homo sapiens,14,years,6.50476077309037,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8N2S1,Latent-transforming growth factor beta-binding protein 4,LTBP4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8N2S1,Latent-transforming growth factor beta-binding protein 4,LTBP4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8N2S1,Latent-transforming growth factor beta-binding protein 4,LTBP4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IVL6,Prolyl 3-hydroxylase 3 {ECO:0000312|HGNC:HGNC:19318},LEPREL2,Skin dermis,Homo sapiens,2,years,9.62963582373893,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IVL6,Prolyl 3-hydroxylase 3 {ECO:0000312|HGNC:HGNC:19318},LEPREL2,Skin dermis,Homo sapiens,2,years,10.6864706142983,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IVL6,Prolyl 3-hydroxylase 3 {ECO:0000312|HGNC:HGNC:19318},LEPREL2,Skin dermis,Homo sapiens,14,years,5.84385136583544,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IVL6,Prolyl 3-hydroxylase 3 {ECO:0000312|HGNC:HGNC:19318},LEPREL2,Skin dermis,Homo sapiens,14,years,4.6931761897647,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IVL6,Prolyl 3-hydroxylase 3 {ECO:0000312|HGNC:HGNC:19318},LEPREL2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IVL6,Prolyl 3-hydroxylase 3 {ECO:0000312|HGNC:HGNC:19318},LEPREL2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IVL6,Prolyl 3-hydroxylase 3 {ECO:0000312|HGNC:HGNC:19318},LEPREL2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IVL6,Prolyl 3-hydroxylase 3 {ECO:0000312|HGNC:HGNC:19318},LEPREL2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5SZK8,FRAS1-related extracellular matrix protein 2,FREM2,Skin dermis,Homo sapiens,2,years,8.73420977356895,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5SZK8,FRAS1-related extracellular matrix protein 2,FREM2,Skin dermis,Homo sapiens,2,years,9.65652006684336,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5SZK8,FRAS1-related extracellular matrix protein 2,FREM2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5SZK8,FRAS1-related extracellular matrix protein 2,FREM2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5SZK8,FRAS1-related extracellular matrix protein 2,FREM2,Skin dermis,Homo sapiens,14,years,1.60528373969367,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5SZK8,FRAS1-related extracellular matrix protein 2,FREM2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5SZK8,FRAS1-related extracellular matrix protein 2,FREM2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5SZK8,FRAS1-related extracellular matrix protein 2,FREM2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9Y2Y8,Proteoglycan 3,PRG3,Skin dermis,Homo sapiens,2,years,9.62773949187072,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y2Y8,Proteoglycan 3,PRG3,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y2Y8,Proteoglycan 3,PRG3,Skin dermis,Homo sapiens,14,years,5.35259902456154,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y2Y8,Proteoglycan 3,PRG3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y2Y8,Proteoglycan 3,PRG3,Skin dermis,Homo sapiens,14,years,8.40090964555947,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y2Y8,Proteoglycan 3,PRG3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y2Y8,Proteoglycan 3,PRG3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y2Y8,Proteoglycan 3,PRG3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q02809,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",PLOD1,Skin dermis,Homo sapiens,2,years,10.8572320708649,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q02809,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",PLOD1,Skin dermis,Homo sapiens,2,years,11.1504153235885,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q02809,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",PLOD1,Skin dermis,Homo sapiens,14,years,7.51661687686352,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q02809,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",PLOD1,Skin dermis,Homo sapiens,14,years,7.21603938050104,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q02809,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",PLOD1,Skin dermis,Homo sapiens,14,years,5.67105964721077,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q02809,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",PLOD1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q02809,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",PLOD1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q02809,"Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1",PLOD1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60911,Cathepsin L2,CTSV,Skin dermis,Homo sapiens,2,years,9.43983404215638,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSV,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60911,Cathepsin L2,CTSV,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSV,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60911,Cathepsin L2,CTSV,Skin dermis,Homo sapiens,14,years,6.3087110291916,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSV,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60911,Cathepsin L2,CTSV,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSV,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60911,Cathepsin L2,CTSV,Skin dermis,Homo sapiens,14,years,7.5265368003764,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSV,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60911,Cathepsin L2,CTSV,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSV,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60911,Cathepsin L2,CTSV,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSV,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60911,Cathepsin L2,CTSV,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSV,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49257,Protein ERGIC-53,LMAN1,Skin dermis,Homo sapiens,2,years,12.653848950276,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LMAN1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49257,Protein ERGIC-53,LMAN1,Skin dermis,Homo sapiens,2,years,13.4306374184369,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LMAN1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49257,Protein ERGIC-53,LMAN1,Skin dermis,Homo sapiens,14,years,11.1153152318146,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LMAN1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49257,Protein ERGIC-53,LMAN1,Skin dermis,Homo sapiens,14,years,11.0573244423396,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LMAN1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49257,Protein ERGIC-53,LMAN1,Skin dermis,Homo sapiens,14,years,11.1038214689429,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LMAN1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49257,Protein ERGIC-53,LMAN1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LMAN1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49257,Protein ERGIC-53,LMAN1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LMAN1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49257,Protein ERGIC-53,LMAN1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LMAN1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q92626,Peroxidasin homolog {ECO:0000305},PXDN,Skin dermis,Homo sapiens,2,years,10.0997796476152,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PXDN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q92626,Peroxidasin homolog {ECO:0000305},PXDN,Skin dermis,Homo sapiens,2,years,10.1822959752431,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PXDN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q92626,Peroxidasin homolog {ECO:0000305},PXDN,Skin dermis,Homo sapiens,14,years,5.81719211193916,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PXDN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q92626,Peroxidasin homolog {ECO:0000305},PXDN,Skin dermis,Homo sapiens,14,years,6.3973664993373,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PXDN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q92626,Peroxidasin homolog {ECO:0000305},PXDN,Skin dermis,Homo sapiens,14,years,6.10448670018887,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PXDN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q92626,Peroxidasin homolog {ECO:0000305},PXDN,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PXDN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q92626,Peroxidasin homolog {ECO:0000305},PXDN,Skin dermis,Homo sapiens,65,years,8.98403922813957,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PXDN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q92626,Peroxidasin homolog {ECO:0000305},PXDN,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PXDN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15828,Cystatin-M,CST6,Skin dermis,Homo sapiens,2,years,11.1151841256738,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CST6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q15828,Cystatin-M,CST6,Skin dermis,Homo sapiens,2,years,10.3752122619542,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CST6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q15828,Cystatin-M,CST6,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CST6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q15828,Cystatin-M,CST6,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CST6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q15828,Cystatin-M,CST6,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CST6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q15828,Cystatin-M,CST6,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CST6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q15828,Cystatin-M,CST6,Skin dermis,Homo sapiens,65,years,8.49615858699394,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CST6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q15828,Cystatin-M,CST6,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CST6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q32P28,Prolyl 3-hydroxylase 1 {ECO:0000312|HGNC:HGNC:19316},LEPRE1,Skin dermis,Homo sapiens,2,years,11.3480320591142,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q32P28,Prolyl 3-hydroxylase 1 {ECO:0000312|HGNC:HGNC:19316},LEPRE1,Skin dermis,Homo sapiens,2,years,11.5761237694529,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q32P28,Prolyl 3-hydroxylase 1 {ECO:0000312|HGNC:HGNC:19316},LEPRE1,Skin dermis,Homo sapiens,14,years,9.16078574832878,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q32P28,Prolyl 3-hydroxylase 1 {ECO:0000312|HGNC:HGNC:19316},LEPRE1,Skin dermis,Homo sapiens,14,years,7.57978880317252,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q32P28,Prolyl 3-hydroxylase 1 {ECO:0000312|HGNC:HGNC:19316},LEPRE1,Skin dermis,Homo sapiens,14,years,7.21231372273225,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q32P28,Prolyl 3-hydroxylase 1 {ECO:0000312|HGNC:HGNC:19316},LEPRE1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q32P28,Prolyl 3-hydroxylase 1 {ECO:0000312|HGNC:HGNC:19316},LEPRE1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q32P28,Prolyl 3-hydroxylase 1 {ECO:0000312|HGNC:HGNC:19316},LEPRE1,Skin dermis,Homo sapiens,65,years,3.57233552290834,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",P3H1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O00468,Agrin,AGRN,Skin dermis,Homo sapiens,2,years,5.94218440320156,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGRN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00468,Agrin,AGRN,Skin dermis,Homo sapiens,2,years,6.85425216521664,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGRN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00468,Agrin,AGRN,Skin dermis,Homo sapiens,14,years,3.88205630103952,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGRN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00468,Agrin,AGRN,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGRN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00468,Agrin,AGRN,Skin dermis,Homo sapiens,14,years,2.60831421483373,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGRN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00468,Agrin,AGRN,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGRN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00468,Agrin,AGRN,Skin dermis,Homo sapiens,65,years,6.68057655665183,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGRN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00468,Agrin,AGRN,Skin dermis,Homo sapiens,65,years,4.45347117254612,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AGRN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P07858,Cathepsin B,CTSB,Skin dermis,Homo sapiens,2,years,10.197785101645,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07858,Cathepsin B,CTSB,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07858,Cathepsin B,CTSB,Skin dermis,Homo sapiens,14,years,9.61351032551602,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07858,Cathepsin B,CTSB,Skin dermis,Homo sapiens,14,years,8.96111397754871,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07858,Cathepsin B,CTSB,Skin dermis,Homo sapiens,14,years,9.28746591774655,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07858,Cathepsin B,CTSB,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07858,Cathepsin B,CTSB,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07858,Cathepsin B,CTSB,Skin dermis,Homo sapiens,65,years,8.86242418223804,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50454,Serpin H1,SERPINH1,Skin dermis,Homo sapiens,2,years,16.6937437136151,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50454,Serpin H1,SERPINH1,Skin dermis,Homo sapiens,2,years,17.3841015587552,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50454,Serpin H1,SERPINH1,Skin dermis,Homo sapiens,14,years,14.391746718173,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50454,Serpin H1,SERPINH1,Skin dermis,Homo sapiens,14,years,14.0900819111444,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50454,Serpin H1,SERPINH1,Skin dermis,Homo sapiens,14,years,13.3334773601746,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50454,Serpin H1,SERPINH1,Skin dermis,Homo sapiens,65,years,7.61079694630527,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50454,Serpin H1,SERPINH1,Skin dermis,Homo sapiens,65,years,7.11330823514012,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50454,Serpin H1,SERPINH1,Skin dermis,Homo sapiens,65,years,10.5793212689487,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86XX4,Extracellular matrix organizing protein FRAS1 {ECO:0000250|UniProtKB:Q80T14},FRAS1,Skin dermis,Homo sapiens,2,years,4.68291880252004,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FRAS1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q86XX4,Extracellular matrix organizing protein FRAS1 {ECO:0000250|UniProtKB:Q80T14},FRAS1,Skin dermis,Homo sapiens,2,years,5.37479457924852,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FRAS1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q86XX4,Extracellular matrix organizing protein FRAS1 {ECO:0000250|UniProtKB:Q80T14},FRAS1,Skin dermis,Homo sapiens,14,years,3.04064685919562,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FRAS1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q86XX4,Extracellular matrix organizing protein FRAS1 {ECO:0000250|UniProtKB:Q80T14},FRAS1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FRAS1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q86XX4,Extracellular matrix organizing protein FRAS1 {ECO:0000250|UniProtKB:Q80T14},FRAS1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FRAS1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q86XX4,Extracellular matrix organizing protein FRAS1 {ECO:0000250|UniProtKB:Q80T14},FRAS1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FRAS1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q86XX4,Extracellular matrix organizing protein FRAS1 {ECO:0000250|UniProtKB:Q80T14},FRAS1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FRAS1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q86XX4,Extracellular matrix organizing protein FRAS1 {ECO:0000250|UniProtKB:Q80T14},FRAS1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FRAS1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UX71,Plexin domain-containing protein 2,PLXDC2,Skin dermis,Homo sapiens,2,years,7.14257927420223,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXDC2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UX71,Plexin domain-containing protein 2,PLXDC2,Skin dermis,Homo sapiens,2,years,8.31868947736337,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXDC2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UX71,Plexin domain-containing protein 2,PLXDC2,Skin dermis,Homo sapiens,14,years,7.21210745954915,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXDC2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UX71,Plexin domain-containing protein 2,PLXDC2,Skin dermis,Homo sapiens,14,years,5.89641123106714,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXDC2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UX71,Plexin domain-containing protein 2,PLXDC2,Skin dermis,Homo sapiens,14,years,6.179995615094,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXDC2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UX71,Plexin domain-containing protein 2,PLXDC2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXDC2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UX71,Plexin domain-containing protein 2,PLXDC2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXDC2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UX71,Plexin domain-containing protein 2,PLXDC2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXDC2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08758,Annexin A5,ANXA5,Skin dermis,Homo sapiens,2,years,14.5295121545382,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA5,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08758,Annexin A5,ANXA5,Skin dermis,Homo sapiens,2,years,15.8305124409377,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA5,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08758,Annexin A5,ANXA5,Skin dermis,Homo sapiens,14,years,13.9590260104722,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA5,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08758,Annexin A5,ANXA5,Skin dermis,Homo sapiens,14,years,13.2380918113615,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA5,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08758,Annexin A5,ANXA5,Skin dermis,Homo sapiens,14,years,13.7020772775921,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA5,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08758,Annexin A5,ANXA5,Skin dermis,Homo sapiens,65,years,12.804264131081,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA5,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08758,Annexin A5,ANXA5,Skin dermis,Homo sapiens,65,years,5.80574431083416,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA5,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08758,Annexin A5,ANXA5,Skin dermis,Homo sapiens,65,years,13.3845085646124,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA5,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15031,Plexin-B2 {ECO:0000303|PubMed:29100074},PLXNB2,Skin dermis,Homo sapiens,2,years,5.07218449785068,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXNB2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15031,Plexin-B2 {ECO:0000303|PubMed:29100074},PLXNB2,Skin dermis,Homo sapiens,2,years,3.74974661589334,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXNB2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15031,Plexin-B2 {ECO:0000303|PubMed:29100074},PLXNB2,Skin dermis,Homo sapiens,14,years,3.27568815398259,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXNB2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15031,Plexin-B2 {ECO:0000303|PubMed:29100074},PLXNB2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXNB2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15031,Plexin-B2 {ECO:0000303|PubMed:29100074},PLXNB2,Skin dermis,Homo sapiens,14,years,2.81520650521568,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXNB2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15031,Plexin-B2 {ECO:0000303|PubMed:29100074},PLXNB2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXNB2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15031,Plexin-B2 {ECO:0000303|PubMed:29100074},PLXNB2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXNB2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O15031,Plexin-B2 {ECO:0000303|PubMed:29100074},PLXNB2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLXNB2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60568,Multifunctional procollagen lysine hydroxylase and glycosyltransferase LH3,PLOD3,Skin dermis,Homo sapiens,2,years,8.7071114004686,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60568,Multifunctional procollagen lysine hydroxylase and glycosyltransferase LH3,PLOD3,Skin dermis,Homo sapiens,2,years,9.36260494007906,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60568,Multifunctional procollagen lysine hydroxylase and glycosyltransferase LH3,PLOD3,Skin dermis,Homo sapiens,14,years,5.897046941522,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60568,Multifunctional procollagen lysine hydroxylase and glycosyltransferase LH3,PLOD3,Skin dermis,Homo sapiens,14,years,4.35317017246263,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60568,Multifunctional procollagen lysine hydroxylase and glycosyltransferase LH3,PLOD3,Skin dermis,Homo sapiens,14,years,5.09996515393742,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60568,Multifunctional procollagen lysine hydroxylase and glycosyltransferase LH3,PLOD3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60568,Multifunctional procollagen lysine hydroxylase and glycosyltransferase LH3,PLOD3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60568,Multifunctional procollagen lysine hydroxylase and glycosyltransferase LH3,PLOD3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLOD3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P12429,Annexin A3,ANXA3,Skin dermis,Homo sapiens,2,years,9.26160618685552,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P12429,Annexin A3,ANXA3,Skin dermis,Homo sapiens,2,years,8.30320849057436,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P12429,Annexin A3,ANXA3,Skin dermis,Homo sapiens,14,years,7.93604398502319,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P12429,Annexin A3,ANXA3,Skin dermis,Homo sapiens,14,years,7.29489408626266,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P12429,Annexin A3,ANXA3,Skin dermis,Homo sapiens,14,years,7.23740986299317,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P12429,Annexin A3,ANXA3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P12429,Annexin A3,ANXA3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P12429,Annexin A3,ANXA3,Skin dermis,Homo sapiens,65,years,7.02893336698863,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8NDA2,Hemicentin-2 {ECO:0000305},HMCN2,Skin dermis,Homo sapiens,2,years,5.55658119642243,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8NDA2,Hemicentin-2 {ECO:0000305},HMCN2,Skin dermis,Homo sapiens,2,years,6.77431138116546,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8NDA2,Hemicentin-2 {ECO:0000305},HMCN2,Skin dermis,Homo sapiens,14,years,3.25297234359594,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8NDA2,Hemicentin-2 {ECO:0000305},HMCN2,Skin dermis,Homo sapiens,14,years,2.54113876319555,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8NDA2,Hemicentin-2 {ECO:0000305},HMCN2,Skin dermis,Homo sapiens,14,years,1.1141692708417,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8NDA2,Hemicentin-2 {ECO:0000305},HMCN2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8NDA2,Hemicentin-2 {ECO:0000305},HMCN2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8NDA2,Hemicentin-2 {ECO:0000305},HMCN2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6N6,Laminin subunit gamma-3,LAMC3,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6N6,Laminin subunit gamma-3,LAMC3,Skin dermis,Homo sapiens,2,years,5.11228415604925,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6N6,Laminin subunit gamma-3,LAMC3,Skin dermis,Homo sapiens,14,years,3.51172291225361,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6N6,Laminin subunit gamma-3,LAMC3,Skin dermis,Homo sapiens,14,years,4.64488843974317,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6N6,Laminin subunit gamma-3,LAMC3,Skin dermis,Homo sapiens,14,years,4.2853396501545,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6N6,Laminin subunit gamma-3,LAMC3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6N6,Laminin subunit gamma-3,LAMC3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6N6,Laminin subunit gamma-3,LAMC3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UBR2,Cathepsin Z,CTSZ,Skin dermis,Homo sapiens,2,years,7.79499026874408,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSZ,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UBR2,Cathepsin Z,CTSZ,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSZ,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UBR2,Cathepsin Z,CTSZ,Skin dermis,Homo sapiens,14,years,8.1395158451235,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSZ,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UBR2,Cathepsin Z,CTSZ,Skin dermis,Homo sapiens,14,years,7.76624465880009,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSZ,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UBR2,Cathepsin Z,CTSZ,Skin dermis,Homo sapiens,14,years,6.27009141419183,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSZ,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UBR2,Cathepsin Z,CTSZ,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSZ,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UBR2,Cathepsin Z,CTSZ,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSZ,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UBR2,Cathepsin Z,CTSZ,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSZ,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08133,Annexin A6,ANXA6,Skin dermis,Homo sapiens,2,years,13.8418313702498,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA6,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08133,Annexin A6,ANXA6,Skin dermis,Homo sapiens,2,years,14.5638011076615,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA6,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08133,Annexin A6,ANXA6,Skin dermis,Homo sapiens,14,years,13.2094828409259,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA6,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08133,Annexin A6,ANXA6,Skin dermis,Homo sapiens,14,years,13.2137399696516,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA6,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08133,Annexin A6,ANXA6,Skin dermis,Homo sapiens,14,years,12.400958876737,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA6,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08133,Annexin A6,ANXA6,Skin dermis,Homo sapiens,65,years,10.2828022239581,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA6,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08133,Annexin A6,ANXA6,Skin dermis,Homo sapiens,65,years,9.55669070900035,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA6,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08133,Annexin A6,ANXA6,Skin dermis,Homo sapiens,65,years,12.033897715021,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA6,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9Y6C2,EMILIN-1,EMILIN1,Skin dermis,Homo sapiens,2,years,14.0657098500916,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6C2,EMILIN-1,EMILIN1,Skin dermis,Homo sapiens,2,years,14.0446568279874,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6C2,EMILIN-1,EMILIN1,Skin dermis,Homo sapiens,14,years,12.6518951557692,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6C2,EMILIN-1,EMILIN1,Skin dermis,Homo sapiens,14,years,12.8995347280479,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6C2,EMILIN-1,EMILIN1,Skin dermis,Homo sapiens,14,years,12.7514995617003,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6C2,EMILIN-1,EMILIN1,Skin dermis,Homo sapiens,65,years,11.2194979688252,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6C2,EMILIN-1,EMILIN1,Skin dermis,Homo sapiens,65,years,12.088323431417,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y6C2,EMILIN-1,EMILIN1,Skin dermis,Homo sapiens,65,years,12.9143072804347,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P05997,Collagen alpha-2(V) chain,COL5A2,Skin dermis,Homo sapiens,2,years,12.5254373406691,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P05997,Collagen alpha-2(V) chain,COL5A2,Skin dermis,Homo sapiens,2,years,12.5702023336554,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P05997,Collagen alpha-2(V) chain,COL5A2,Skin dermis,Homo sapiens,14,years,11.8425600084707,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P05997,Collagen alpha-2(V) chain,COL5A2,Skin dermis,Homo sapiens,14,years,12.6516807695804,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P05997,Collagen alpha-2(V) chain,COL5A2,Skin dermis,Homo sapiens,14,years,11.7789717988499,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P05997,Collagen alpha-2(V) chain,COL5A2,Skin dermis,Homo sapiens,65,years,14.1731812094881,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P05997,Collagen alpha-2(V) chain,COL5A2,Skin dermis,Homo sapiens,65,years,9.78829464037936,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P05997,Collagen alpha-2(V) chain,COL5A2,Skin dermis,Homo sapiens,65,years,13.6339668325446,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
O75095,Multiple epidermal growth factor-like domains protein 6,MEGF6,Skin dermis,Homo sapiens,2,years,9.17841711939419,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MEGF6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75095,Multiple epidermal growth factor-like domains protein 6,MEGF6,Skin dermis,Homo sapiens,2,years,6.65380746181619,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MEGF6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75095,Multiple epidermal growth factor-like domains protein 6,MEGF6,Skin dermis,Homo sapiens,14,years,7.12445808759998,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MEGF6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75095,Multiple epidermal growth factor-like domains protein 6,MEGF6,Skin dermis,Homo sapiens,14,years,5.81364808434599,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MEGF6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75095,Multiple epidermal growth factor-like domains protein 6,MEGF6,Skin dermis,Homo sapiens,14,years,6.01152347117051,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MEGF6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75095,Multiple epidermal growth factor-like domains protein 6,MEGF6,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MEGF6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75095,Multiple epidermal growth factor-like domains protein 6,MEGF6,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MEGF6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75095,Multiple epidermal growth factor-like domains protein 6,MEGF6,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MEGF6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50453,Serpin B9,SERPINB9,Skin dermis,Homo sapiens,2,years,7.39186825750215,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50453,Serpin B9,SERPINB9,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50453,Serpin B9,SERPINB9,Skin dermis,Homo sapiens,14,years,7.67352572199902,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50453,Serpin B9,SERPINB9,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50453,Serpin B9,SERPINB9,Skin dermis,Homo sapiens,14,years,5.64389375101456,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50453,Serpin B9,SERPINB9,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50453,Serpin B9,SERPINB9,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50453,Serpin B9,SERPINB9,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O60687,Sushi repeat-containing protein SRPX2,SRPX2,Skin dermis,Homo sapiens,2,years,6.74251963922411,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O60687,Sushi repeat-containing protein SRPX2,SRPX2,Skin dermis,Homo sapiens,2,years,8.1169346955937,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O60687,Sushi repeat-containing protein SRPX2,SRPX2,Skin dermis,Homo sapiens,14,years,4.24855809920279,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O60687,Sushi repeat-containing protein SRPX2,SRPX2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O60687,Sushi repeat-containing protein SRPX2,SRPX2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O60687,Sushi repeat-containing protein SRPX2,SRPX2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O60687,Sushi repeat-containing protein SRPX2,SRPX2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O60687,Sushi repeat-containing protein SRPX2,SRPX2,Skin dermis,Homo sapiens,65,years,7.08543553483455,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6ZMP0,Thrombospondin type-1 domain-containing protein 4,THSD4,Skin dermis,Homo sapiens,2,years,7.24087580147716,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THSD4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6ZMP0,Thrombospondin type-1 domain-containing protein 4,THSD4,Skin dermis,Homo sapiens,2,years,7.06132939562285,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THSD4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6ZMP0,Thrombospondin type-1 domain-containing protein 4,THSD4,Skin dermis,Homo sapiens,14,years,6.4911941897338,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THSD4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6ZMP0,Thrombospondin type-1 domain-containing protein 4,THSD4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THSD4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6ZMP0,Thrombospondin type-1 domain-containing protein 4,THSD4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THSD4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6ZMP0,Thrombospondin type-1 domain-containing protein 4,THSD4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THSD4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6ZMP0,Thrombospondin type-1 domain-containing protein 4,THSD4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THSD4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6ZMP0,Thrombospondin type-1 domain-containing protein 4,THSD4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THSD4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P19823,Inter-alpha-trypsin inhibitor heavy chain H2,ITIH2,Skin dermis,Homo sapiens,2,years,13.0790493022236,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19823,Inter-alpha-trypsin inhibitor heavy chain H2,ITIH2,Skin dermis,Homo sapiens,2,years,13.1567790460303,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19823,Inter-alpha-trypsin inhibitor heavy chain H2,ITIH2,Skin dermis,Homo sapiens,14,years,12.0803323066943,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19823,Inter-alpha-trypsin inhibitor heavy chain H2,ITIH2,Skin dermis,Homo sapiens,14,years,12.5765437538781,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19823,Inter-alpha-trypsin inhibitor heavy chain H2,ITIH2,Skin dermis,Homo sapiens,14,years,12.1845709838094,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19823,Inter-alpha-trypsin inhibitor heavy chain H2,ITIH2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19823,Inter-alpha-trypsin inhibitor heavy chain H2,ITIH2,Skin dermis,Homo sapiens,65,years,5.97421857886665,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19823,Inter-alpha-trypsin inhibitor heavy chain H2,ITIH2,Skin dermis,Homo sapiens,65,years,10.8052985134379,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q4ZHG4,Fibronectin type III domain-containing protein 1,FNDC1,Skin dermis,Homo sapiens,2,years,7.57660174641357,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FNDC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q4ZHG4,Fibronectin type III domain-containing protein 1,FNDC1,Skin dermis,Homo sapiens,2,years,9.09543311502207,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FNDC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q4ZHG4,Fibronectin type III domain-containing protein 1,FNDC1,Skin dermis,Homo sapiens,14,years,3.84128532983682,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FNDC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q4ZHG4,Fibronectin type III domain-containing protein 1,FNDC1,Skin dermis,Homo sapiens,14,years,7.9861959711939,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FNDC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q4ZHG4,Fibronectin type III domain-containing protein 1,FNDC1,Skin dermis,Homo sapiens,14,years,7.23163436042667,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FNDC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q4ZHG4,Fibronectin type III domain-containing protein 1,FNDC1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FNDC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q4ZHG4,Fibronectin type III domain-containing protein 1,FNDC1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FNDC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q4ZHG4,Fibronectin type III domain-containing protein 1,FNDC1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FNDC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P33764,Protein S100-A3,S100A3,Skin dermis,Homo sapiens,2,years,10.9622340294453,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A3,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P33764,Protein S100-A3,S100A3,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A3,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P33764,Protein S100-A3,S100A3,Skin dermis,Homo sapiens,14,years,7.74750991115757,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A3,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P33764,Protein S100-A3,S100A3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A3,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P33764,Protein S100-A3,S100A3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A3,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P33764,Protein S100-A3,S100A3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A3,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P33764,Protein S100-A3,S100A3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A3,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P33764,Protein S100-A3,S100A3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A3,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5H8C1,FRAS1-related extracellular matrix protein 1 {ECO:0000305},FREM1,Skin dermis,Homo sapiens,2,years,3.72526979944787,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5H8C1,FRAS1-related extracellular matrix protein 1 {ECO:0000305},FREM1,Skin dermis,Homo sapiens,2,years,5.13106686113903,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5H8C1,FRAS1-related extracellular matrix protein 1 {ECO:0000305},FREM1,Skin dermis,Homo sapiens,14,years,3.76177303238308,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5H8C1,FRAS1-related extracellular matrix protein 1 {ECO:0000305},FREM1,Skin dermis,Homo sapiens,14,years,1.80977010863319,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5H8C1,FRAS1-related extracellular matrix protein 1 {ECO:0000305},FREM1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5H8C1,FRAS1-related extracellular matrix protein 1 {ECO:0000305},FREM1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5H8C1,FRAS1-related extracellular matrix protein 1 {ECO:0000305},FREM1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5H8C1,FRAS1-related extracellular matrix protein 1 {ECO:0000305},FREM1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FREM1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UY14,ADAMTS-like protein 4,ADAMTSL4,Skin dermis,Homo sapiens,2,years,5.35022468367629,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UY14,ADAMTS-like protein 4,ADAMTSL4,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UY14,ADAMTS-like protein 4,ADAMTSL4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UY14,ADAMTS-like protein 4,ADAMTSL4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UY14,ADAMTS-like protein 4,ADAMTSL4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UY14,ADAMTS-like protein 4,ADAMTSL4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UY14,ADAMTS-like protein 4,ADAMTSL4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UY14,ADAMTS-like protein 4,ADAMTSL4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADAMTSL4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O95715,C-X-C motif chemokine 14,CXCL14,Skin dermis,Homo sapiens,2,years,11.1880511235705,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O95715,C-X-C motif chemokine 14,CXCL14,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O95715,C-X-C motif chemokine 14,CXCL14,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O95715,C-X-C motif chemokine 14,CXCL14,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O95715,C-X-C motif chemokine 14,CXCL14,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O95715,C-X-C motif chemokine 14,CXCL14,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O95715,C-X-C motif chemokine 14,CXCL14,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O95715,C-X-C motif chemokine 14,CXCL14,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50281,Matrix metalloproteinase-14,MMP14,Skin dermis,Homo sapiens,2,years,4.81333172035102,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP14,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50281,Matrix metalloproteinase-14,MMP14,Skin dermis,Homo sapiens,2,years,7.66690887006966,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP14,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50281,Matrix metalloproteinase-14,MMP14,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP14,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50281,Matrix metalloproteinase-14,MMP14,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP14,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50281,Matrix metalloproteinase-14,MMP14,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP14,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50281,Matrix metalloproteinase-14,MMP14,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP14,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50281,Matrix metalloproteinase-14,MMP14,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP14,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50281,Matrix metalloproteinase-14,MMP14,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP14,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q5GFL6,von Willebrand factor A domain-containing protein 2,VWA2,Skin dermis,Homo sapiens,2,years,7.88546063643375,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q5GFL6,von Willebrand factor A domain-containing protein 2,VWA2,Skin dermis,Homo sapiens,2,years,8.6824873823889,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q5GFL6,von Willebrand factor A domain-containing protein 2,VWA2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q5GFL6,von Willebrand factor A domain-containing protein 2,VWA2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q5GFL6,von Willebrand factor A domain-containing protein 2,VWA2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q5GFL6,von Willebrand factor A domain-containing protein 2,VWA2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q5GFL6,von Willebrand factor A domain-containing protein 2,VWA2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q5GFL6,von Willebrand factor A domain-containing protein 2,VWA2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96IV0,Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase,NGLY1,Skin dermis,Homo sapiens,2,years,3.58052446877333,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NGLY1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96IV0,Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase,NGLY1,Skin dermis,Homo sapiens,2,years,5.87797163901755,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NGLY1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96IV0,Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase,NGLY1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NGLY1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96IV0,Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase,NGLY1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NGLY1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96IV0,Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase,NGLY1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NGLY1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96IV0,Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase,NGLY1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NGLY1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96IV0,Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase,NGLY1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NGLY1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96IV0,Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase,NGLY1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NGLY1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96S86,Hyaluronan and proteoglycan link protein 3,HAPLN3,Skin dermis,Homo sapiens,2,years,5.58788996323257,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q96S86,Hyaluronan and proteoglycan link protein 3,HAPLN3,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q96S86,Hyaluronan and proteoglycan link protein 3,HAPLN3,Skin dermis,Homo sapiens,14,years,4.46381233455881,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q96S86,Hyaluronan and proteoglycan link protein 3,HAPLN3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q96S86,Hyaluronan and proteoglycan link protein 3,HAPLN3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q96S86,Hyaluronan and proteoglycan link protein 3,HAPLN3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q96S86,Hyaluronan and proteoglycan link protein 3,HAPLN3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q96S86,Hyaluronan and proteoglycan link protein 3,HAPLN3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN3,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P12107,Collagen alpha-1(XI) chain,COL11A1,Skin dermis,Homo sapiens,2,years,5.55379780842917,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL11A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12107,Collagen alpha-1(XI) chain,COL11A1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL11A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12107,Collagen alpha-1(XI) chain,COL11A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL11A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12107,Collagen alpha-1(XI) chain,COL11A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL11A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12107,Collagen alpha-1(XI) chain,COL11A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL11A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12107,Collagen alpha-1(XI) chain,COL11A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL11A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12107,Collagen alpha-1(XI) chain,COL11A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL11A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12107,Collagen alpha-1(XI) chain,COL11A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL11A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q6YHK3,CD109 antigen,CD109,Skin dermis,Homo sapiens,2,years,9.24945166823462,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CD109,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6YHK3,CD109 antigen,CD109,Skin dermis,Homo sapiens,2,years,9.61236937807357,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CD109,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6YHK3,CD109 antigen,CD109,Skin dermis,Homo sapiens,14,years,9.31428228142563,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CD109,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6YHK3,CD109 antigen,CD109,Skin dermis,Homo sapiens,14,years,8.67768706941135,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CD109,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6YHK3,CD109 antigen,CD109,Skin dermis,Homo sapiens,14,years,9.23783621521282,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CD109,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6YHK3,CD109 antigen,CD109,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CD109,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6YHK3,CD109 antigen,CD109,Skin dermis,Homo sapiens,65,years,4.36512098954475,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CD109,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6YHK3,CD109 antigen,CD109,Skin dermis,Homo sapiens,65,years,5.68607051735815,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CD109,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P53634,Dipeptidyl peptidase 1,CTSC,Skin dermis,Homo sapiens,2,years,8.9768231184689,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSC,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P53634,Dipeptidyl peptidase 1,CTSC,Skin dermis,Homo sapiens,2,years,8.76412684437676,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSC,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P53634,Dipeptidyl peptidase 1,CTSC,Skin dermis,Homo sapiens,14,years,7.47855263665184,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSC,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P53634,Dipeptidyl peptidase 1,CTSC,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSC,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P53634,Dipeptidyl peptidase 1,CTSC,Skin dermis,Homo sapiens,14,years,5.25128231899045,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSC,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P53634,Dipeptidyl peptidase 1,CTSC,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSC,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P53634,Dipeptidyl peptidase 1,CTSC,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSC,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P53634,Dipeptidyl peptidase 1,CTSC,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSC,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04083,Annexin A1,ANXA1,Skin dermis,Homo sapiens,2,years,13.3312711558947,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04083,Annexin A1,ANXA1,Skin dermis,Homo sapiens,2,years,13.467830327823,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04083,Annexin A1,ANXA1,Skin dermis,Homo sapiens,14,years,13.2428923575355,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04083,Annexin A1,ANXA1,Skin dermis,Homo sapiens,14,years,12.872408529803,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04083,Annexin A1,ANXA1,Skin dermis,Homo sapiens,14,years,13.902285899883,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04083,Annexin A1,ANXA1,Skin dermis,Homo sapiens,65,years,12.9235124122601,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04083,Annexin A1,ANXA1,Skin dermis,Homo sapiens,65,years,7.70260396323051,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04083,Annexin A1,ANXA1,Skin dermis,Homo sapiens,65,years,11.2945225755769,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ5,Complement C1q tumor necrosis factor-related protein 2,C1QTNF2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ5,Complement C1q tumor necrosis factor-related protein 2,C1QTNF2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ5,Complement C1q tumor necrosis factor-related protein 2,C1QTNF2,Skin dermis,Homo sapiens,14,years,6.86760895308646,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ5,Complement C1q tumor necrosis factor-related protein 2,C1QTNF2,Skin dermis,Homo sapiens,14,years,8.11633328357928,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ5,Complement C1q tumor necrosis factor-related protein 2,C1QTNF2,Skin dermis,Homo sapiens,14,years,8.82859341616309,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ5,Complement C1q tumor necrosis factor-related protein 2,C1QTNF2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ5,Complement C1q tumor necrosis factor-related protein 2,C1QTNF2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ5,Complement C1q tumor necrosis factor-related protein 2,C1QTNF2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
O43405,Cochlin,COCH,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COCH,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O43405,Cochlin,COCH,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COCH,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O43405,Cochlin,COCH,Skin dermis,Homo sapiens,14,years,6.64054945235854,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COCH,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O43405,Cochlin,COCH,Skin dermis,Homo sapiens,14,years,6.43700058046305,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COCH,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O43405,Cochlin,COCH,Skin dermis,Homo sapiens,14,years,5.69095323936425,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COCH,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O43405,Cochlin,COCH,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COCH,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O43405,Cochlin,COCH,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COCH,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O43405,Cochlin,COCH,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COCH,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P22735,Protein-glutamine gamma-glutamyltransferase K,TGM1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22735,Protein-glutamine gamma-glutamyltransferase K,TGM1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22735,Protein-glutamine gamma-glutamyltransferase K,TGM1,Skin dermis,Homo sapiens,14,years,3.39497915953939,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22735,Protein-glutamine gamma-glutamyltransferase K,TGM1,Skin dermis,Homo sapiens,14,years,4.04425495622725,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22735,Protein-glutamine gamma-glutamyltransferase K,TGM1,Skin dermis,Homo sapiens,14,years,6.52769157234911,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22735,Protein-glutamine gamma-glutamyltransferase K,TGM1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22735,Protein-glutamine gamma-glutamyltransferase K,TGM1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22735,Protein-glutamine gamma-glutamyltransferase K,TGM1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09525,Annexin A4 {ECO:0000305},ANXA4,Skin dermis,Homo sapiens,2,years,11.7130627514249,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09525,Annexin A4 {ECO:0000305},ANXA4,Skin dermis,Homo sapiens,2,years,12.3560433254607,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09525,Annexin A4 {ECO:0000305},ANXA4,Skin dermis,Homo sapiens,14,years,12.5779249830229,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09525,Annexin A4 {ECO:0000305},ANXA4,Skin dermis,Homo sapiens,14,years,13.686050542346,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09525,Annexin A4 {ECO:0000305},ANXA4,Skin dermis,Homo sapiens,14,years,13.190041961321,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09525,Annexin A4 {ECO:0000305},ANXA4,Skin dermis,Homo sapiens,65,years,11.49379539429,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09525,Annexin A4 {ECO:0000305},ANXA4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09525,Annexin A4 {ECO:0000305},ANXA4,Skin dermis,Homo sapiens,65,years,12.4350584385944,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA4,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q2UY09,Collagen alpha-1(XXVIII) chain,COL28A1,Skin dermis,Homo sapiens,2,years,8.32701474219825,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL28A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q2UY09,Collagen alpha-1(XXVIII) chain,COL28A1,Skin dermis,Homo sapiens,2,years,8.678646952498,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL28A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q2UY09,Collagen alpha-1(XXVIII) chain,COL28A1,Skin dermis,Homo sapiens,14,years,11.6773227986782,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL28A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q2UY09,Collagen alpha-1(XXVIII) chain,COL28A1,Skin dermis,Homo sapiens,14,years,11.2832625898435,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL28A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q2UY09,Collagen alpha-1(XXVIII) chain,COL28A1,Skin dermis,Homo sapiens,14,years,11.2368252616273,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL28A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q2UY09,Collagen alpha-1(XXVIII) chain,COL28A1,Skin dermis,Homo sapiens,65,years,8.90229234432885,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL28A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q2UY09,Collagen alpha-1(XXVIII) chain,COL28A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL28A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q2UY09,Collagen alpha-1(XXVIII) chain,COL28A1,Skin dermis,Homo sapiens,65,years,7.56890749037657,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL28A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q9HCY8,Protein S100-A14,S100A14,Skin dermis,Homo sapiens,2,years,9.31443415706246,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9HCY8,Protein S100-A14,S100A14,Skin dermis,Homo sapiens,2,years,8.62729004060374,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9HCY8,Protein S100-A14,S100A14,Skin dermis,Homo sapiens,14,years,10.5229587599865,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9HCY8,Protein S100-A14,S100A14,Skin dermis,Homo sapiens,14,years,9.206041640798,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9HCY8,Protein S100-A14,S100A14,Skin dermis,Homo sapiens,14,years,11.76297272843,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9HCY8,Protein S100-A14,S100A14,Skin dermis,Homo sapiens,65,years,9.49260785305865,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9HCY8,Protein S100-A14,S100A14,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9HCY8,Protein S100-A14,S100A14,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A14,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q7Z7G0,Target of Nesh-SH3 {ECO:0000305},ABI3BP,Skin dermis,Homo sapiens,2,years,8.58010612373328,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ABI3BP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z7G0,Target of Nesh-SH3 {ECO:0000305},ABI3BP,Skin dermis,Homo sapiens,2,years,6.71467974527149,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ABI3BP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z7G0,Target of Nesh-SH3 {ECO:0000305},ABI3BP,Skin dermis,Homo sapiens,14,years,12.3265686547535,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ABI3BP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z7G0,Target of Nesh-SH3 {ECO:0000305},ABI3BP,Skin dermis,Homo sapiens,14,years,13.1680075263322,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ABI3BP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z7G0,Target of Nesh-SH3 {ECO:0000305},ABI3BP,Skin dermis,Homo sapiens,14,years,12.7909183503468,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ABI3BP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z7G0,Target of Nesh-SH3 {ECO:0000305},ABI3BP,Skin dermis,Homo sapiens,65,years,9.33517904791253,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ABI3BP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z7G0,Target of Nesh-SH3 {ECO:0000305},ABI3BP,Skin dermis,Homo sapiens,65,years,10.6985994666982,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ABI3BP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z7G0,Target of Nesh-SH3 {ECO:0000305},ABI3BP,Skin dermis,Homo sapiens,65,years,10.0289206240776,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ABI3BP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P36952,Serpin B5,SERPINB5,Skin dermis,Homo sapiens,2,years,11.2514108645172,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36952,Serpin B5,SERPINB5,Skin dermis,Homo sapiens,2,years,11.172634882983,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36952,Serpin B5,SERPINB5,Skin dermis,Homo sapiens,14,years,12.1850563031052,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36952,Serpin B5,SERPINB5,Skin dermis,Homo sapiens,14,years,11.8324174186685,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36952,Serpin B5,SERPINB5,Skin dermis,Homo sapiens,14,years,12.0338807018638,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36952,Serpin B5,SERPINB5,Skin dermis,Homo sapiens,65,years,10.381910368971,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36952,Serpin B5,SERPINB5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36952,Serpin B5,SERPINB5,Skin dermis,Homo sapiens,65,years,11.0985876697153,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXN1,Asporin,ASPN,Skin dermis,Homo sapiens,2,years,12.8320194962336,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ASPN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXN1,Asporin,ASPN,Skin dermis,Homo sapiens,2,years,11.9871689074243,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ASPN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXN1,Asporin,ASPN,Skin dermis,Homo sapiens,14,years,14.4057251628891,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ASPN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXN1,Asporin,ASPN,Skin dermis,Homo sapiens,14,years,14.6586128137954,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ASPN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXN1,Asporin,ASPN,Skin dermis,Homo sapiens,14,years,14.5648267893113,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ASPN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXN1,Asporin,ASPN,Skin dermis,Homo sapiens,65,years,10.9868850654858,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ASPN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXN1,Asporin,ASPN,Skin dermis,Homo sapiens,65,years,13.8223438403906,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ASPN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXN1,Asporin,ASPN,Skin dermis,Homo sapiens,65,years,14.9884856979392,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ASPN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P47929,Galectin-7,LGALS7,Skin dermis,Homo sapiens,2,years,13.3143661408792,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P47929,Galectin-7,LGALS7,Skin dermis,Homo sapiens,2,years,13.9437684601075,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P47929,Galectin-7,LGALS7,Skin dermis,Homo sapiens,14,years,15.4637825824687,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P47929,Galectin-7,LGALS7,Skin dermis,Homo sapiens,14,years,16.2276609570085,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P47929,Galectin-7,LGALS7,Skin dermis,Homo sapiens,14,years,16.5973784667931,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P47929,Galectin-7,LGALS7,Skin dermis,Homo sapiens,65,years,15.0290388565717,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P47929,Galectin-7,LGALS7,Skin dermis,Homo sapiens,65,years,8.46515859926548,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P47929,Galectin-7,LGALS7,Skin dermis,Homo sapiens,65,years,13.6311889912023,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P51884,Lumican,LUM,Skin dermis,Homo sapiens,2,years,16.0731209902209,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LUM,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51884,Lumican,LUM,Skin dermis,Homo sapiens,2,years,16.2600254427096,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LUM,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51884,Lumican,LUM,Skin dermis,Homo sapiens,14,years,18.2115276070513,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LUM,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51884,Lumican,LUM,Skin dermis,Homo sapiens,14,years,17.7994779326943,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LUM,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51884,Lumican,LUM,Skin dermis,Homo sapiens,14,years,18.2809613768997,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LUM,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51884,Lumican,LUM,Skin dermis,Homo sapiens,65,years,15.7427141805525,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LUM,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51884,Lumican,LUM,Skin dermis,Homo sapiens,65,years,14.6902910210601,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LUM,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51884,Lumican,LUM,Skin dermis,Homo sapiens,65,years,17.6314119399893,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LUM,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P78539,Sushi repeat-containing protein SRPX,SRPX,Skin dermis,Homo sapiens,2,years,8.60710855955832,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P78539,Sushi repeat-containing protein SRPX,SRPX,Skin dermis,Homo sapiens,2,years,8.99660097540331,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P78539,Sushi repeat-containing protein SRPX,SRPX,Skin dermis,Homo sapiens,14,years,10.0781668974566,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P78539,Sushi repeat-containing protein SRPX,SRPX,Skin dermis,Homo sapiens,14,years,11.8074057484586,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P78539,Sushi repeat-containing protein SRPX,SRPX,Skin dermis,Homo sapiens,14,years,11.150111513066,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P78539,Sushi repeat-containing protein SRPX,SRPX,Skin dermis,Homo sapiens,65,years,11.2526849113247,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P78539,Sushi repeat-containing protein SRPX,SRPX,Skin dermis,Homo sapiens,65,years,7.07680534972146,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P78539,Sushi repeat-containing protein SRPX,SRPX,Skin dermis,Homo sapiens,65,years,10.4736521533513,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SRPX,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P22105,Tenascin-X {ECO:0000305},TNXB,Skin dermis,Homo sapiens,2,years,9.85758478014024,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNXB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P22105,Tenascin-X {ECO:0000305},TNXB,Skin dermis,Homo sapiens,2,years,10.5468236400244,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNXB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P22105,Tenascin-X {ECO:0000305},TNXB,Skin dermis,Homo sapiens,14,years,13.1105807312658,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNXB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P22105,Tenascin-X {ECO:0000305},TNXB,Skin dermis,Homo sapiens,14,years,13.5780969288461,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNXB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P22105,Tenascin-X {ECO:0000305},TNXB,Skin dermis,Homo sapiens,14,years,13.3993169314839,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNXB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P22105,Tenascin-X {ECO:0000305},TNXB,Skin dermis,Homo sapiens,65,years,9.81014269286171,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNXB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P22105,Tenascin-X {ECO:0000305},TNXB,Skin dermis,Homo sapiens,65,years,9.51928367696589,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNXB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P22105,Tenascin-X {ECO:0000305},TNXB,Skin dermis,Homo sapiens,65,years,9.35427251128998,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNXB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16787,Laminin subunit alpha-3,LAMA3,Skin dermis,Homo sapiens,2,years,7.5390134781012,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16787,Laminin subunit alpha-3,LAMA3,Skin dermis,Homo sapiens,2,years,8.07132324826545,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16787,Laminin subunit alpha-3,LAMA3,Skin dermis,Homo sapiens,14,years,11.27784626215,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16787,Laminin subunit alpha-3,LAMA3,Skin dermis,Homo sapiens,14,years,11.8543067234277,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16787,Laminin subunit alpha-3,LAMA3,Skin dermis,Homo sapiens,14,years,11.7891640089014,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16787,Laminin subunit alpha-3,LAMA3,Skin dermis,Homo sapiens,65,years,10.5533914040132,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16787,Laminin subunit alpha-3,LAMA3,Skin dermis,Homo sapiens,65,years,5.99149280880848,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16787,Laminin subunit alpha-3,LAMA3,Skin dermis,Homo sapiens,65,years,8.59891773947356,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q08431,Lactadherin,MFGE8,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFGE8,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q08431,Lactadherin,MFGE8,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFGE8,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q08431,Lactadherin,MFGE8,Skin dermis,Homo sapiens,14,years,7.9914047327094,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFGE8,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q08431,Lactadherin,MFGE8,Skin dermis,Homo sapiens,14,years,7.98546677494442,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFGE8,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q08431,Lactadherin,MFGE8,Skin dermis,Homo sapiens,14,years,8.43784901127096,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFGE8,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q08431,Lactadherin,MFGE8,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFGE8,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q08431,Lactadherin,MFGE8,Skin dermis,Homo sapiens,65,years,5.75285267767595,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFGE8,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q08431,Lactadherin,MFGE8,Skin dermis,Homo sapiens,65,years,8.62157209403933,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFGE8,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P60903,Protein S100-A10,S100A10,Skin dermis,Homo sapiens,2,years,13.0974362775236,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A10,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P60903,Protein S100-A10,S100A10,Skin dermis,Homo sapiens,2,years,11.9019071074962,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A10,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P60903,Protein S100-A10,S100A10,Skin dermis,Homo sapiens,14,years,15.4891473307773,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A10,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P60903,Protein S100-A10,S100A10,Skin dermis,Homo sapiens,14,years,15.8889528662346,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A10,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P60903,Protein S100-A10,S100A10,Skin dermis,Homo sapiens,14,years,15.6597409051218,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A10,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P60903,Protein S100-A10,S100A10,Skin dermis,Homo sapiens,65,years,12.7925583804901,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A10,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P60903,Protein S100-A10,S100A10,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A10,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P60903,Protein S100-A10,S100A10,Skin dermis,Homo sapiens,65,years,13.0107756969161,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A10,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UMD9,Collagen alpha-1(XVII) chain,COL17A1,Skin dermis,Homo sapiens,2,years,8.34807635772608,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL17A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UMD9,Collagen alpha-1(XVII) chain,COL17A1,Skin dermis,Homo sapiens,2,years,7.51779767444262,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL17A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UMD9,Collagen alpha-1(XVII) chain,COL17A1,Skin dermis,Homo sapiens,14,years,8.93736433529452,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL17A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UMD9,Collagen alpha-1(XVII) chain,COL17A1,Skin dermis,Homo sapiens,14,years,10.7692419943863,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL17A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UMD9,Collagen alpha-1(XVII) chain,COL17A1,Skin dermis,Homo sapiens,14,years,10.9452189087068,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL17A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UMD9,Collagen alpha-1(XVII) chain,COL17A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL17A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UMD9,Collagen alpha-1(XVII) chain,COL17A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL17A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UMD9,Collagen alpha-1(XVII) chain,COL17A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL17A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q13751,Laminin subunit beta-3,LAMB3,Skin dermis,Homo sapiens,2,years,9.11165719821136,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13751,Laminin subunit beta-3,LAMB3,Skin dermis,Homo sapiens,2,years,10.9843326649978,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13751,Laminin subunit beta-3,LAMB3,Skin dermis,Homo sapiens,14,years,13.0570042360775,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13751,Laminin subunit beta-3,LAMB3,Skin dermis,Homo sapiens,14,years,13.5700678256073,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13751,Laminin subunit beta-3,LAMB3,Skin dermis,Homo sapiens,14,years,13.6330591367785,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13751,Laminin subunit beta-3,LAMB3,Skin dermis,Homo sapiens,65,years,9.03443073604079,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13751,Laminin subunit beta-3,LAMB3,Skin dermis,Homo sapiens,65,years,7.01518088094937,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13751,Laminin subunit beta-3,LAMB3,Skin dermis,Homo sapiens,65,years,9.44545464556488,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q08188,Protein-glutamine gamma-glutamyltransferase E,TGM3,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08188,Protein-glutamine gamma-glutamyltransferase E,TGM3,Skin dermis,Homo sapiens,2,years,5.01188266950067,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08188,Protein-glutamine gamma-glutamyltransferase E,TGM3,Skin dermis,Homo sapiens,14,years,9.00101642451753,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08188,Protein-glutamine gamma-glutamyltransferase E,TGM3,Skin dermis,Homo sapiens,14,years,9.01599237027006,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08188,Protein-glutamine gamma-glutamyltransferase E,TGM3,Skin dermis,Homo sapiens,14,years,9.91027452738646,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08188,Protein-glutamine gamma-glutamyltransferase E,TGM3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08188,Protein-glutamine gamma-glutamyltransferase E,TGM3,Skin dermis,Homo sapiens,65,years,7.41936125559823,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08188,Protein-glutamine gamma-glutamyltransferase E,TGM3,Skin dermis,Homo sapiens,65,years,8.57398186264079,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96P63,Serpin B12,SERPINB12,Skin dermis,Homo sapiens,2,years,9.10188280417734,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96P63,Serpin B12,SERPINB12,Skin dermis,Homo sapiens,2,years,8.99085157783411,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96P63,Serpin B12,SERPINB12,Skin dermis,Homo sapiens,14,years,9.59507032991245,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96P63,Serpin B12,SERPINB12,Skin dermis,Homo sapiens,14,years,10.203501684084,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96P63,Serpin B12,SERPINB12,Skin dermis,Homo sapiens,14,years,10.5514350219431,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96P63,Serpin B12,SERPINB12,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96P63,Serpin B12,SERPINB12,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96P63,Serpin B12,SERPINB12,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q06828,Fibromodulin,FMOD,Skin dermis,Homo sapiens,2,years,12.0104070711652,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FMOD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q06828,Fibromodulin,FMOD,Skin dermis,Homo sapiens,2,years,11.5521333735986,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FMOD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q06828,Fibromodulin,FMOD,Skin dermis,Homo sapiens,14,years,13.0940481501472,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FMOD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q06828,Fibromodulin,FMOD,Skin dermis,Homo sapiens,14,years,12.9797757602627,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FMOD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q06828,Fibromodulin,FMOD,Skin dermis,Homo sapiens,14,years,13.118595735688,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FMOD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q06828,Fibromodulin,FMOD,Skin dermis,Homo sapiens,65,years,12.2140581096635,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FMOD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q06828,Fibromodulin,FMOD,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FMOD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q06828,Fibromodulin,FMOD,Skin dermis,Homo sapiens,65,years,10.2384032637939,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FMOD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P08253,"72 kDa type IV collagenase {ECO:0000303|PubMed:2162831, ECO:0000303|PubMed:2834383}",MMP2,Skin dermis,Homo sapiens,2,years,6.58038771547191,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08253,"72 kDa type IV collagenase {ECO:0000303|PubMed:2162831, ECO:0000303|PubMed:2834383}",MMP2,Skin dermis,Homo sapiens,2,years,8.15004092715705,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08253,"72 kDa type IV collagenase {ECO:0000303|PubMed:2162831, ECO:0000303|PubMed:2834383}",MMP2,Skin dermis,Homo sapiens,14,years,9.21660197676454,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08253,"72 kDa type IV collagenase {ECO:0000303|PubMed:2162831, ECO:0000303|PubMed:2834383}",MMP2,Skin dermis,Homo sapiens,14,years,9.89491122627254,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08253,"72 kDa type IV collagenase {ECO:0000303|PubMed:2162831, ECO:0000303|PubMed:2834383}",MMP2,Skin dermis,Homo sapiens,14,years,9.21725766100564,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08253,"72 kDa type IV collagenase {ECO:0000303|PubMed:2162831, ECO:0000303|PubMed:2834383}",MMP2,Skin dermis,Homo sapiens,65,years,8.39084235674408,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08253,"72 kDa type IV collagenase {ECO:0000303|PubMed:2162831, ECO:0000303|PubMed:2834383}",MMP2,Skin dermis,Homo sapiens,65,years,6.58584285734319,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08253,"72 kDa type IV collagenase {ECO:0000303|PubMed:2162831, ECO:0000303|PubMed:2834383}",MMP2,Skin dermis,Homo sapiens,65,years,7.08052581565176,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P55083,Microfibril-associated glycoprotein 4,MFAP4,Skin dermis,Homo sapiens,2,years,14.5037294095222,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55083,Microfibril-associated glycoprotein 4,MFAP4,Skin dermis,Homo sapiens,2,years,14.3924602392995,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55083,Microfibril-associated glycoprotein 4,MFAP4,Skin dermis,Homo sapiens,14,years,18.4525074368017,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55083,Microfibril-associated glycoprotein 4,MFAP4,Skin dermis,Homo sapiens,14,years,18.8103430315382,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55083,Microfibril-associated glycoprotein 4,MFAP4,Skin dermis,Homo sapiens,14,years,18.0447658353342,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55083,Microfibril-associated glycoprotein 4,MFAP4,Skin dermis,Homo sapiens,65,years,20.4921127555647,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55083,Microfibril-associated glycoprotein 4,MFAP4,Skin dermis,Homo sapiens,65,years,16.0820663002597,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55083,Microfibril-associated glycoprotein 4,MFAP4,Skin dermis,Homo sapiens,65,years,13.7137691873968,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O94769,Extracellular matrix protein 2,ECM2,Skin dermis,Homo sapiens,2,years,7.56080739646943,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O94769,Extracellular matrix protein 2,ECM2,Skin dermis,Homo sapiens,2,years,7.64259035396233,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O94769,Extracellular matrix protein 2,ECM2,Skin dermis,Homo sapiens,14,years,7.09127449049643,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O94769,Extracellular matrix protein 2,ECM2,Skin dermis,Homo sapiens,14,years,8.52045546116449,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O94769,Extracellular matrix protein 2,ECM2,Skin dermis,Homo sapiens,14,years,8.32323530967956,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O94769,Extracellular matrix protein 2,ECM2,Skin dermis,Homo sapiens,65,years,8.18941376584712,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O94769,Extracellular matrix protein 2,ECM2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O94769,Extracellular matrix protein 2,ECM2,Skin dermis,Homo sapiens,65,years,6.13593230723465,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
A8K2U0,Alpha-2-macroglobulin-like protein 1,A2ML1,Skin dermis,Homo sapiens,2,years,6.51008084332863,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2ML1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
A8K2U0,Alpha-2-macroglobulin-like protein 1,A2ML1,Skin dermis,Homo sapiens,2,years,7.11903332648067,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2ML1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
A8K2U0,Alpha-2-macroglobulin-like protein 1,A2ML1,Skin dermis,Homo sapiens,14,years,8.71976760852708,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2ML1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
A8K2U0,Alpha-2-macroglobulin-like protein 1,A2ML1,Skin dermis,Homo sapiens,14,years,7.01664843019269,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2ML1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
A8K2U0,Alpha-2-macroglobulin-like protein 1,A2ML1,Skin dermis,Homo sapiens,14,years,9.3178913459915,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2ML1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
A8K2U0,Alpha-2-macroglobulin-like protein 1,A2ML1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2ML1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
A8K2U0,Alpha-2-macroglobulin-like protein 1,A2ML1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2ML1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
A8K2U0,Alpha-2-macroglobulin-like protein 1,A2ML1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2ML1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q15063,Periostin,POSTN,Skin dermis,Homo sapiens,2,years,15.0047513609543,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",POSTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15063,Periostin,POSTN,Skin dermis,Homo sapiens,2,years,15.5966085883975,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",POSTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15063,Periostin,POSTN,Skin dermis,Homo sapiens,14,years,17.8819843835915,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",POSTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15063,Periostin,POSTN,Skin dermis,Homo sapiens,14,years,17.8294947528978,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",POSTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15063,Periostin,POSTN,Skin dermis,Homo sapiens,14,years,18.0771712669464,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",POSTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15063,Periostin,POSTN,Skin dermis,Homo sapiens,65,years,13.5346368980499,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",POSTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15063,Periostin,POSTN,Skin dermis,Homo sapiens,65,years,12.6810575603804,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",POSTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15063,Periostin,POSTN,Skin dermis,Homo sapiens,65,years,15.2888967971046,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",POSTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13361,Microfibrillar-associated protein 5,MFAP5,Skin dermis,Homo sapiens,2,years,13.8745423605175,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13361,Microfibrillar-associated protein 5,MFAP5,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13361,Microfibrillar-associated protein 5,MFAP5,Skin dermis,Homo sapiens,14,years,16.2602591616653,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13361,Microfibrillar-associated protein 5,MFAP5,Skin dermis,Homo sapiens,14,years,16.6907337765281,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13361,Microfibrillar-associated protein 5,MFAP5,Skin dermis,Homo sapiens,14,years,16.0979293686512,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13361,Microfibrillar-associated protein 5,MFAP5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13361,Microfibrillar-associated protein 5,MFAP5,Skin dermis,Homo sapiens,65,years,14.7759074664347,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13361,Microfibrillar-associated protein 5,MFAP5,Skin dermis,Homo sapiens,65,years,13.2399384596867,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P17931,Galectin-3,LGALS3,Skin dermis,Homo sapiens,2,years,10.3784961497106,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P17931,Galectin-3,LGALS3,Skin dermis,Homo sapiens,2,years,11.2938244647683,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P17931,Galectin-3,LGALS3,Skin dermis,Homo sapiens,14,years,12.2859701046479,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P17931,Galectin-3,LGALS3,Skin dermis,Homo sapiens,14,years,13.0218309337999,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P17931,Galectin-3,LGALS3,Skin dermis,Homo sapiens,14,years,13.0206985170801,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P17931,Galectin-3,LGALS3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P17931,Galectin-3,LGALS3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P17931,Galectin-3,LGALS3,Skin dermis,Homo sapiens,65,years,9.20436408960516,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS3,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q02388,Collagen alpha-1(VII) chain,COL7A1,Skin dermis,Homo sapiens,2,years,11.9906798489258,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL7A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q02388,Collagen alpha-1(VII) chain,COL7A1,Skin dermis,Homo sapiens,2,years,13.5464549135391,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL7A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q02388,Collagen alpha-1(VII) chain,COL7A1,Skin dermis,Homo sapiens,14,years,15.3966683866102,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL7A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q02388,Collagen alpha-1(VII) chain,COL7A1,Skin dermis,Homo sapiens,14,years,15.9976312389285,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL7A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q02388,Collagen alpha-1(VII) chain,COL7A1,Skin dermis,Homo sapiens,14,years,15.5128719631482,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL7A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q02388,Collagen alpha-1(VII) chain,COL7A1,Skin dermis,Homo sapiens,65,years,10.057694489056,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL7A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q02388,Collagen alpha-1(VII) chain,COL7A1,Skin dermis,Homo sapiens,65,years,10.8236048416847,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL7A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q02388,Collagen alpha-1(VII) chain,COL7A1,Skin dermis,Homo sapiens,65,years,12.8927624487667,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL7A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q99983,Osteomodulin,OMD,Skin dermis,Homo sapiens,2,years,5.10275121414653,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OMD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q99983,Osteomodulin,OMD,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OMD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q99983,Osteomodulin,OMD,Skin dermis,Homo sapiens,14,years,9.57916511165179,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OMD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q99983,Osteomodulin,OMD,Skin dermis,Homo sapiens,14,years,9.34688647149097,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OMD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q99983,Osteomodulin,OMD,Skin dermis,Homo sapiens,14,years,8.86958510844039,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OMD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q99983,Osteomodulin,OMD,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OMD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q99983,Osteomodulin,OMD,Skin dermis,Homo sapiens,65,years,7.7183702426227,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OMD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q99983,Osteomodulin,OMD,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OMD,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q13753,Laminin subunit gamma-2,LAMC2,Skin dermis,Homo sapiens,2,years,7.77702698009822,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13753,Laminin subunit gamma-2,LAMC2,Skin dermis,Homo sapiens,2,years,7.58384451484562,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13753,Laminin subunit gamma-2,LAMC2,Skin dermis,Homo sapiens,14,years,12.1988841569605,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13753,Laminin subunit gamma-2,LAMC2,Skin dermis,Homo sapiens,14,years,12.6870357568686,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13753,Laminin subunit gamma-2,LAMC2,Skin dermis,Homo sapiens,14,years,12.7290603570214,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13753,Laminin subunit gamma-2,LAMC2,Skin dermis,Homo sapiens,65,years,4.94817766834766,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13753,Laminin subunit gamma-2,LAMC2,Skin dermis,Homo sapiens,65,years,4.13293607254733,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13753,Laminin subunit gamma-2,LAMC2,Skin dermis,Homo sapiens,65,years,8.05449707434541,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00339,Matrilin-2,MATN2,Skin dermis,Homo sapiens,2,years,8.70212926773018,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00339,Matrilin-2,MATN2,Skin dermis,Homo sapiens,2,years,9.09713170750574,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00339,Matrilin-2,MATN2,Skin dermis,Homo sapiens,14,years,11.2403892909548,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00339,Matrilin-2,MATN2,Skin dermis,Homo sapiens,14,years,11.3217140544083,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00339,Matrilin-2,MATN2,Skin dermis,Homo sapiens,14,years,10.9776213810041,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00339,Matrilin-2,MATN2,Skin dermis,Homo sapiens,65,years,8.18646396064656,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00339,Matrilin-2,MATN2,Skin dermis,Homo sapiens,65,years,3.48749571425835,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00339,Matrilin-2,MATN2,Skin dermis,Homo sapiens,65,years,11.0108563462182,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9Y240,C-type lectin domain family 11 member A,CLEC11A,Skin dermis,Homo sapiens,2,years,5.39491329565542,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CLEC11A,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9Y240,C-type lectin domain family 11 member A,CLEC11A,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CLEC11A,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9Y240,C-type lectin domain family 11 member A,CLEC11A,Skin dermis,Homo sapiens,14,years,4.93139037130591,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CLEC11A,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9Y240,C-type lectin domain family 11 member A,CLEC11A,Skin dermis,Homo sapiens,14,years,5.75379921080943,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CLEC11A,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9Y240,C-type lectin domain family 11 member A,CLEC11A,Skin dermis,Homo sapiens,14,years,6.6109951714443,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CLEC11A,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9Y240,C-type lectin domain family 11 member A,CLEC11A,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CLEC11A,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9Y240,C-type lectin domain family 11 member A,CLEC11A,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CLEC11A,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9Y240,C-type lectin domain family 11 member A,CLEC11A,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CLEC11A,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P24043,Laminin subunit alpha-2,LAMA2,Skin dermis,Homo sapiens,2,years,5.67311494632524,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24043,Laminin subunit alpha-2,LAMA2,Skin dermis,Homo sapiens,2,years,4.37657837867135,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24043,Laminin subunit alpha-2,LAMA2,Skin dermis,Homo sapiens,14,years,7.50996141945766,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24043,Laminin subunit alpha-2,LAMA2,Skin dermis,Homo sapiens,14,years,7.29209162271757,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24043,Laminin subunit alpha-2,LAMA2,Skin dermis,Homo sapiens,14,years,7.3220710410798,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24043,Laminin subunit alpha-2,LAMA2,Skin dermis,Homo sapiens,65,years,5.83313163020153,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24043,Laminin subunit alpha-2,LAMA2,Skin dermis,Homo sapiens,65,years,4.80460753322936,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24043,Laminin subunit alpha-2,LAMA2,Skin dermis,Homo sapiens,65,years,6.66549651315453,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P21810,Biglycan,BGN,Skin dermis,Homo sapiens,2,years,13.480511628642,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",BGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P21810,Biglycan,BGN,Skin dermis,Homo sapiens,2,years,13.3125163831796,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",BGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P21810,Biglycan,BGN,Skin dermis,Homo sapiens,14,years,16.2181519332259,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",BGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P21810,Biglycan,BGN,Skin dermis,Homo sapiens,14,years,15.75298812079,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",BGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P21810,Biglycan,BGN,Skin dermis,Homo sapiens,14,years,16.1829375662494,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",BGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P21810,Biglycan,BGN,Skin dermis,Homo sapiens,65,years,15.1118116524722,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",BGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P21810,Biglycan,BGN,Skin dermis,Homo sapiens,65,years,15.2375870129239,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",BGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P21810,Biglycan,BGN,Skin dermis,Homo sapiens,65,years,16.7764183700013,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",BGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q15582,Transforming growth factor-beta-induced protein ig-h3,TGFBI,Skin dermis,Homo sapiens,2,years,13.6222064546135,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFBI,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15582,Transforming growth factor-beta-induced protein ig-h3,TGFBI,Skin dermis,Homo sapiens,2,years,13.3786635985509,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFBI,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15582,Transforming growth factor-beta-induced protein ig-h3,TGFBI,Skin dermis,Homo sapiens,14,years,15.9703524509692,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFBI,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15582,Transforming growth factor-beta-induced protein ig-h3,TGFBI,Skin dermis,Homo sapiens,14,years,16.3008377431784,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFBI,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15582,Transforming growth factor-beta-induced protein ig-h3,TGFBI,Skin dermis,Homo sapiens,14,years,16.2410985975115,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFBI,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15582,Transforming growth factor-beta-induced protein ig-h3,TGFBI,Skin dermis,Homo sapiens,65,years,13.004467329605,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFBI,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15582,Transforming growth factor-beta-induced protein ig-h3,TGFBI,Skin dermis,Homo sapiens,65,years,14.2392313442498,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFBI,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15582,Transforming growth factor-beta-induced protein ig-h3,TGFBI,Skin dermis,Homo sapiens,65,years,13.6008906854028,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFBI,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P05120,Plasminogen activator inhibitor 2,SERPINB2,Skin dermis,Homo sapiens,2,years,6.60337236269586,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05120,Plasminogen activator inhibitor 2,SERPINB2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05120,Plasminogen activator inhibitor 2,SERPINB2,Skin dermis,Homo sapiens,14,years,7.89767078268059,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05120,Plasminogen activator inhibitor 2,SERPINB2,Skin dermis,Homo sapiens,14,years,8.13358512678706,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05120,Plasminogen activator inhibitor 2,SERPINB2,Skin dermis,Homo sapiens,14,years,9.23599759053951,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05120,Plasminogen activator inhibitor 2,SERPINB2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05120,Plasminogen activator inhibitor 2,SERPINB2,Skin dermis,Homo sapiens,65,years,8.9885433699738,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05120,Plasminogen activator inhibitor 2,SERPINB2,Skin dermis,Homo sapiens,65,years,7.32253042849638,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00488,Coagulation factor XIII A chain,F13A1,Skin dermis,Homo sapiens,2,years,12.3673786797144,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F13A1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00488,Coagulation factor XIII A chain,F13A1,Skin dermis,Homo sapiens,2,years,12.2632825447731,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F13A1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00488,Coagulation factor XIII A chain,F13A1,Skin dermis,Homo sapiens,14,years,15.0487999353862,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F13A1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00488,Coagulation factor XIII A chain,F13A1,Skin dermis,Homo sapiens,14,years,15.4203223107508,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F13A1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00488,Coagulation factor XIII A chain,F13A1,Skin dermis,Homo sapiens,14,years,15.3191553839157,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F13A1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00488,Coagulation factor XIII A chain,F13A1,Skin dermis,Homo sapiens,65,years,10.9575233292297,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F13A1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00488,Coagulation factor XIII A chain,F13A1,Skin dermis,Homo sapiens,65,years,8.58961177669406,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F13A1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00488,Coagulation factor XIII A chain,F13A1,Skin dermis,Homo sapiens,65,years,12.2151281084995,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F13A1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6PCB0,von Willebrand factor A domain-containing protein 1 {ECO:0000305},VWA1,Skin dermis,Homo sapiens,2,years,7.78368027791943,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6PCB0,von Willebrand factor A domain-containing protein 1 {ECO:0000305},VWA1,Skin dermis,Homo sapiens,2,years,9.57861951461848,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6PCB0,von Willebrand factor A domain-containing protein 1 {ECO:0000305},VWA1,Skin dermis,Homo sapiens,14,years,11.452316695721,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6PCB0,von Willebrand factor A domain-containing protein 1 {ECO:0000305},VWA1,Skin dermis,Homo sapiens,14,years,10.5927288498134,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6PCB0,von Willebrand factor A domain-containing protein 1 {ECO:0000305},VWA1,Skin dermis,Homo sapiens,14,years,11.2036058001715,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6PCB0,von Willebrand factor A domain-containing protein 1 {ECO:0000305},VWA1,Skin dermis,Homo sapiens,65,years,8.36775030781937,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6PCB0,von Willebrand factor A domain-containing protein 1 {ECO:0000305},VWA1,Skin dermis,Homo sapiens,65,years,7.24540549464824,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6PCB0,von Willebrand factor A domain-containing protein 1 {ECO:0000305},VWA1,Skin dermis,Homo sapiens,65,years,8.13673665652315,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P09382,Galectin-1,LGALS1,Skin dermis,Homo sapiens,2,years,13.4291252140651,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09382,Galectin-1,LGALS1,Skin dermis,Homo sapiens,2,years,10.7406138028817,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09382,Galectin-1,LGALS1,Skin dermis,Homo sapiens,14,years,14.2173517858026,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09382,Galectin-1,LGALS1,Skin dermis,Homo sapiens,14,years,15.160087863036,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09382,Galectin-1,LGALS1,Skin dermis,Homo sapiens,14,years,14.1228802810539,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09382,Galectin-1,LGALS1,Skin dermis,Homo sapiens,65,years,9.36183903362434,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09382,Galectin-1,LGALS1,Skin dermis,Homo sapiens,65,years,9.9722721083953,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P09382,Galectin-1,LGALS1,Skin dermis,Homo sapiens,65,years,10.5380806360622,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LGALS1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96FQ6,Protein S100-A16,S100A16,Skin dermis,Homo sapiens,2,years,10.2716054127855,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A16,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96FQ6,Protein S100-A16,S100A16,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A16,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96FQ6,Protein S100-A16,S100A16,Skin dermis,Homo sapiens,14,years,9.17185234299805,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A16,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96FQ6,Protein S100-A16,S100A16,Skin dermis,Homo sapiens,14,years,9.94143298864853,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A16,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96FQ6,Protein S100-A16,S100A16,Skin dermis,Homo sapiens,14,years,12.2969503818462,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A16,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96FQ6,Protein S100-A16,S100A16,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A16,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96FQ6,Protein S100-A16,S100A16,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A16,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96FQ6,Protein S100-A16,S100A16,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A16,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35237,Serpin B6,SERPINB6,Skin dermis,Homo sapiens,2,years,10.2186419815747,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35237,Serpin B6,SERPINB6,Skin dermis,Homo sapiens,2,years,10.3574253036985,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35237,Serpin B6,SERPINB6,Skin dermis,Homo sapiens,14,years,11.4163079098208,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35237,Serpin B6,SERPINB6,Skin dermis,Homo sapiens,14,years,11.6332090699958,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35237,Serpin B6,SERPINB6,Skin dermis,Homo sapiens,14,years,11.1858478147888,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35237,Serpin B6,SERPINB6,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35237,Serpin B6,SERPINB6,Skin dermis,Homo sapiens,65,years,6.572912650564,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35237,Serpin B6,SERPINB6,Skin dermis,Homo sapiens,65,years,9.47550006825915,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9NR99,Matrix-remodeling-associated protein 5,MXRA5,Skin dermis,Homo sapiens,2,years,2.69229920627999,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MXRA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NR99,Matrix-remodeling-associated protein 5,MXRA5,Skin dermis,Homo sapiens,2,years,4.4329634917529,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MXRA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NR99,Matrix-remodeling-associated protein 5,MXRA5,Skin dermis,Homo sapiens,14,years,6.5272787534022,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MXRA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NR99,Matrix-remodeling-associated protein 5,MXRA5,Skin dermis,Homo sapiens,14,years,5.73853442409697,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MXRA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NR99,Matrix-remodeling-associated protein 5,MXRA5,Skin dermis,Homo sapiens,14,years,4.59878613947019,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MXRA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NR99,Matrix-remodeling-associated protein 5,MXRA5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MXRA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NR99,Matrix-remodeling-associated protein 5,MXRA5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MXRA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9NR99,Matrix-remodeling-associated protein 5,MXRA5,Skin dermis,Homo sapiens,65,years,1.4136423316468,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MXRA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IUX7,Adipocyte enhancer-binding protein 1,AEBP1,Skin dermis,Homo sapiens,2,years,10.0028674390028,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AEBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IUX7,Adipocyte enhancer-binding protein 1,AEBP1,Skin dermis,Homo sapiens,2,years,10.8073805011047,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AEBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IUX7,Adipocyte enhancer-binding protein 1,AEBP1,Skin dermis,Homo sapiens,14,years,11.3711185176364,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AEBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IUX7,Adipocyte enhancer-binding protein 1,AEBP1,Skin dermis,Homo sapiens,14,years,11.4209829532147,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AEBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IUX7,Adipocyte enhancer-binding protein 1,AEBP1,Skin dermis,Homo sapiens,14,years,11.0237069999647,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AEBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IUX7,Adipocyte enhancer-binding protein 1,AEBP1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AEBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IUX7,Adipocyte enhancer-binding protein 1,AEBP1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AEBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IUX7,Adipocyte enhancer-binding protein 1,AEBP1,Skin dermis,Homo sapiens,65,years,7.09220801731893,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AEBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P19827,Inter-alpha-trypsin inhibitor heavy chain H1,ITIH1,Skin dermis,Homo sapiens,2,years,12.2425893389254,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19827,Inter-alpha-trypsin inhibitor heavy chain H1,ITIH1,Skin dermis,Homo sapiens,2,years,12.4188008242952,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19827,Inter-alpha-trypsin inhibitor heavy chain H1,ITIH1,Skin dermis,Homo sapiens,14,years,12.3398993483352,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19827,Inter-alpha-trypsin inhibitor heavy chain H1,ITIH1,Skin dermis,Homo sapiens,14,years,12.9089843736189,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19827,Inter-alpha-trypsin inhibitor heavy chain H1,ITIH1,Skin dermis,Homo sapiens,14,years,13.160491463701,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19827,Inter-alpha-trypsin inhibitor heavy chain H1,ITIH1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19827,Inter-alpha-trypsin inhibitor heavy chain H1,ITIH1,Skin dermis,Homo sapiens,65,years,8.13465103061063,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P19827,Inter-alpha-trypsin inhibitor heavy chain H1,ITIH1,Skin dermis,Homo sapiens,65,years,11.7768037566848,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q05707,Collagen alpha-1(XIV) chain,COL14A1,Skin dermis,Homo sapiens,2,years,14.0558440750653,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL14A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q05707,Collagen alpha-1(XIV) chain,COL14A1,Skin dermis,Homo sapiens,2,years,14.856958593819,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL14A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q05707,Collagen alpha-1(XIV) chain,COL14A1,Skin dermis,Homo sapiens,14,years,14.4521508134105,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL14A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q05707,Collagen alpha-1(XIV) chain,COL14A1,Skin dermis,Homo sapiens,14,years,15.4687191353099,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL14A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q05707,Collagen alpha-1(XIV) chain,COL14A1,Skin dermis,Homo sapiens,14,years,14.4650125126789,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL14A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q05707,Collagen alpha-1(XIV) chain,COL14A1,Skin dermis,Homo sapiens,65,years,11.5270127555002,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL14A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q05707,Collagen alpha-1(XIV) chain,COL14A1,Skin dermis,Homo sapiens,65,years,12.6215462010173,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL14A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q05707,Collagen alpha-1(XIV) chain,COL14A1,Skin dermis,Homo sapiens,65,years,13.697150934688,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL14A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02461,Collagen alpha-1(III) chain,COL3A1,Skin dermis,Homo sapiens,2,years,15.6743685745296,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL3A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02461,Collagen alpha-1(III) chain,COL3A1,Skin dermis,Homo sapiens,2,years,12.2179265004285,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL3A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02461,Collagen alpha-1(III) chain,COL3A1,Skin dermis,Homo sapiens,14,years,16.2715370942107,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL3A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02461,Collagen alpha-1(III) chain,COL3A1,Skin dermis,Homo sapiens,14,years,16.7509511508443,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL3A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02461,Collagen alpha-1(III) chain,COL3A1,Skin dermis,Homo sapiens,14,years,15.5174203650741,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL3A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02461,Collagen alpha-1(III) chain,COL3A1,Skin dermis,Homo sapiens,65,years,15.9712681712452,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL3A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02461,Collagen alpha-1(III) chain,COL3A1,Skin dermis,Homo sapiens,65,years,17.0883519406413,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL3A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02461,Collagen alpha-1(III) chain,COL3A1,Skin dermis,Homo sapiens,65,years,14.2853007541978,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL3A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P14543,Nidogen-1,NID1,Skin dermis,Homo sapiens,2,years,10.088864225358,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P14543,Nidogen-1,NID1,Skin dermis,Homo sapiens,2,years,10.8950553972873,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P14543,Nidogen-1,NID1,Skin dermis,Homo sapiens,14,years,12.1195496686943,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P14543,Nidogen-1,NID1,Skin dermis,Homo sapiens,14,years,12.2543907187637,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P14543,Nidogen-1,NID1,Skin dermis,Homo sapiens,14,years,11.7547777580844,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P14543,Nidogen-1,NID1,Skin dermis,Homo sapiens,65,years,10.7437127715213,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P14543,Nidogen-1,NID1,Skin dermis,Homo sapiens,65,years,10.9267729770795,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P14543,Nidogen-1,NID1,Skin dermis,Homo sapiens,65,years,13.1458356097909,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14314,Fibroleukin,FGL2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGL2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14314,Fibroleukin,FGL2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGL2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14314,Fibroleukin,FGL2,Skin dermis,Homo sapiens,14,years,9.32556930265904,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGL2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14314,Fibroleukin,FGL2,Skin dermis,Homo sapiens,14,years,9.93312711876071,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGL2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14314,Fibroleukin,FGL2,Skin dermis,Homo sapiens,14,years,9.42370356819582,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGL2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14314,Fibroleukin,FGL2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGL2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14314,Fibroleukin,FGL2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGL2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14314,Fibroleukin,FGL2,Skin dermis,Homo sapiens,65,years,7.43029046813661,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGL2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95460,Matrilin-4,MATN4,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95460,Matrilin-4,MATN4,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95460,Matrilin-4,MATN4,Skin dermis,Homo sapiens,14,years,6.34904547449102,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95460,Matrilin-4,MATN4,Skin dermis,Homo sapiens,14,years,4.90649098923715,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95460,Matrilin-4,MATN4,Skin dermis,Homo sapiens,14,years,6.68591930139428,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95460,Matrilin-4,MATN4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95460,Matrilin-4,MATN4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95460,Matrilin-4,MATN4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MATN4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04271,Protein S100-B,S100B,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100B,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04271,Protein S100-B,S100B,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100B,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04271,Protein S100-B,S100B,Skin dermis,Homo sapiens,14,years,11.3965821860879,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100B,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04271,Protein S100-B,S100B,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100B,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04271,Protein S100-B,S100B,Skin dermis,Homo sapiens,14,years,10.1385446398413,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100B,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04271,Protein S100-B,S100B,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100B,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04271,Protein S100-B,S100B,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100B,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04271,Protein S100-B,S100B,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100B,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08519,Apolipoprotein(a),LPA,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LPA,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08519,Apolipoprotein(a),LPA,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LPA,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08519,Apolipoprotein(a),LPA,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LPA,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08519,Apolipoprotein(a),LPA,Skin dermis,Homo sapiens,14,years,3.82398571420568,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LPA,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08519,Apolipoprotein(a),LPA,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LPA,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08519,Apolipoprotein(a),LPA,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LPA,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08519,Apolipoprotein(a),LPA,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LPA,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08519,Apolipoprotein(a),LPA,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LPA,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86XS5,Angiopoietin-related protein 5,ANGPTL5,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL5,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86XS5,Angiopoietin-related protein 5,ANGPTL5,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL5,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86XS5,Angiopoietin-related protein 5,ANGPTL5,Skin dermis,Homo sapiens,14,years,7.07895094470289,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL5,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86XS5,Angiopoietin-related protein 5,ANGPTL5,Skin dermis,Homo sapiens,14,years,7.10556307668356,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL5,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86XS5,Angiopoietin-related protein 5,ANGPTL5,Skin dermis,Homo sapiens,14,years,6.12115802839665,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL5,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86XS5,Angiopoietin-related protein 5,ANGPTL5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL5,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86XS5,Angiopoietin-related protein 5,ANGPTL5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL5,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86XS5,Angiopoietin-related protein 5,ANGPTL5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL5,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99584,Protein S100-A13,S100A13,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99584,Protein S100-A13,S100A13,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99584,Protein S100-A13,S100A13,Skin dermis,Homo sapiens,14,years,12.4195694674441,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99584,Protein S100-A13,S100A13,Skin dermis,Homo sapiens,14,years,12.4330489528312,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99584,Protein S100-A13,S100A13,Skin dermis,Homo sapiens,14,years,11.6029886667225,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99584,Protein S100-A13,S100A13,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99584,Protein S100-A13,S100A13,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99584,Protein S100-A13,S100A13,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
A4D0S4,Laminin subunit beta-4,LAMB4,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
A4D0S4,Laminin subunit beta-4,LAMB4,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
A4D0S4,Laminin subunit beta-4,LAMB4,Skin dermis,Homo sapiens,14,years,7.78503253196343,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
A4D0S4,Laminin subunit beta-4,LAMB4,Skin dermis,Homo sapiens,14,years,8.299943865477,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
A4D0S4,Laminin subunit beta-4,LAMB4,Skin dermis,Homo sapiens,14,years,7.18768675136115,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
A4D0S4,Laminin subunit beta-4,LAMB4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
A4D0S4,Laminin subunit beta-4,LAMB4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
A4D0S4,Laminin subunit beta-4,LAMB4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IW75,Serpin A12,SERPINA12,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IW75,Serpin A12,SERPINA12,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IW75,Serpin A12,SERPINA12,Skin dermis,Homo sapiens,14,years,6.42928855795821,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IW75,Serpin A12,SERPINA12,Skin dermis,Homo sapiens,14,years,5.40375325613683,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IW75,Serpin A12,SERPINA12,Skin dermis,Homo sapiens,14,years,8.04465555139988,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IW75,Serpin A12,SERPINA12,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IW75,Serpin A12,SERPINA12,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q8IW75,Serpin A12,SERPINA12,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ2,Complement C1q tumor necrosis factor-related protein 7,C1QTNF7,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ2,Complement C1q tumor necrosis factor-related protein 7,C1QTNF7,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ2,Complement C1q tumor necrosis factor-related protein 7,C1QTNF7,Skin dermis,Homo sapiens,14,years,9.16616785621334,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ2,Complement C1q tumor necrosis factor-related protein 7,C1QTNF7,Skin dermis,Homo sapiens,14,years,9.74216746224549,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ2,Complement C1q tumor necrosis factor-related protein 7,C1QTNF7,Skin dermis,Homo sapiens,14,years,10.4387125270995,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ2,Complement C1q tumor necrosis factor-related protein 7,C1QTNF7,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ2,Complement C1q tumor necrosis factor-related protein 7,C1QTNF7,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9BXJ2,Complement C1q tumor necrosis factor-related protein 7,C1QTNF7,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QTNF7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07355,Annexin A2,ANXA2,Skin dermis,Homo sapiens,2,years,16.1045445938124,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07355,Annexin A2,ANXA2,Skin dermis,Homo sapiens,2,years,16.1377254368771,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07355,Annexin A2,ANXA2,Skin dermis,Homo sapiens,14,years,15.8924754188282,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07355,Annexin A2,ANXA2,Skin dermis,Homo sapiens,14,years,17.0246739348447,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07355,Annexin A2,ANXA2,Skin dermis,Homo sapiens,14,years,16.52459280237,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07355,Annexin A2,ANXA2,Skin dermis,Homo sapiens,65,years,14.7511738869486,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07355,Annexin A2,ANXA2,Skin dermis,Homo sapiens,65,years,10.6136444667233,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07355,Annexin A2,ANXA2,Skin dermis,Homo sapiens,65,years,14.8217438888136,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA2,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06703,Protein S100-A6,S100A6,Skin dermis,Homo sapiens,2,years,11.3892129176779,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06703,Protein S100-A6,S100A6,Skin dermis,Homo sapiens,2,years,11.7777980201868,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06703,Protein S100-A6,S100A6,Skin dermis,Homo sapiens,14,years,15.6179151518821,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06703,Protein S100-A6,S100A6,Skin dermis,Homo sapiens,14,years,14.1054689804706,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06703,Protein S100-A6,S100A6,Skin dermis,Homo sapiens,14,years,15.3225164154789,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06703,Protein S100-A6,S100A6,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06703,Protein S100-A6,S100A6,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06703,Protein S100-A6,S100A6,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A6,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P51888,Prolargin,PRELP,Skin dermis,Homo sapiens,2,years,13.0312942460582,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRELP,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51888,Prolargin,PRELP,Skin dermis,Homo sapiens,2,years,12.7462207926728,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRELP,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51888,Prolargin,PRELP,Skin dermis,Homo sapiens,14,years,16.3906651565053,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRELP,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51888,Prolargin,PRELP,Skin dermis,Homo sapiens,14,years,16.7774768951766,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRELP,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51888,Prolargin,PRELP,Skin dermis,Homo sapiens,14,years,16.5503904715496,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRELP,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51888,Prolargin,PRELP,Skin dermis,Homo sapiens,65,years,16.1113901634174,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRELP,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51888,Prolargin,PRELP,Skin dermis,Homo sapiens,65,years,15.7541126206667,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRELP,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P51888,Prolargin,PRELP,Skin dermis,Homo sapiens,65,years,17.797521665531,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRELP,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
O00534,von Willebrand factor A domain-containing protein 5A,VWA5A,Skin dermis,Homo sapiens,2,years,6.52127110415792,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA5A,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00534,von Willebrand factor A domain-containing protein 5A,VWA5A,Skin dermis,Homo sapiens,2,years,6.36944896830004,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA5A,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00534,von Willebrand factor A domain-containing protein 5A,VWA5A,Skin dermis,Homo sapiens,14,years,7.94902791236331,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA5A,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00534,von Willebrand factor A domain-containing protein 5A,VWA5A,Skin dermis,Homo sapiens,14,years,7.52648355709807,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA5A,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00534,von Willebrand factor A domain-containing protein 5A,VWA5A,Skin dermis,Homo sapiens,14,years,8.04722455216898,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA5A,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00534,von Willebrand factor A domain-containing protein 5A,VWA5A,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA5A,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00534,von Willebrand factor A domain-containing protein 5A,VWA5A,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA5A,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O00534,von Willebrand factor A domain-containing protein 5A,VWA5A,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWA5A,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P01023,Alpha-2-macroglobulin,A2M,Skin dermis,Homo sapiens,2,years,13.311567140656,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2M,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01023,Alpha-2-macroglobulin,A2M,Skin dermis,Homo sapiens,2,years,13.428495119809,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2M,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01023,Alpha-2-macroglobulin,A2M,Skin dermis,Homo sapiens,14,years,13.6208550718294,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2M,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01023,Alpha-2-macroglobulin,A2M,Skin dermis,Homo sapiens,14,years,12.9248759496971,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2M,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01023,Alpha-2-macroglobulin,A2M,Skin dermis,Homo sapiens,14,years,13.8470141063849,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2M,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01023,Alpha-2-macroglobulin,A2M,Skin dermis,Homo sapiens,65,years,10.8079410382813,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2M,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01023,Alpha-2-macroglobulin,A2M,Skin dermis,Homo sapiens,65,years,15.0786261912297,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2M,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01023,Alpha-2-macroglobulin,A2M,Skin dermis,Homo sapiens,65,years,11.7666187528573,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",A2M,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20073,Annexin A7,ANXA7,Skin dermis,Homo sapiens,2,years,10.1477663970857,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20073,Annexin A7,ANXA7,Skin dermis,Homo sapiens,2,years,11.1022011826965,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20073,Annexin A7,ANXA7,Skin dermis,Homo sapiens,14,years,10.6039136754603,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20073,Annexin A7,ANXA7,Skin dermis,Homo sapiens,14,years,11.0356407379689,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20073,Annexin A7,ANXA7,Skin dermis,Homo sapiens,14,years,10.8772020374319,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20073,Annexin A7,ANXA7,Skin dermis,Homo sapiens,65,years,8.67650203880695,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20073,Annexin A7,ANXA7,Skin dermis,Homo sapiens,65,years,4.035430848917,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20073,Annexin A7,ANXA7,Skin dermis,Homo sapiens,65,years,10.4709579129317,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA7,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36955,Pigment epithelium-derived factor,SERPINF1,Skin dermis,Homo sapiens,2,years,11.6634927491989,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36955,Pigment epithelium-derived factor,SERPINF1,Skin dermis,Homo sapiens,2,years,12.0036865818364,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36955,Pigment epithelium-derived factor,SERPINF1,Skin dermis,Homo sapiens,14,years,12.0879540772269,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36955,Pigment epithelium-derived factor,SERPINF1,Skin dermis,Homo sapiens,14,years,12.0389687556867,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36955,Pigment epithelium-derived factor,SERPINF1,Skin dermis,Homo sapiens,14,years,11.9341031252004,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36955,Pigment epithelium-derived factor,SERPINF1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36955,Pigment epithelium-derived factor,SERPINF1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P36955,Pigment epithelium-derived factor,SERPINF1,Skin dermis,Homo sapiens,65,years,9.73644467365317,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P26447,Protein S100-A4,S100A4,Skin dermis,Homo sapiens,2,years,10.106254557686,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A4,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P26447,Protein S100-A4,S100A4,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A4,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P26447,Protein S100-A4,S100A4,Skin dermis,Homo sapiens,14,years,12.8695420558244,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A4,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P26447,Protein S100-A4,S100A4,Skin dermis,Homo sapiens,14,years,12.7503984097399,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A4,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P26447,Protein S100-A4,S100A4,Skin dermis,Homo sapiens,14,years,13.5150531951785,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A4,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P26447,Protein S100-A4,S100A4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A4,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P26447,Protein S100-A4,S100A4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A4,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P26447,Protein S100-A4,S100A4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A4,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50995,Annexin A11,ANXA11,Skin dermis,Homo sapiens,2,years,10.1275383352239,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA11,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50995,Annexin A11,ANXA11,Skin dermis,Homo sapiens,2,years,10.8614862880688,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA11,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50995,Annexin A11,ANXA11,Skin dermis,Homo sapiens,14,years,10.6136764539641,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA11,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50995,Annexin A11,ANXA11,Skin dermis,Homo sapiens,14,years,11.6170607759125,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA11,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50995,Annexin A11,ANXA11,Skin dermis,Homo sapiens,14,years,9.76192534422516,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA11,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50995,Annexin A11,ANXA11,Skin dermis,Homo sapiens,65,years,8.52766103882562,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA11,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50995,Annexin A11,ANXA11,Skin dermis,Homo sapiens,65,years,5.28879760530922,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA11,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50995,Annexin A11,ANXA11,Skin dermis,Homo sapiens,65,years,8.80747299671648,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANXA11,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99542,Matrix metalloproteinase-19,MMP19,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP19,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99542,Matrix metalloproteinase-19,MMP19,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP19,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99542,Matrix metalloproteinase-19,MMP19,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP19,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99542,Matrix metalloproteinase-19,MMP19,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP19,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99542,Matrix metalloproteinase-19,MMP19,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP19,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99542,Matrix metalloproteinase-19,MMP19,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP19,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99542,Matrix metalloproteinase-19,MMP19,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP19,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q99542,Matrix metalloproteinase-19,MMP19,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP19,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O00585,C-C motif chemokine 21,CCL21,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL21,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O00585,C-C motif chemokine 21,CCL21,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL21,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O00585,C-C motif chemokine 21,CCL21,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL21,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O00585,C-C motif chemokine 21,CCL21,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL21,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O00585,C-C motif chemokine 21,CCL21,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL21,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O00585,C-C motif chemokine 21,CCL21,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL21,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O00585,C-C motif chemokine 21,CCL21,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL21,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O00585,C-C motif chemokine 21,CCL21,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL21,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P43235,Cathepsin K,CTSK,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSK,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P43235,Cathepsin K,CTSK,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSK,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P43235,Cathepsin K,CTSK,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSK,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P43235,Cathepsin K,CTSK,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSK,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P43235,Cathepsin K,CTSK,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSK,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P43235,Cathepsin K,CTSK,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSK,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P43235,Cathepsin K,CTSK,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSK,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P43235,Cathepsin K,CTSK,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSK,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q15848,Adiponectin,ADIPOQ,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADIPOQ,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15848,Adiponectin,ADIPOQ,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADIPOQ,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15848,Adiponectin,ADIPOQ,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADIPOQ,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15848,Adiponectin,ADIPOQ,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADIPOQ,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15848,Adiponectin,ADIPOQ,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADIPOQ,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15848,Adiponectin,ADIPOQ,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADIPOQ,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15848,Adiponectin,ADIPOQ,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADIPOQ,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15848,Adiponectin,ADIPOQ,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ADIPOQ,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55774,C-C motif chemokine 18,CCL18,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL18,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P55774,C-C motif chemokine 18,CCL18,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL18,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P55774,C-C motif chemokine 18,CCL18,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL18,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P55774,C-C motif chemokine 18,CCL18,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL18,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P55774,C-C motif chemokine 18,CCL18,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL18,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P55774,C-C motif chemokine 18,CCL18,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL18,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P55774,C-C motif chemokine 18,CCL18,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL18,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P55774,C-C motif chemokine 18,CCL18,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL18,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P18827,Syndecan-1 {ECO:0000312|HGNC:HGNC:10658},SDC1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SDC1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P18827,Syndecan-1 {ECO:0000312|HGNC:HGNC:10658},SDC1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SDC1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P18827,Syndecan-1 {ECO:0000312|HGNC:HGNC:10658},SDC1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SDC1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P18827,Syndecan-1 {ECO:0000312|HGNC:HGNC:10658},SDC1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SDC1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P18827,Syndecan-1 {ECO:0000312|HGNC:HGNC:10658},SDC1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SDC1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P18827,Syndecan-1 {ECO:0000312|HGNC:HGNC:10658},SDC1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SDC1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P18827,Syndecan-1 {ECO:0000312|HGNC:HGNC:10658},SDC1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SDC1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P18827,Syndecan-1 {ECO:0000312|HGNC:HGNC:10658},SDC1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SDC1,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01137,Transforming growth factor beta-1 proprotein,TGFB1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFB1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01137,Transforming growth factor beta-1 proprotein,TGFB1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFB1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01137,Transforming growth factor beta-1 proprotein,TGFB1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFB1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01137,Transforming growth factor beta-1 proprotein,TGFB1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFB1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01137,Transforming growth factor beta-1 proprotein,TGFB1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFB1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01137,Transforming growth factor beta-1 proprotein,TGFB1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFB1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01137,Transforming growth factor beta-1 proprotein,TGFB1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFB1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01137,Transforming growth factor beta-1 proprotein,TGFB1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGFB1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q13201,Multimerin-1,MMRN1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13201,Multimerin-1,MMRN1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13201,Multimerin-1,MMRN1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13201,Multimerin-1,MMRN1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13201,Multimerin-1,MMRN1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13201,Multimerin-1,MMRN1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13201,Multimerin-1,MMRN1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q13201,Multimerin-1,MMRN1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P29622,Kallistatin,SERPINA4,Skin dermis,Homo sapiens,2,years,7.009335591496,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29622,Kallistatin,SERPINA4,Skin dermis,Homo sapiens,2,years,7.96352450405131,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29622,Kallistatin,SERPINA4,Skin dermis,Homo sapiens,14,years,7.53112355371334,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29622,Kallistatin,SERPINA4,Skin dermis,Homo sapiens,14,years,7.373040597017,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29622,Kallistatin,SERPINA4,Skin dermis,Homo sapiens,14,years,7.75970544310274,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29622,Kallistatin,SERPINA4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29622,Kallistatin,SERPINA4,Skin dermis,Homo sapiens,65,years,7.48932089559973,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29622,Kallistatin,SERPINA4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01042,Kininogen-1,KNG1,Skin dermis,Homo sapiens,2,years,10.4931790766975,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",KNG1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01042,Kininogen-1,KNG1,Skin dermis,Homo sapiens,2,years,10.0422976527848,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",KNG1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01042,Kininogen-1,KNG1,Skin dermis,Homo sapiens,14,years,10.2751781292163,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",KNG1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01042,Kininogen-1,KNG1,Skin dermis,Homo sapiens,14,years,9.72000563171608,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",KNG1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01042,Kininogen-1,KNG1,Skin dermis,Homo sapiens,14,years,10.7530046001974,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",KNG1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01042,Kininogen-1,KNG1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",KNG1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01042,Kininogen-1,KNG1,Skin dermis,Homo sapiens,65,years,10.2759420903229,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",KNG1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01042,Kininogen-1,KNG1,Skin dermis,Homo sapiens,65,years,10.5293243481376,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",KNG1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96HF1,Secreted frizzled-related protein 2,SFRP2,Skin dermis,Homo sapiens,2,years,4.69760463137444,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SFRP2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96HF1,Secreted frizzled-related protein 2,SFRP2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SFRP2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96HF1,Secreted frizzled-related protein 2,SFRP2,Skin dermis,Homo sapiens,14,years,5.00676730875839,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SFRP2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96HF1,Secreted frizzled-related protein 2,SFRP2,Skin dermis,Homo sapiens,14,years,5.55593335651921,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SFRP2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96HF1,Secreted frizzled-related protein 2,SFRP2,Skin dermis,Homo sapiens,14,years,5.19473141196338,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SFRP2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96HF1,Secreted frizzled-related protein 2,SFRP2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SFRP2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96HF1,Secreted frizzled-related protein 2,SFRP2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SFRP2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96HF1,Secreted frizzled-related protein 2,SFRP2,Skin dermis,Homo sapiens,65,years,5.62661645793895,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SFRP2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P24821,Tenascin,TNC,Skin dermis,Homo sapiens,2,years,8.18411921668869,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24821,Tenascin,TNC,Skin dermis,Homo sapiens,2,years,9.63124958262837,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24821,Tenascin,TNC,Skin dermis,Homo sapiens,14,years,9.67807193815433,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24821,Tenascin,TNC,Skin dermis,Homo sapiens,14,years,8.44648352195542,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24821,Tenascin,TNC,Skin dermis,Homo sapiens,14,years,9.53328393225559,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24821,Tenascin,TNC,Skin dermis,Homo sapiens,65,years,6.12563055042364,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24821,Tenascin,TNC,Skin dermis,Homo sapiens,65,years,9.69827073586127,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P24821,Tenascin,TNC,Skin dermis,Homo sapiens,65,years,8.4200269567737,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
A6NMZ7,Collagen alpha-6(VI) chain,COL6A6,Skin dermis,Homo sapiens,2,years,11.4618351553938,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A6NMZ7,Collagen alpha-6(VI) chain,COL6A6,Skin dermis,Homo sapiens,2,years,12.0395753318617,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A6NMZ7,Collagen alpha-6(VI) chain,COL6A6,Skin dermis,Homo sapiens,14,years,12.6470336948374,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A6NMZ7,Collagen alpha-6(VI) chain,COL6A6,Skin dermis,Homo sapiens,14,years,11.4780534459674,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A6NMZ7,Collagen alpha-6(VI) chain,COL6A6,Skin dermis,Homo sapiens,14,years,12.1037004848449,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A6NMZ7,Collagen alpha-6(VI) chain,COL6A6,Skin dermis,Homo sapiens,65,years,9.31726563352629,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A6NMZ7,Collagen alpha-6(VI) chain,COL6A6,Skin dermis,Homo sapiens,65,years,12.8464805394467,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A6NMZ7,Collagen alpha-6(VI) chain,COL6A6,Skin dermis,Homo sapiens,65,years,10.2735143500638,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P98160,Basement membrane-specific heparan sulfate proteoglycan core protein,HSPG2,Skin dermis,Homo sapiens,2,years,12.8739527886972,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HSPG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P98160,Basement membrane-specific heparan sulfate proteoglycan core protein,HSPG2,Skin dermis,Homo sapiens,2,years,12.7522400888816,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HSPG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P98160,Basement membrane-specific heparan sulfate proteoglycan core protein,HSPG2,Skin dermis,Homo sapiens,14,years,12.8511909174839,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HSPG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P98160,Basement membrane-specific heparan sulfate proteoglycan core protein,HSPG2,Skin dermis,Homo sapiens,14,years,12.8773303654293,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HSPG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P98160,Basement membrane-specific heparan sulfate proteoglycan core protein,HSPG2,Skin dermis,Homo sapiens,14,years,12.7867796995884,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HSPG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P98160,Basement membrane-specific heparan sulfate proteoglycan core protein,HSPG2,Skin dermis,Homo sapiens,65,years,14.529561090079,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HSPG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P98160,Basement membrane-specific heparan sulfate proteoglycan core protein,HSPG2,Skin dermis,Homo sapiens,65,years,11.977552102296,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HSPG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P98160,Basement membrane-specific heparan sulfate proteoglycan core protein,HSPG2,Skin dermis,Homo sapiens,65,years,12.7472411647554,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HSPG2,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P02790,Hemopexin,HPX,Skin dermis,Homo sapiens,2,years,12.3101656015093,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HPX,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02790,Hemopexin,HPX,Skin dermis,Homo sapiens,2,years,11.7298444400917,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HPX,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02790,Hemopexin,HPX,Skin dermis,Homo sapiens,14,years,13.3810164387758,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HPX,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02790,Hemopexin,HPX,Skin dermis,Homo sapiens,14,years,12.4652997716337,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HPX,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02790,Hemopexin,HPX,Skin dermis,Homo sapiens,14,years,13.9903180513118,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HPX,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02790,Hemopexin,HPX,Skin dermis,Homo sapiens,65,years,9.90254915608027,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HPX,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02790,Hemopexin,HPX,Skin dermis,Homo sapiens,65,years,12.4646139904674,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HPX,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02790,Hemopexin,HPX,Skin dermis,Homo sapiens,65,years,13.0644466272011,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HPX,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01008,Antithrombin-III,SERPINC1,Skin dermis,Homo sapiens,2,years,10.7228439271557,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINC1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01008,Antithrombin-III,SERPINC1,Skin dermis,Homo sapiens,2,years,11.1184522546506,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINC1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01008,Antithrombin-III,SERPINC1,Skin dermis,Homo sapiens,14,years,11.4895191739819,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINC1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01008,Antithrombin-III,SERPINC1,Skin dermis,Homo sapiens,14,years,10.2705581016514,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINC1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01008,Antithrombin-III,SERPINC1,Skin dermis,Homo sapiens,14,years,11.7387662999891,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINC1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01008,Antithrombin-III,SERPINC1,Skin dermis,Homo sapiens,65,years,9.07873963254776,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINC1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01008,Antithrombin-III,SERPINC1,Skin dermis,Homo sapiens,65,years,9.7392862723249,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINC1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01008,Antithrombin-III,SERPINC1,Skin dermis,Homo sapiens,65,years,11.8450686487909,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINC1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31949,Protein S100-A11,S100A11,Skin dermis,Homo sapiens,2,years,12.6120358015092,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A11,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31949,Protein S100-A11,S100A11,Skin dermis,Homo sapiens,2,years,11.4053856875747,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A11,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31949,Protein S100-A11,S100A11,Skin dermis,Homo sapiens,14,years,12.674765986602,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A11,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31949,Protein S100-A11,S100A11,Skin dermis,Homo sapiens,14,years,11.0936697884991,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A11,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31949,Protein S100-A11,S100A11,Skin dermis,Homo sapiens,14,years,13.5086709231607,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A11,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31949,Protein S100-A11,S100A11,Skin dermis,Homo sapiens,65,years,14.0879409467949,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A11,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31949,Protein S100-A11,S100A11,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A11,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31949,Protein S100-A11,S100A11,Skin dermis,Homo sapiens,65,years,8.81377347059705,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A11,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9H8L6,Multimerin-2,MMRN2,Skin dermis,Homo sapiens,2,years,2.29926695874196,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9H8L6,Multimerin-2,MMRN2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9H8L6,Multimerin-2,MMRN2,Skin dermis,Homo sapiens,14,years,4.67429048822861,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9H8L6,Multimerin-2,MMRN2,Skin dermis,Homo sapiens,14,years,4.0624000318334,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9H8L6,Multimerin-2,MMRN2,Skin dermis,Homo sapiens,14,years,3.58686996309467,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9H8L6,Multimerin-2,MMRN2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9H8L6,Multimerin-2,MMRN2,Skin dermis,Homo sapiens,65,years,3.3216272193366,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9H8L6,Multimerin-2,MMRN2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMRN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P08697,Alpha-2-antiplasmin,SERPINF2,Skin dermis,Homo sapiens,2,years,9.69838134476689,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08697,Alpha-2-antiplasmin,SERPINF2,Skin dermis,Homo sapiens,2,years,9.66234623265314,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08697,Alpha-2-antiplasmin,SERPINF2,Skin dermis,Homo sapiens,14,years,10.3471398115522,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08697,Alpha-2-antiplasmin,SERPINF2,Skin dermis,Homo sapiens,14,years,9.49879749466949,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08697,Alpha-2-antiplasmin,SERPINF2,Skin dermis,Homo sapiens,14,years,10.2696744897779,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08697,Alpha-2-antiplasmin,SERPINF2,Skin dermis,Homo sapiens,65,years,7.84134557578753,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08697,Alpha-2-antiplasmin,SERPINF2,Skin dermis,Homo sapiens,65,years,8.61908550170024,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08697,Alpha-2-antiplasmin,SERPINF2,Skin dermis,Homo sapiens,65,years,9.90675112486635,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINF2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01009,Alpha-1-antitrypsin {ECO:0000305},SERPINA1,Skin dermis,Homo sapiens,2,years,15.4366956930644,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01009,Alpha-1-antitrypsin {ECO:0000305},SERPINA1,Skin dermis,Homo sapiens,2,years,14.7031194055968,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01009,Alpha-1-antitrypsin {ECO:0000305},SERPINA1,Skin dermis,Homo sapiens,14,years,14.6803566798779,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01009,Alpha-1-antitrypsin {ECO:0000305},SERPINA1,Skin dermis,Homo sapiens,14,years,14.1965734854931,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01009,Alpha-1-antitrypsin {ECO:0000305},SERPINA1,Skin dermis,Homo sapiens,14,years,15.1784570505023,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01009,Alpha-1-antitrypsin {ECO:0000305},SERPINA1,Skin dermis,Homo sapiens,65,years,12.4959092335559,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01009,Alpha-1-antitrypsin {ECO:0000305},SERPINA1,Skin dermis,Homo sapiens,65,years,16.1912193104785,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01009,Alpha-1-antitrypsin {ECO:0000305},SERPINA1,Skin dermis,Homo sapiens,65,years,15.0445138823189,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00747,Plasminogen {ECO:0000303|PubMed:2318848},PLG,Skin dermis,Homo sapiens,2,years,10.7206329697052,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00747,Plasminogen {ECO:0000303|PubMed:2318848},PLG,Skin dermis,Homo sapiens,2,years,9.99003057530301,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00747,Plasminogen {ECO:0000303|PubMed:2318848},PLG,Skin dermis,Homo sapiens,14,years,11.3440534649109,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00747,Plasminogen {ECO:0000303|PubMed:2318848},PLG,Skin dermis,Homo sapiens,14,years,11.5326821940419,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00747,Plasminogen {ECO:0000303|PubMed:2318848},PLG,Skin dermis,Homo sapiens,14,years,11.1242824476277,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00747,Plasminogen {ECO:0000303|PubMed:2318848},PLG,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00747,Plasminogen {ECO:0000303|PubMed:2318848},PLG,Skin dermis,Homo sapiens,65,years,9.68143559540098,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00747,Plasminogen {ECO:0000303|PubMed:2318848},PLG,Skin dermis,Homo sapiens,65,years,11.5588152131481,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PLG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07339,Cathepsin D,CTSD,Skin dermis,Homo sapiens,2,years,10.7990532199543,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSD,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07339,Cathepsin D,CTSD,Skin dermis,Homo sapiens,2,years,10.9493775228901,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSD,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07339,Cathepsin D,CTSD,Skin dermis,Homo sapiens,14,years,11.2494289551396,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSD,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07339,Cathepsin D,CTSD,Skin dermis,Homo sapiens,14,years,10.8269821885147,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSD,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07339,Cathepsin D,CTSD,Skin dermis,Homo sapiens,14,years,10.834972400494,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSD,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07339,Cathepsin D,CTSD,Skin dermis,Homo sapiens,65,years,10.3944205943573,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSD,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07339,Cathepsin D,CTSD,Skin dermis,Homo sapiens,65,years,8.85721503703004,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSD,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07339,Cathepsin D,CTSD,Skin dermis,Homo sapiens,65,years,11.5308549159107,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSD,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q14624,Inter-alpha-trypsin inhibitor heavy chain H4,ITIH4,Skin dermis,Homo sapiens,2,years,7.80242382783127,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q14624,Inter-alpha-trypsin inhibitor heavy chain H4,ITIH4,Skin dermis,Homo sapiens,2,years,7.69341491633745,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q14624,Inter-alpha-trypsin inhibitor heavy chain H4,ITIH4,Skin dermis,Homo sapiens,14,years,9.21710189275374,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q14624,Inter-alpha-trypsin inhibitor heavy chain H4,ITIH4,Skin dermis,Homo sapiens,14,years,8.31049436230594,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q14624,Inter-alpha-trypsin inhibitor heavy chain H4,ITIH4,Skin dermis,Homo sapiens,14,years,9.70394070903232,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q14624,Inter-alpha-trypsin inhibitor heavy chain H4,ITIH4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q14624,Inter-alpha-trypsin inhibitor heavy chain H4,ITIH4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q14624,Inter-alpha-trypsin inhibitor heavy chain H4,ITIH4,Skin dermis,Homo sapiens,65,years,7.00059713537297,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50452,Serpin B8,SERPINB8,Skin dermis,Homo sapiens,2,years,5.316234663715,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB8,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50452,Serpin B8,SERPINB8,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB8,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50452,Serpin B8,SERPINB8,Skin dermis,Homo sapiens,14,years,6.08712363307662,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB8,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50452,Serpin B8,SERPINB8,Skin dermis,Homo sapiens,14,years,4.8491463337793,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB8,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50452,Serpin B8,SERPINB8,Skin dermis,Homo sapiens,14,years,5.75068850555826,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB8,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50452,Serpin B8,SERPINB8,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB8,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50452,Serpin B8,SERPINB8,Skin dermis,Homo sapiens,65,years,3.77427887345937,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB8,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P50452,Serpin B8,SERPINB8,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB8,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35443,Thrombospondin-4,THBS4,Skin dermis,Homo sapiens,2,years,3.76031860921447,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35443,Thrombospondin-4,THBS4,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35443,Thrombospondin-4,THBS4,Skin dermis,Homo sapiens,14,years,4.09562007558934,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35443,Thrombospondin-4,THBS4,Skin dermis,Homo sapiens,14,years,3.43173222831273,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35443,Thrombospondin-4,THBS4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35443,Thrombospondin-4,THBS4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35443,Thrombospondin-4,THBS4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35443,Thrombospondin-4,THBS4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04080,Cystatin-B,CSTB,Skin dermis,Homo sapiens,2,years,7.52553918819696,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSTB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04080,Cystatin-B,CSTB,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSTB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04080,Cystatin-B,CSTB,Skin dermis,Homo sapiens,14,years,9.14537177447512,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSTB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04080,Cystatin-B,CSTB,Skin dermis,Homo sapiens,14,years,6.31655591714916,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSTB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04080,Cystatin-B,CSTB,Skin dermis,Homo sapiens,14,years,7.57723590364829,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSTB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04080,Cystatin-B,CSTB,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSTB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04080,Cystatin-B,CSTB,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSTB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04080,Cystatin-B,CSTB,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CSTB,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04196,Histidine-rich glycoprotein,HRG,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HRG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04196,Histidine-rich glycoprotein,HRG,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HRG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04196,Histidine-rich glycoprotein,HRG,Skin dermis,Homo sapiens,14,years,10.5471170111058,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HRG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04196,Histidine-rich glycoprotein,HRG,Skin dermis,Homo sapiens,14,years,9.43548616699472,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HRG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04196,Histidine-rich glycoprotein,HRG,Skin dermis,Homo sapiens,14,years,9.54402364716825,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HRG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04196,Histidine-rich glycoprotein,HRG,Skin dermis,Homo sapiens,65,years,10.0097984089137,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HRG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04196,Histidine-rich glycoprotein,HRG,Skin dermis,Homo sapiens,65,years,9.8555543344361,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HRG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P04196,Histidine-rich glycoprotein,HRG,Skin dermis,Homo sapiens,65,years,10.7631566426979,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HRG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q6UXI7,Vitrin,VIT,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VIT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI7,Vitrin,VIT,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VIT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI7,Vitrin,VIT,Skin dermis,Homo sapiens,14,years,5.33123759820821,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VIT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI7,Vitrin,VIT,Skin dermis,Homo sapiens,14,years,5.91026735335991,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VIT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI7,Vitrin,VIT,Skin dermis,Homo sapiens,14,years,5.66966548628484,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VIT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI7,Vitrin,VIT,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VIT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI7,Vitrin,VIT,Skin dermis,Homo sapiens,65,years,5.43692103069029,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VIT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q6UXI7,Vitrin,VIT,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VIT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P21980,Protein-glutamine gamma-glutamyltransferase 2 {ECO:0000305},TGM2,Skin dermis,Homo sapiens,2,years,6.92881946881448,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P21980,Protein-glutamine gamma-glutamyltransferase 2 {ECO:0000305},TGM2,Skin dermis,Homo sapiens,2,years,7.24362870974808,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P21980,Protein-glutamine gamma-glutamyltransferase 2 {ECO:0000305},TGM2,Skin dermis,Homo sapiens,14,years,7.24152311925692,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P21980,Protein-glutamine gamma-glutamyltransferase 2 {ECO:0000305},TGM2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P21980,Protein-glutamine gamma-glutamyltransferase 2 {ECO:0000305},TGM2,Skin dermis,Homo sapiens,14,years,4.03090016843374,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P21980,Protein-glutamine gamma-glutamyltransferase 2 {ECO:0000305},TGM2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P21980,Protein-glutamine gamma-glutamyltransferase 2 {ECO:0000305},TGM2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P21980,Protein-glutamine gamma-glutamyltransferase 2 {ECO:0000305},TGM2,Skin dermis,Homo sapiens,65,years,6.65655076226675,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02747,Complement C1q subcomponent subunit C {ECO:0000305},C1QC,Skin dermis,Homo sapiens,2,years,10.3810673615779,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QC,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02747,Complement C1q subcomponent subunit C {ECO:0000305},C1QC,Skin dermis,Homo sapiens,2,years,10.7250579903481,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QC,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02747,Complement C1q subcomponent subunit C {ECO:0000305},C1QC,Skin dermis,Homo sapiens,14,years,10.6892851189022,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QC,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02747,Complement C1q subcomponent subunit C {ECO:0000305},C1QC,Skin dermis,Homo sapiens,14,years,12.1857029083493,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QC,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02747,Complement C1q subcomponent subunit C {ECO:0000305},C1QC,Skin dermis,Homo sapiens,14,years,11.4476371653172,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QC,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02747,Complement C1q subcomponent subunit C {ECO:0000305},C1QC,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QC,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02747,Complement C1q subcomponent subunit C {ECO:0000305},C1QC,Skin dermis,Homo sapiens,65,years,9.9832053995786,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QC,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02747,Complement C1q subcomponent subunit C {ECO:0000305},C1QC,Skin dermis,Homo sapiens,65,years,11.2453296645375,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QC,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08185,Corticosteroid-binding globulin,SERPINA6,Skin dermis,Homo sapiens,2,years,8.06986567328362,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08185,Corticosteroid-binding globulin,SERPINA6,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08185,Corticosteroid-binding globulin,SERPINA6,Skin dermis,Homo sapiens,14,years,7.30502406288337,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08185,Corticosteroid-binding globulin,SERPINA6,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08185,Corticosteroid-binding globulin,SERPINA6,Skin dermis,Homo sapiens,14,years,7.64779340824819,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08185,Corticosteroid-binding globulin,SERPINA6,Skin dermis,Homo sapiens,65,years,8.50623910749021,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08185,Corticosteroid-binding globulin,SERPINA6,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08185,Corticosteroid-binding globulin,SERPINA6,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA6,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29034,Protein S100-A2,S100A2,Skin dermis,Homo sapiens,2,years,7.20964641449906,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29034,Protein S100-A2,S100A2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29034,Protein S100-A2,S100A2,Skin dermis,Homo sapiens,14,years,9.39878729930419,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29034,Protein S100-A2,S100A2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29034,Protein S100-A2,S100A2,Skin dermis,Homo sapiens,14,years,6.78151022293437,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29034,Protein S100-A2,S100A2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29034,Protein S100-A2,S100A2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29034,Protein S100-A2,S100A2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q92743,Serine protease HTRA1,HTRA1,Skin dermis,Homo sapiens,2,years,5.18070066345434,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HTRA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q92743,Serine protease HTRA1,HTRA1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HTRA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q92743,Serine protease HTRA1,HTRA1,Skin dermis,Homo sapiens,14,years,6.87050366447072,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HTRA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q92743,Serine protease HTRA1,HTRA1,Skin dermis,Homo sapiens,14,years,6.55322277173299,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HTRA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q92743,Serine protease HTRA1,HTRA1,Skin dermis,Homo sapiens,14,years,6.32824203120419,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HTRA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q92743,Serine protease HTRA1,HTRA1,Skin dermis,Homo sapiens,65,years,12.2390586239488,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HTRA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q92743,Serine protease HTRA1,HTRA1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HTRA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q92743,Serine protease HTRA1,HTRA1,Skin dermis,Homo sapiens,65,years,6.67399605533657,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HTRA1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02751,Fibronectin {ECO:0000305},FN1,Skin dermis,Homo sapiens,2,years,12.3233692410989,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02751,Fibronectin {ECO:0000305},FN1,Skin dermis,Homo sapiens,2,years,13.0277553645972,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02751,Fibronectin {ECO:0000305},FN1,Skin dermis,Homo sapiens,14,years,12.8971015383939,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02751,Fibronectin {ECO:0000305},FN1,Skin dermis,Homo sapiens,14,years,13.0114012591554,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02751,Fibronectin {ECO:0000305},FN1,Skin dermis,Homo sapiens,14,years,12.8141490561498,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02751,Fibronectin {ECO:0000305},FN1,Skin dermis,Homo sapiens,65,years,9.72961751084659,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02751,Fibronectin {ECO:0000305},FN1,Skin dermis,Homo sapiens,65,years,11.3408854407588,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02751,Fibronectin {ECO:0000305},FN1,Skin dermis,Homo sapiens,65,years,12.5188255634193,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P30740,Leukocyte elastase inhibitor,SERPINB1,Skin dermis,Homo sapiens,2,years,10.5835719085952,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P30740,Leukocyte elastase inhibitor,SERPINB1,Skin dermis,Homo sapiens,2,years,9.70680811752336,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P30740,Leukocyte elastase inhibitor,SERPINB1,Skin dermis,Homo sapiens,14,years,11.9521919080795,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P30740,Leukocyte elastase inhibitor,SERPINB1,Skin dermis,Homo sapiens,14,years,12.5198260835612,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P30740,Leukocyte elastase inhibitor,SERPINB1,Skin dermis,Homo sapiens,14,years,12.2476150012628,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P30740,Leukocyte elastase inhibitor,SERPINB1,Skin dermis,Homo sapiens,65,years,8.19451651244819,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P30740,Leukocyte elastase inhibitor,SERPINB1,Skin dermis,Homo sapiens,65,years,11.315039553974,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P30740,Leukocyte elastase inhibitor,SERPINB1,Skin dermis,Homo sapiens,65,years,10.3584362827763,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02745,Complement C1q subcomponent subunit A {ECO:0000305},C1QA,Skin dermis,Homo sapiens,2,years,9.72341321279771,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QA,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02745,Complement C1q subcomponent subunit A {ECO:0000305},C1QA,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QA,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02745,Complement C1q subcomponent subunit A {ECO:0000305},C1QA,Skin dermis,Homo sapiens,14,years,9.82041998739832,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QA,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02745,Complement C1q subcomponent subunit A {ECO:0000305},C1QA,Skin dermis,Homo sapiens,14,years,11.4535906723497,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QA,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02745,Complement C1q subcomponent subunit A {ECO:0000305},C1QA,Skin dermis,Homo sapiens,14,years,10.2988891330328,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QA,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02745,Complement C1q subcomponent subunit A {ECO:0000305},C1QA,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QA,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02745,Complement C1q subcomponent subunit A {ECO:0000305},C1QA,Skin dermis,Homo sapiens,65,years,9.74189843135988,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QA,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02745,Complement C1q subcomponent subunit A {ECO:0000305},C1QA,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QA,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05109,Protein S100-A8 {ECO:0000305},S100A8,Skin dermis,Homo sapiens,2,years,8.26404989334414,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A8,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05109,Protein S100-A8 {ECO:0000305},S100A8,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A8,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05109,Protein S100-A8 {ECO:0000305},S100A8,Skin dermis,Homo sapiens,14,years,10.9056167085532,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A8,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05109,Protein S100-A8 {ECO:0000305},S100A8,Skin dermis,Homo sapiens,14,years,9.47926138878509,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A8,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05109,Protein S100-A8 {ECO:0000305},S100A8,Skin dermis,Homo sapiens,14,years,10.5999897449934,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A8,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05109,Protein S100-A8 {ECO:0000305},S100A8,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A8,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05109,Protein S100-A8 {ECO:0000305},S100A8,Skin dermis,Homo sapiens,65,years,13.7576306028027,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A8,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05109,Protein S100-A8 {ECO:0000305},S100A8,Skin dermis,Homo sapiens,65,years,10.0407863682976,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A8,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02746,Complement C1q subcomponent subunit B {ECO:0000305},C1QB,Skin dermis,Homo sapiens,2,years,10.2962125759332,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QB,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02746,Complement C1q subcomponent subunit B {ECO:0000305},C1QB,Skin dermis,Homo sapiens,2,years,10.1640078545161,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QB,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02746,Complement C1q subcomponent subunit B {ECO:0000305},C1QB,Skin dermis,Homo sapiens,14,years,10.9186033575474,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QB,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02746,Complement C1q subcomponent subunit B {ECO:0000305},C1QB,Skin dermis,Homo sapiens,14,years,11.8981610130171,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QB,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02746,Complement C1q subcomponent subunit B {ECO:0000305},C1QB,Skin dermis,Homo sapiens,14,years,11.435736016359,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QB,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02746,Complement C1q subcomponent subunit B {ECO:0000305},C1QB,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QB,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02746,Complement C1q subcomponent subunit B {ECO:0000305},C1QB,Skin dermis,Homo sapiens,65,years,9.76496915653555,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QB,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02746,Complement C1q subcomponent subunit B {ECO:0000305},C1QB,Skin dermis,Homo sapiens,65,years,11.3895106456554,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C1QB,ECM-affiliated Proteins,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q7Z5L7,Podocan,PODN,Skin dermis,Homo sapiens,2,years,7.95392161623086,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PODN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z5L7,Podocan,PODN,Skin dermis,Homo sapiens,2,years,8.35999346643986,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PODN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z5L7,Podocan,PODN,Skin dermis,Homo sapiens,14,years,10.0180429775792,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PODN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z5L7,Podocan,PODN,Skin dermis,Homo sapiens,14,years,9.85592500182605,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PODN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z5L7,Podocan,PODN,Skin dermis,Homo sapiens,14,years,9.83263833540692,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PODN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z5L7,Podocan,PODN,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PODN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z5L7,Podocan,PODN,Skin dermis,Homo sapiens,65,years,7.41883898153404,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PODN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q7Z5L7,Podocan,PODN,Skin dermis,Homo sapiens,65,years,8.35238979463048,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PODN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
O95967,EGF-containing fibulin-like extracellular matrix protein 2 {ECO:0000305},EFEMP2,Skin dermis,Homo sapiens,2,years,10.3422468006735,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95967,EGF-containing fibulin-like extracellular matrix protein 2 {ECO:0000305},EFEMP2,Skin dermis,Homo sapiens,2,years,8.13700141623632,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95967,EGF-containing fibulin-like extracellular matrix protein 2 {ECO:0000305},EFEMP2,Skin dermis,Homo sapiens,14,years,10.461101059756,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95967,EGF-containing fibulin-like extracellular matrix protein 2 {ECO:0000305},EFEMP2,Skin dermis,Homo sapiens,14,years,9.77133014175017,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95967,EGF-containing fibulin-like extracellular matrix protein 2 {ECO:0000305},EFEMP2,Skin dermis,Homo sapiens,14,years,9.53633497720627,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95967,EGF-containing fibulin-like extracellular matrix protein 2 {ECO:0000305},EFEMP2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95967,EGF-containing fibulin-like extracellular matrix protein 2 {ECO:0000305},EFEMP2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95967,EGF-containing fibulin-like extracellular matrix protein 2 {ECO:0000305},EFEMP2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P00748,Coagulation factor XII,F12,Skin dermis,Homo sapiens,2,years,3.69429288625611,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00748,Coagulation factor XII,F12,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00748,Coagulation factor XII,F12,Skin dermis,Homo sapiens,14,years,5.58516102836015,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00748,Coagulation factor XII,F12,Skin dermis,Homo sapiens,14,years,5.0168181853469,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00748,Coagulation factor XII,F12,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00748,Coagulation factor XII,F12,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00748,Coagulation factor XII,F12,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00748,Coagulation factor XII,F12,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86UX2,Inter-alpha-trypsin inhibitor heavy chain H5,ITIH5,Skin dermis,Homo sapiens,2,years,4.57880203983293,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86UX2,Inter-alpha-trypsin inhibitor heavy chain H5,ITIH5,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86UX2,Inter-alpha-trypsin inhibitor heavy chain H5,ITIH5,Skin dermis,Homo sapiens,14,years,7.54570473946345,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86UX2,Inter-alpha-trypsin inhibitor heavy chain H5,ITIH5,Skin dermis,Homo sapiens,14,years,5.96415814612523,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86UX2,Inter-alpha-trypsin inhibitor heavy chain H5,ITIH5,Skin dermis,Homo sapiens,14,years,5.90328487341935,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86UX2,Inter-alpha-trypsin inhibitor heavy chain H5,ITIH5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86UX2,Inter-alpha-trypsin inhibitor heavy chain H5,ITIH5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q86UX2,Inter-alpha-trypsin inhibitor heavy chain H5,ITIH5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q16610,Extracellular matrix protein 1,ECM1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16610,Extracellular matrix protein 1,ECM1,Skin dermis,Homo sapiens,2,years,5.25570188864201,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16610,Extracellular matrix protein 1,ECM1,Skin dermis,Homo sapiens,14,years,8.55722106875964,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16610,Extracellular matrix protein 1,ECM1,Skin dermis,Homo sapiens,14,years,6.78946376804292,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16610,Extracellular matrix protein 1,ECM1,Skin dermis,Homo sapiens,14,years,9.29624473495474,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16610,Extracellular matrix protein 1,ECM1,Skin dermis,Homo sapiens,65,years,6.65253372273345,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16610,Extracellular matrix protein 1,ECM1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16610,Extracellular matrix protein 1,ECM1,Skin dermis,Homo sapiens,65,years,6.82945653208143,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ECM1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P25940,Collagen alpha-3(V) chain,COL5A3,Skin dermis,Homo sapiens,2,years,8.29477305079072,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P25940,Collagen alpha-3(V) chain,COL5A3,Skin dermis,Homo sapiens,2,years,5.91604875086955,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P25940,Collagen alpha-3(V) chain,COL5A3,Skin dermis,Homo sapiens,14,years,9.42076352683657,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P25940,Collagen alpha-3(V) chain,COL5A3,Skin dermis,Homo sapiens,14,years,9.68692968916367,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P25940,Collagen alpha-3(V) chain,COL5A3,Skin dermis,Homo sapiens,14,years,9.00892450063122,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P25940,Collagen alpha-3(V) chain,COL5A3,Skin dermis,Homo sapiens,65,years,9.22437820042209,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P25940,Collagen alpha-3(V) chain,COL5A3,Skin dermis,Homo sapiens,65,years,7.40572030141388,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P25940,Collagen alpha-3(V) chain,COL5A3,Skin dermis,Homo sapiens,65,years,8.82680563567594,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL5A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02671,Fibrinogen alpha chain,FGA,Skin dermis,Homo sapiens,2,years,13.739617303069,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGA,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02671,Fibrinogen alpha chain,FGA,Skin dermis,Homo sapiens,2,years,13.6426149966707,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGA,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02671,Fibrinogen alpha chain,FGA,Skin dermis,Homo sapiens,14,years,14.8506120929196,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGA,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02671,Fibrinogen alpha chain,FGA,Skin dermis,Homo sapiens,14,years,13.6412784999717,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGA,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02671,Fibrinogen alpha chain,FGA,Skin dermis,Homo sapiens,14,years,15.7139156240363,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGA,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02671,Fibrinogen alpha chain,FGA,Skin dermis,Homo sapiens,65,years,12.6185448421236,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGA,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02671,Fibrinogen alpha chain,FGA,Skin dermis,Homo sapiens,65,years,9.83552970048517,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGA,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02671,Fibrinogen alpha chain,FGA,Skin dermis,Homo sapiens,65,years,16.2538048729679,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGA,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UKU9,Angiopoietin-related protein 2,ANGPTL2,Skin dermis,Homo sapiens,2,years,6.76357448195281,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UKU9,Angiopoietin-related protein 2,ANGPTL2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UKU9,Angiopoietin-related protein 2,ANGPTL2,Skin dermis,Homo sapiens,14,years,5.33961815534937,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UKU9,Angiopoietin-related protein 2,ANGPTL2,Skin dermis,Homo sapiens,14,years,5.31906103158462,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UKU9,Angiopoietin-related protein 2,ANGPTL2,Skin dermis,Homo sapiens,14,years,4.55767839554745,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UKU9,Angiopoietin-related protein 2,ANGPTL2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UKU9,Angiopoietin-related protein 2,ANGPTL2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UKU9,Angiopoietin-related protein 2,ANGPTL2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ANGPTL2,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02679,Fibrinogen gamma chain,FGG,Skin dermis,Homo sapiens,2,years,14.6565938728016,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGG,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02679,Fibrinogen gamma chain,FGG,Skin dermis,Homo sapiens,2,years,13.5636058982653,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGG,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02679,Fibrinogen gamma chain,FGG,Skin dermis,Homo sapiens,14,years,15.7741120862859,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGG,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02679,Fibrinogen gamma chain,FGG,Skin dermis,Homo sapiens,14,years,14.6288497754104,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGG,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02679,Fibrinogen gamma chain,FGG,Skin dermis,Homo sapiens,14,years,16.5767340576439,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGG,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02679,Fibrinogen gamma chain,FGG,Skin dermis,Homo sapiens,65,years,14.4995214368793,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGG,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02679,Fibrinogen gamma chain,FGG,Skin dermis,Homo sapiens,65,years,13.9063421283013,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGG,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02679,Fibrinogen gamma chain,FGG,Skin dermis,Homo sapiens,65,years,17.4597175641131,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGG,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P05546,Heparin cofactor 2,SERPIND1,Skin dermis,Homo sapiens,2,years,9.02194861870536,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPIND1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05546,Heparin cofactor 2,SERPIND1,Skin dermis,Homo sapiens,2,years,10.1045646720105,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPIND1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05546,Heparin cofactor 2,SERPIND1,Skin dermis,Homo sapiens,14,years,11.2382205528988,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPIND1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05546,Heparin cofactor 2,SERPIND1,Skin dermis,Homo sapiens,14,years,10.563050924709,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPIND1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05546,Heparin cofactor 2,SERPIND1,Skin dermis,Homo sapiens,14,years,10.8741553613886,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPIND1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05546,Heparin cofactor 2,SERPIND1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPIND1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05546,Heparin cofactor 2,SERPIND1,Skin dermis,Homo sapiens,65,years,6.90848418800089,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPIND1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05546,Heparin cofactor 2,SERPIND1,Skin dermis,Homo sapiens,65,years,11.0899255515607,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPIND1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00734,Prothrombin,F2,Skin dermis,Homo sapiens,2,years,9.41009940011301,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00734,Prothrombin,F2,Skin dermis,Homo sapiens,2,years,9.01894695650455,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00734,Prothrombin,F2,Skin dermis,Homo sapiens,14,years,11.0469777267941,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00734,Prothrombin,F2,Skin dermis,Homo sapiens,14,years,8.74152562908897,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00734,Prothrombin,F2,Skin dermis,Homo sapiens,14,years,11.0771834619836,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00734,Prothrombin,F2,Skin dermis,Homo sapiens,65,years,6.75734714054374,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00734,Prothrombin,F2,Skin dermis,Homo sapiens,65,years,6.88388698829498,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00734,Prothrombin,F2,Skin dermis,Homo sapiens,65,years,5.84047642370847,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
A8TX70,Collagen alpha-5(VI) chain,COL6A5,Skin dermis,Homo sapiens,2,years,5.84474888540912,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A8TX70,Collagen alpha-5(VI) chain,COL6A5,Skin dermis,Homo sapiens,2,years,6.70700797778134,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A8TX70,Collagen alpha-5(VI) chain,COL6A5,Skin dermis,Homo sapiens,14,years,13.2918773920819,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A8TX70,Collagen alpha-5(VI) chain,COL6A5,Skin dermis,Homo sapiens,14,years,13.4251675814011,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A8TX70,Collagen alpha-5(VI) chain,COL6A5,Skin dermis,Homo sapiens,14,years,13.8503229034338,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A8TX70,Collagen alpha-5(VI) chain,COL6A5,Skin dermis,Homo sapiens,65,years,5.16435411992187,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A8TX70,Collagen alpha-5(VI) chain,COL6A5,Skin dermis,Homo sapiens,65,years,2.70388591623322,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
A8TX70,Collagen alpha-5(VI) chain,COL6A5,Skin dermis,Homo sapiens,65,years,9.88737830318687,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P06702,Protein S100-A9,S100A9,Skin dermis,Homo sapiens,2,years,9.51246499297686,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A9,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06702,Protein S100-A9,S100A9,Skin dermis,Homo sapiens,2,years,10.4869245105117,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A9,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06702,Protein S100-A9,S100A9,Skin dermis,Homo sapiens,14,years,11.4176677883652,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A9,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06702,Protein S100-A9,S100A9,Skin dermis,Homo sapiens,14,years,10.5387401287917,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A9,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06702,Protein S100-A9,S100A9,Skin dermis,Homo sapiens,14,years,11.5944037259427,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A9,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06702,Protein S100-A9,S100A9,Skin dermis,Homo sapiens,65,years,12.8244931454005,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A9,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06702,Protein S100-A9,S100A9,Skin dermis,Homo sapiens,65,years,13.7107694096858,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A9,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P06702,Protein S100-A9,S100A9,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A9,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q07092,Collagen alpha-1(XVI) chain,COL16A1,Skin dermis,Homo sapiens,2,years,9.04457613584128,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL16A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q07092,Collagen alpha-1(XVI) chain,COL16A1,Skin dermis,Homo sapiens,2,years,8.70282399534514,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL16A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q07092,Collagen alpha-1(XVI) chain,COL16A1,Skin dermis,Homo sapiens,14,years,9.14109731422227,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL16A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q07092,Collagen alpha-1(XVI) chain,COL16A1,Skin dermis,Homo sapiens,14,years,9.5906244976275,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL16A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q07092,Collagen alpha-1(XVI) chain,COL16A1,Skin dermis,Homo sapiens,14,years,9.71944659521375,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL16A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q07092,Collagen alpha-1(XVI) chain,COL16A1,Skin dermis,Homo sapiens,65,years,9.43417102632195,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL16A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q07092,Collagen alpha-1(XVI) chain,COL16A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL16A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q07092,Collagen alpha-1(XVI) chain,COL16A1,Skin dermis,Homo sapiens,65,years,6.52897298877714,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL16A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q14112,Nidogen-2,NID2,Skin dermis,Homo sapiens,2,years,9.81253574593097,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14112,Nidogen-2,NID2,Skin dermis,Homo sapiens,2,years,10.3416038693114,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14112,Nidogen-2,NID2,Skin dermis,Homo sapiens,14,years,10.4733152301365,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14112,Nidogen-2,NID2,Skin dermis,Homo sapiens,14,years,10.2875259767165,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14112,Nidogen-2,NID2,Skin dermis,Homo sapiens,14,years,9.7675365688399,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14112,Nidogen-2,NID2,Skin dermis,Homo sapiens,65,years,4.55035316783342,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14112,Nidogen-2,NID2,Skin dermis,Homo sapiens,65,years,6.66372836719194,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14112,Nidogen-2,NID2,Skin dermis,Homo sapiens,65,years,9.40934732194003,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",NID2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16363,Laminin subunit alpha-4,LAMA4,Skin dermis,Homo sapiens,2,years,9.53775041715273,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16363,Laminin subunit alpha-4,LAMA4,Skin dermis,Homo sapiens,2,years,10.229129140053,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16363,Laminin subunit alpha-4,LAMA4,Skin dermis,Homo sapiens,14,years,10.066354767982,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16363,Laminin subunit alpha-4,LAMA4,Skin dermis,Homo sapiens,14,years,9.31625814565646,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16363,Laminin subunit alpha-4,LAMA4,Skin dermis,Homo sapiens,14,years,8.95754453896147,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16363,Laminin subunit alpha-4,LAMA4,Skin dermis,Homo sapiens,65,years,8.2378451851884,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16363,Laminin subunit alpha-4,LAMA4,Skin dermis,Homo sapiens,65,years,6.37221218617761,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q16363,Laminin subunit alpha-4,LAMA4,Skin dermis,Homo sapiens,65,years,9.05793571120327,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA4,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14766,Latent-transforming growth factor beta-binding protein 1 {ECO:0000303|PubMed:8537398},LTBP1,Skin dermis,Homo sapiens,2,years,10.418476935842,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14766,Latent-transforming growth factor beta-binding protein 1 {ECO:0000303|PubMed:8537398},LTBP1,Skin dermis,Homo sapiens,2,years,6.20879481663153,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14766,Latent-transforming growth factor beta-binding protein 1 {ECO:0000303|PubMed:8537398},LTBP1,Skin dermis,Homo sapiens,14,years,7.90840527433265,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14766,Latent-transforming growth factor beta-binding protein 1 {ECO:0000303|PubMed:8537398},LTBP1,Skin dermis,Homo sapiens,14,years,5.58349223626367,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14766,Latent-transforming growth factor beta-binding protein 1 {ECO:0000303|PubMed:8537398},LTBP1,Skin dermis,Homo sapiens,14,years,6.94630779972631,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14766,Latent-transforming growth factor beta-binding protein 1 {ECO:0000303|PubMed:8537398},LTBP1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14766,Latent-transforming growth factor beta-binding protein 1 {ECO:0000303|PubMed:8537398},LTBP1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q14766,Latent-transforming growth factor beta-binding protein 1 {ECO:0000303|PubMed:8537398},LTBP1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LTBP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95428,Papilin,PAPLN,Skin dermis,Homo sapiens,2,years,6.78079511419193,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PAPLN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95428,Papilin,PAPLN,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PAPLN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95428,Papilin,PAPLN,Skin dermis,Homo sapiens,14,years,7.47734288189134,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PAPLN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95428,Papilin,PAPLN,Skin dermis,Homo sapiens,14,years,8.46144272172937,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PAPLN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95428,Papilin,PAPLN,Skin dermis,Homo sapiens,14,years,7.0539861515126,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PAPLN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95428,Papilin,PAPLN,Skin dermis,Homo sapiens,65,years,4.59868449051998,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PAPLN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95428,Papilin,PAPLN,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PAPLN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O95428,Papilin,PAPLN,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PAPLN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P12110,Collagen alpha-2(VI) chain,COL6A2,Skin dermis,Homo sapiens,2,years,17.3620920298044,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12110,Collagen alpha-2(VI) chain,COL6A2,Skin dermis,Homo sapiens,2,years,17.6710265007457,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12110,Collagen alpha-2(VI) chain,COL6A2,Skin dermis,Homo sapiens,14,years,17.9903392769048,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12110,Collagen alpha-2(VI) chain,COL6A2,Skin dermis,Homo sapiens,14,years,18.5110585971949,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12110,Collagen alpha-2(VI) chain,COL6A2,Skin dermis,Homo sapiens,14,years,18.5999048633664,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12110,Collagen alpha-2(VI) chain,COL6A2,Skin dermis,Homo sapiens,65,years,17.4911125212567,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12110,Collagen alpha-2(VI) chain,COL6A2,Skin dermis,Homo sapiens,65,years,18.6922900913924,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12110,Collagen alpha-2(VI) chain,COL6A2,Skin dermis,Homo sapiens,65,years,19.3197516574059,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P04275,von Willebrand factor,VWF,Skin dermis,Homo sapiens,2,years,8.56270210098322,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWF,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04275,von Willebrand factor,VWF,Skin dermis,Homo sapiens,2,years,8.65562164164638,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWF,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04275,von Willebrand factor,VWF,Skin dermis,Homo sapiens,14,years,8.35777698039728,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWF,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04275,von Willebrand factor,VWF,Skin dermis,Homo sapiens,14,years,9.24879684530243,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWF,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04275,von Willebrand factor,VWF,Skin dermis,Homo sapiens,14,years,8.35041016355183,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWF,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04275,von Willebrand factor,VWF,Skin dermis,Homo sapiens,65,years,6.22988534757001,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWF,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04275,von Willebrand factor,VWF,Skin dermis,Homo sapiens,65,years,6.62712085613832,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWF,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04275,von Willebrand factor,VWF,Skin dermis,Homo sapiens,65,years,8.86898806002442,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VWF,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q12805,EGF-containing fibulin-like extracellular matrix protein 1,EFEMP1,Skin dermis,Homo sapiens,2,years,10.7145753948992,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q12805,EGF-containing fibulin-like extracellular matrix protein 1,EFEMP1,Skin dermis,Homo sapiens,2,years,10.2091675854093,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q12805,EGF-containing fibulin-like extracellular matrix protein 1,EFEMP1,Skin dermis,Homo sapiens,14,years,11.6038419964672,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q12805,EGF-containing fibulin-like extracellular matrix protein 1,EFEMP1,Skin dermis,Homo sapiens,14,years,11.2301379731757,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q12805,EGF-containing fibulin-like extracellular matrix protein 1,EFEMP1,Skin dermis,Homo sapiens,14,years,11.9733678832293,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q12805,EGF-containing fibulin-like extracellular matrix protein 1,EFEMP1,Skin dermis,Homo sapiens,65,years,13.526626025826,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q12805,EGF-containing fibulin-like extracellular matrix protein 1,EFEMP1,Skin dermis,Homo sapiens,65,years,12.4445313866047,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q12805,EGF-containing fibulin-like extracellular matrix protein 1,EFEMP1,Skin dermis,Homo sapiens,65,years,10.5691923027256,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EFEMP1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q53RD9,Fibulin-7,FBLN7,Skin dermis,Homo sapiens,2,years,13.4190393352413,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN7,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q53RD9,Fibulin-7,FBLN7,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN7,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q53RD9,Fibulin-7,FBLN7,Skin dermis,Homo sapiens,14,years,10.5450777252281,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN7,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q53RD9,Fibulin-7,FBLN7,Skin dermis,Homo sapiens,14,years,11.7443242624416,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN7,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q53RD9,Fibulin-7,FBLN7,Skin dermis,Homo sapiens,14,years,14.6496937145245,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN7,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q53RD9,Fibulin-7,FBLN7,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN7,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q53RD9,Fibulin-7,FBLN7,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN7,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q53RD9,Fibulin-7,FBLN7,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN7,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O76076,CCN family member 5,WISP2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O76076,CCN family member 5,WISP2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O76076,CCN family member 5,WISP2,Skin dermis,Homo sapiens,14,years,8.51495080629905,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O76076,CCN family member 5,WISP2,Skin dermis,Homo sapiens,14,years,10.4616907322725,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O76076,CCN family member 5,WISP2,Skin dermis,Homo sapiens,14,years,9.26000839684458,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O76076,CCN family member 5,WISP2,Skin dermis,Homo sapiens,65,years,10.6795452030216,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O76076,CCN family member 5,WISP2,Skin dermis,Homo sapiens,65,years,13.4978766949032,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O76076,CCN family member 5,WISP2,Skin dermis,Homo sapiens,65,years,11.6162386497363,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P98095,Fibulin-2,FBLN2,Skin dermis,Homo sapiens,2,years,10.50437879757,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P98095,Fibulin-2,FBLN2,Skin dermis,Homo sapiens,2,years,9.41319552021175,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P98095,Fibulin-2,FBLN2,Skin dermis,Homo sapiens,14,years,13.7118746462451,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P98095,Fibulin-2,FBLN2,Skin dermis,Homo sapiens,14,years,13.390973667108,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P98095,Fibulin-2,FBLN2,Skin dermis,Homo sapiens,14,years,13.7019440832015,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P98095,Fibulin-2,FBLN2,Skin dermis,Homo sapiens,65,years,14.7078128781187,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P98095,Fibulin-2,FBLN2,Skin dermis,Homo sapiens,65,years,14.2727343179266,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P98095,Fibulin-2,FBLN2,Skin dermis,Homo sapiens,65,years,13.134998759092,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35858,Insulin-like growth factor-binding protein complex acid labile subunit,IGFALS,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",IGFALS,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35858,Insulin-like growth factor-binding protein complex acid labile subunit,IGFALS,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",IGFALS,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35858,Insulin-like growth factor-binding protein complex acid labile subunit,IGFALS,Skin dermis,Homo sapiens,14,years,8.03181940479585,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",IGFALS,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35858,Insulin-like growth factor-binding protein complex acid labile subunit,IGFALS,Skin dermis,Homo sapiens,14,years,8.63509519268688,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",IGFALS,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35858,Insulin-like growth factor-binding protein complex acid labile subunit,IGFALS,Skin dermis,Homo sapiens,14,years,8.13500511397645,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",IGFALS,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35858,Insulin-like growth factor-binding protein complex acid labile subunit,IGFALS,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",IGFALS,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35858,Insulin-like growth factor-binding protein complex acid labile subunit,IGFALS,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",IGFALS,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35858,Insulin-like growth factor-binding protein complex acid labile subunit,IGFALS,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",IGFALS,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02750,Leucine-rich alpha-2-glycoprotein,LRG1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LRG1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02750,Leucine-rich alpha-2-glycoprotein,LRG1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LRG1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02750,Leucine-rich alpha-2-glycoprotein,LRG1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LRG1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02750,Leucine-rich alpha-2-glycoprotein,LRG1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LRG1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02750,Leucine-rich alpha-2-glycoprotein,LRG1,Skin dermis,Homo sapiens,14,years,4.79986730707427,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LRG1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02750,Leucine-rich alpha-2-glycoprotein,LRG1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LRG1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02750,Leucine-rich alpha-2-glycoprotein,LRG1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LRG1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02750,Leucine-rich alpha-2-glycoprotein,LRG1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LRG1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8TER0,"Sushi, nidogen and EGF-like domain-containing protein 1 {ECO:0000305}",SNED1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SNED1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8TER0,"Sushi, nidogen and EGF-like domain-containing protein 1 {ECO:0000305}",SNED1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SNED1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8TER0,"Sushi, nidogen and EGF-like domain-containing protein 1 {ECO:0000305}",SNED1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SNED1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8TER0,"Sushi, nidogen and EGF-like domain-containing protein 1 {ECO:0000305}",SNED1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SNED1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8TER0,"Sushi, nidogen and EGF-like domain-containing protein 1 {ECO:0000305}",SNED1,Skin dermis,Homo sapiens,14,years,2.72995263952041,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SNED1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8TER0,"Sushi, nidogen and EGF-like domain-containing protein 1 {ECO:0000305}",SNED1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SNED1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8TER0,"Sushi, nidogen and EGF-like domain-containing protein 1 {ECO:0000305}",SNED1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SNED1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8TER0,"Sushi, nidogen and EGF-like domain-containing protein 1 {ECO:0000305}",SNED1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SNED1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75635,Serpin B7,SERPINB7,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB7,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75635,Serpin B7,SERPINB7,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB7,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75635,Serpin B7,SERPINB7,Skin dermis,Homo sapiens,14,years,6.20783786471677,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB7,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75635,Serpin B7,SERPINB7,Skin dermis,Homo sapiens,14,years,5.43769235465079,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB7,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75635,Serpin B7,SERPINB7,Skin dermis,Homo sapiens,14,years,7.1154409619426,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB7,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75635,Serpin B7,SERPINB7,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB7,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75635,Serpin B7,SERPINB7,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB7,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75635,Serpin B7,SERPINB7,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB7,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07093,Glia-derived nexin,SERPINE2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINE2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07093,Glia-derived nexin,SERPINE2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINE2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07093,Glia-derived nexin,SERPINE2,Skin dermis,Homo sapiens,14,years,4.73663732498912,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINE2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07093,Glia-derived nexin,SERPINE2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINE2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07093,Glia-derived nexin,SERPINE2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINE2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07093,Glia-derived nexin,SERPINE2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINE2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07093,Glia-derived nexin,SERPINE2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINE2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07093,Glia-derived nexin,SERPINE2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINE2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P39900,Macrophage metalloelastase,MMP12,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P39900,Macrophage metalloelastase,MMP12,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P39900,Macrophage metalloelastase,MMP12,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P39900,Macrophage metalloelastase,MMP12,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P39900,Macrophage metalloelastase,MMP12,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P39900,Macrophage metalloelastase,MMP12,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P39900,Macrophage metalloelastase,MMP12,Skin dermis,Homo sapiens,65,years,5.45887785893646,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P39900,Macrophage metalloelastase,MMP12,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MMP12,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00740,Coagulation factor IX {ECO:0000303|PubMed:3857619},F9,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00740,Coagulation factor IX {ECO:0000303|PubMed:3857619},F9,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00740,Coagulation factor IX {ECO:0000303|PubMed:3857619},F9,Skin dermis,Homo sapiens,14,years,4.8941112692493,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00740,Coagulation factor IX {ECO:0000303|PubMed:3857619},F9,Skin dermis,Homo sapiens,14,years,5.74385820039886,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00740,Coagulation factor IX {ECO:0000303|PubMed:3857619},F9,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00740,Coagulation factor IX {ECO:0000303|PubMed:3857619},F9,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00740,Coagulation factor IX {ECO:0000303|PubMed:3857619},F9,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00740,Coagulation factor IX {ECO:0000303|PubMed:3857619},F9,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F9,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22792,Carboxypeptidase N subunit 2,CPN2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CPN2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22792,Carboxypeptidase N subunit 2,CPN2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CPN2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22792,Carboxypeptidase N subunit 2,CPN2,Skin dermis,Homo sapiens,14,years,6.78366631941709,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CPN2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22792,Carboxypeptidase N subunit 2,CPN2,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CPN2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22792,Carboxypeptidase N subunit 2,CPN2,Skin dermis,Homo sapiens,14,years,6.64096207499422,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CPN2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22792,Carboxypeptidase N subunit 2,CPN2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CPN2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22792,Carboxypeptidase N subunit 2,CPN2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CPN2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P22792,Carboxypeptidase N subunit 2,CPN2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CPN2,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P29400,Collagen alpha-5(IV) chain,COL4A5,Skin dermis,Homo sapiens,2,years,2.67142412276119,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P29400,Collagen alpha-5(IV) chain,COL4A5,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P29400,Collagen alpha-5(IV) chain,COL4A5,Skin dermis,Homo sapiens,14,years,5.84831161348246,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P29400,Collagen alpha-5(IV) chain,COL4A5,Skin dermis,Homo sapiens,14,years,6.66062808024227,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P29400,Collagen alpha-5(IV) chain,COL4A5,Skin dermis,Homo sapiens,14,years,6.93934634755681,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P29400,Collagen alpha-5(IV) chain,COL4A5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P29400,Collagen alpha-5(IV) chain,COL4A5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P29400,Collagen alpha-5(IV) chain,COL4A5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A5,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q9GZM7,Tubulointerstitial nephritis antigen-like,TINAGL1,Skin dermis,Homo sapiens,2,years,8.56443164638941,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TINAGL1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9GZM7,Tubulointerstitial nephritis antigen-like,TINAGL1,Skin dermis,Homo sapiens,2,years,7.9816544900858,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TINAGL1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9GZM7,Tubulointerstitial nephritis antigen-like,TINAGL1,Skin dermis,Homo sapiens,14,years,11.6117054128043,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TINAGL1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9GZM7,Tubulointerstitial nephritis antigen-like,TINAGL1,Skin dermis,Homo sapiens,14,years,12.2722760170083,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TINAGL1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9GZM7,Tubulointerstitial nephritis antigen-like,TINAGL1,Skin dermis,Homo sapiens,14,years,12.0537440178396,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TINAGL1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9GZM7,Tubulointerstitial nephritis antigen-like,TINAGL1,Skin dermis,Homo sapiens,65,years,13.6062796351566,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TINAGL1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9GZM7,Tubulointerstitial nephritis antigen-like,TINAGL1,Skin dermis,Homo sapiens,65,years,12.2854233619616,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TINAGL1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9GZM7,Tubulointerstitial nephritis antigen-like,TINAGL1,Skin dermis,Homo sapiens,65,years,12.8095329427767,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TINAGL1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9HCB6,Spondin-1,SPON1,Skin dermis,Homo sapiens,2,years,7.14774603858402,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPON1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9HCB6,Spondin-1,SPON1,Skin dermis,Homo sapiens,2,years,6.53689631525383,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPON1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9HCB6,Spondin-1,SPON1,Skin dermis,Homo sapiens,14,years,3.54396036745373,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPON1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9HCB6,Spondin-1,SPON1,Skin dermis,Homo sapiens,14,years,5.10720910743775,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPON1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9HCB6,Spondin-1,SPON1,Skin dermis,Homo sapiens,14,years,4.17206633884483,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPON1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9HCB6,Spondin-1,SPON1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPON1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9HCB6,Spondin-1,SPON1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPON1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9HCB6,Spondin-1,SPON1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPON1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P05154,Plasma serine protease inhibitor,SERPINA5,Skin dermis,Homo sapiens,2,years,3.52856938606806,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05154,Plasma serine protease inhibitor,SERPINA5,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05154,Plasma serine protease inhibitor,SERPINA5,Skin dermis,Homo sapiens,14,years,7.82764004134366,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05154,Plasma serine protease inhibitor,SERPINA5,Skin dermis,Homo sapiens,14,years,6.90606615388176,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05154,Plasma serine protease inhibitor,SERPINA5,Skin dermis,Homo sapiens,14,years,6.28763633828197,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05154,Plasma serine protease inhibitor,SERPINA5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05154,Plasma serine protease inhibitor,SERPINA5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05154,Plasma serine protease inhibitor,SERPINA5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P39060,Collagen alpha-1(XVIII) chain {ECO:0000305},COL18A1,Skin dermis,Homo sapiens,2,years,9.9451940497367,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL18A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39060,Collagen alpha-1(XVIII) chain {ECO:0000305},COL18A1,Skin dermis,Homo sapiens,2,years,10.3778200427069,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL18A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39060,Collagen alpha-1(XVIII) chain {ECO:0000305},COL18A1,Skin dermis,Homo sapiens,14,years,10.8097910212414,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL18A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39060,Collagen alpha-1(XVIII) chain {ECO:0000305},COL18A1,Skin dermis,Homo sapiens,14,years,10.630469804683,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL18A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39060,Collagen alpha-1(XVIII) chain {ECO:0000305},COL18A1,Skin dermis,Homo sapiens,14,years,10.5437263987813,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL18A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39060,Collagen alpha-1(XVIII) chain {ECO:0000305},COL18A1,Skin dermis,Homo sapiens,65,years,7.38360658233064,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL18A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39060,Collagen alpha-1(XVIII) chain {ECO:0000305},COL18A1,Skin dermis,Homo sapiens,65,years,5.82304026867904,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL18A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P39060,Collagen alpha-1(XVIII) chain {ECO:0000305},COL18A1,Skin dermis,Homo sapiens,65,years,5.81350718425042,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL18A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q06033,Inter-alpha-trypsin inhibitor heavy chain H3,ITIH3,Skin dermis,Homo sapiens,2,years,2.98208191093939,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q06033,Inter-alpha-trypsin inhibitor heavy chain H3,ITIH3,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q06033,Inter-alpha-trypsin inhibitor heavy chain H3,ITIH3,Skin dermis,Homo sapiens,14,years,7.5902061990173,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q06033,Inter-alpha-trypsin inhibitor heavy chain H3,ITIH3,Skin dermis,Homo sapiens,14,years,8.33060645523981,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q06033,Inter-alpha-trypsin inhibitor heavy chain H3,ITIH3,Skin dermis,Homo sapiens,14,years,8.16645211457119,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q06033,Inter-alpha-trypsin inhibitor heavy chain H3,ITIH3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q06033,Inter-alpha-trypsin inhibitor heavy chain H3,ITIH3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q06033,Inter-alpha-trypsin inhibitor heavy chain H3,ITIH3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ITIH3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96RW7,Hemicentin-1,HMCN1,Skin dermis,Homo sapiens,2,years,9.22984018817961,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96RW7,Hemicentin-1,HMCN1,Skin dermis,Homo sapiens,2,years,8.94975998081865,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96RW7,Hemicentin-1,HMCN1,Skin dermis,Homo sapiens,14,years,8.28143595059291,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96RW7,Hemicentin-1,HMCN1,Skin dermis,Homo sapiens,14,years,9.19184536964439,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96RW7,Hemicentin-1,HMCN1,Skin dermis,Homo sapiens,14,years,7.84279311306299,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96RW7,Hemicentin-1,HMCN1,Skin dermis,Homo sapiens,65,years,4.7315599224989,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96RW7,Hemicentin-1,HMCN1,Skin dermis,Homo sapiens,65,years,3.97241645471944,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96RW7,Hemicentin-1,HMCN1,Skin dermis,Homo sapiens,65,years,3.42124302267313,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HMCN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P11047,Laminin subunit gamma-1,LAMC1,Skin dermis,Homo sapiens,2,years,11.5186968331041,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P11047,Laminin subunit gamma-1,LAMC1,Skin dermis,Homo sapiens,2,years,11.7876818291391,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P11047,Laminin subunit gamma-1,LAMC1,Skin dermis,Homo sapiens,14,years,12.7627873683515,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P11047,Laminin subunit gamma-1,LAMC1,Skin dermis,Homo sapiens,14,years,12.6461578152225,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P11047,Laminin subunit gamma-1,LAMC1,Skin dermis,Homo sapiens,14,years,12.3804654701073,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P11047,Laminin subunit gamma-1,LAMC1,Skin dermis,Homo sapiens,65,years,12.4095685854496,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P11047,Laminin subunit gamma-1,LAMC1,Skin dermis,Homo sapiens,65,years,12.2396421344123,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P11047,Laminin subunit gamma-1,LAMC1,Skin dermis,Homo sapiens,65,years,12.8167012263877,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXX0,EMILIN-2,EMILIN2,Skin dermis,Homo sapiens,2,years,8.88414147803363,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXX0,EMILIN-2,EMILIN2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXX0,EMILIN-2,EMILIN2,Skin dermis,Homo sapiens,14,years,8.59905534628693,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXX0,EMILIN-2,EMILIN2,Skin dermis,Homo sapiens,14,years,8.89275814564082,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXX0,EMILIN-2,EMILIN2,Skin dermis,Homo sapiens,14,years,9.15377783026377,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXX0,EMILIN-2,EMILIN2,Skin dermis,Homo sapiens,65,years,7.63581592102396,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXX0,EMILIN-2,EMILIN2,Skin dermis,Homo sapiens,65,years,5.64623496732496,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9BXX0,EMILIN-2,EMILIN2,Skin dermis,Homo sapiens,65,years,7.99846427894021,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",EMILIN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15113,Procollagen C-endopeptidase enhancer 1,PCOLCE,Skin dermis,Homo sapiens,2,years,12.4826317299689,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PCOLCE,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15113,Procollagen C-endopeptidase enhancer 1,PCOLCE,Skin dermis,Homo sapiens,2,years,11.3854974260594,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PCOLCE,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15113,Procollagen C-endopeptidase enhancer 1,PCOLCE,Skin dermis,Homo sapiens,14,years,12.41698800932,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PCOLCE,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15113,Procollagen C-endopeptidase enhancer 1,PCOLCE,Skin dermis,Homo sapiens,14,years,11.7900169118715,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PCOLCE,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15113,Procollagen C-endopeptidase enhancer 1,PCOLCE,Skin dermis,Homo sapiens,14,years,11.9460738924588,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PCOLCE,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15113,Procollagen C-endopeptidase enhancer 1,PCOLCE,Skin dermis,Homo sapiens,65,years,11.3075323493641,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PCOLCE,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15113,Procollagen C-endopeptidase enhancer 1,PCOLCE,Skin dermis,Homo sapiens,65,years,6.89923650994592,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PCOLCE,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q15113,Procollagen C-endopeptidase enhancer 1,PCOLCE,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PCOLCE,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P05155,Plasma protease C1 inhibitor {ECO:0000303|PubMed:3488058},SERPING1,Skin dermis,Homo sapiens,2,years,11.0968652175928,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPING1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05155,Plasma protease C1 inhibitor {ECO:0000303|PubMed:3488058},SERPING1,Skin dermis,Homo sapiens,2,years,11.4638470959136,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPING1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05155,Plasma protease C1 inhibitor {ECO:0000303|PubMed:3488058},SERPING1,Skin dermis,Homo sapiens,14,years,11.029988945398,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPING1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05155,Plasma protease C1 inhibitor {ECO:0000303|PubMed:3488058},SERPING1,Skin dermis,Homo sapiens,14,years,10.9438951644147,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPING1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05155,Plasma protease C1 inhibitor {ECO:0000303|PubMed:3488058},SERPING1,Skin dermis,Homo sapiens,14,years,11.7040737192238,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPING1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05155,Plasma protease C1 inhibitor {ECO:0000303|PubMed:3488058},SERPING1,Skin dermis,Homo sapiens,65,years,6.26397953944391,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPING1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05155,Plasma protease C1 inhibitor {ECO:0000303|PubMed:3488058},SERPING1,Skin dermis,Homo sapiens,65,years,11.4206552452299,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPING1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P05155,Plasma protease C1 inhibitor {ECO:0000303|PubMed:3488058},SERPING1,Skin dermis,Homo sapiens,65,years,10.7923700140742,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPING1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q2M2W7,UPF0450 protein C17orf58,C17orf58,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C17orf58,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q2M2W7,UPF0450 protein C17orf58,C17orf58,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C17orf58,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q2M2W7,UPF0450 protein C17orf58,C17orf58,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C17orf58,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q2M2W7,UPF0450 protein C17orf58,C17orf58,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C17orf58,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q2M2W7,UPF0450 protein C17orf58,C17orf58,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C17orf58,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q2M2W7,UPF0450 protein C17orf58,C17orf58,Skin dermis,Homo sapiens,65,years,13.021669019859,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C17orf58,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q2M2W7,UPF0450 protein C17orf58,C17orf58,Skin dermis,Homo sapiens,65,years,11.0141247703342,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C17orf58,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q2M2W7,UPF0450 protein C17orf58,C17orf58,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",C17orf58,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9NRJ3,C-C motif chemokine 28,CCL28,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL28,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9NRJ3,C-C motif chemokine 28,CCL28,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL28,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9NRJ3,C-C motif chemokine 28,CCL28,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL28,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9NRJ3,C-C motif chemokine 28,CCL28,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL28,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9NRJ3,C-C motif chemokine 28,CCL28,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL28,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9NRJ3,C-C motif chemokine 28,CCL28,Skin dermis,Homo sapiens,65,years,11.5234091803192,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL28,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9NRJ3,C-C motif chemokine 28,CCL28,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL28,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9NRJ3,C-C motif chemokine 28,CCL28,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CCL28,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02458,Collagen alpha-1(II) chain {ECO:0000305},COL2A1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL2A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02458,Collagen alpha-1(II) chain {ECO:0000305},COL2A1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL2A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02458,Collagen alpha-1(II) chain {ECO:0000305},COL2A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL2A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02458,Collagen alpha-1(II) chain {ECO:0000305},COL2A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL2A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02458,Collagen alpha-1(II) chain {ECO:0000305},COL2A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL2A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02458,Collagen alpha-1(II) chain {ECO:0000305},COL2A1,Skin dermis,Homo sapiens,65,years,9.62289316695759,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL2A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02458,Collagen alpha-1(II) chain {ECO:0000305},COL2A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL2A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02458,Collagen alpha-1(II) chain {ECO:0000305},COL2A1,Skin dermis,Homo sapiens,65,years,7.01062083761678,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL2A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P27658,Collagen alpha-1(VIII) chain,COL8A1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL8A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P27658,Collagen alpha-1(VIII) chain,COL8A1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL8A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P27658,Collagen alpha-1(VIII) chain,COL8A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL8A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P27658,Collagen alpha-1(VIII) chain,COL8A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL8A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P27658,Collagen alpha-1(VIII) chain,COL8A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL8A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P27658,Collagen alpha-1(VIII) chain,COL8A1,Skin dermis,Homo sapiens,65,years,8.29020979477111,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL8A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P27658,Collagen alpha-1(VIII) chain,COL8A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL8A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P27658,Collagen alpha-1(VIII) chain,COL8A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL8A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P49765,Vascular endothelial growth factor B,VEGFB,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VEGFB,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49765,Vascular endothelial growth factor B,VEGFB,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VEGFB,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49765,Vascular endothelial growth factor B,VEGFB,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VEGFB,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49765,Vascular endothelial growth factor B,VEGFB,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VEGFB,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49765,Vascular endothelial growth factor B,VEGFB,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VEGFB,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49765,Vascular endothelial growth factor B,VEGFB,Skin dermis,Homo sapiens,65,years,10.2622938307609,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VEGFB,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49765,Vascular endothelial growth factor B,VEGFB,Skin dermis,Homo sapiens,65,years,7.10572066911125,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VEGFB,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P49765,Vascular endothelial growth factor B,VEGFB,Skin dermis,Homo sapiens,65,years,6.22960953414291,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VEGFB,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P23297,Protein S100-A1,S100A1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P23297,Protein S100-A1,S100A1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P23297,Protein S100-A1,S100A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P23297,Protein S100-A1,S100A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P23297,Protein S100-A1,S100A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P23297,Protein S100-A1,S100A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P23297,Protein S100-A1,S100A1,Skin dermis,Homo sapiens,65,years,7.75813820676297,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P23297,Protein S100-A1,S100A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A1,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O43548,Protein-glutamine gamma-glutamyltransferase 5,TGM5,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O43548,Protein-glutamine gamma-glutamyltransferase 5,TGM5,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O43548,Protein-glutamine gamma-glutamyltransferase 5,TGM5,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O43548,Protein-glutamine gamma-glutamyltransferase 5,TGM5,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O43548,Protein-glutamine gamma-glutamyltransferase 5,TGM5,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O43548,Protein-glutamine gamma-glutamyltransferase 5,TGM5,Skin dermis,Homo sapiens,65,years,8.26987827608905,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O43548,Protein-glutamine gamma-glutamyltransferase 5,TGM5,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
O43548,Protein-glutamine gamma-glutamyltransferase 5,TGM5,Skin dermis,Homo sapiens,65,years,5.38877105784873,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TGM5,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20742,Pregnancy zone protein,PZP,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PZP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20742,Pregnancy zone protein,PZP,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PZP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20742,Pregnancy zone protein,PZP,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PZP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20742,Pregnancy zone protein,PZP,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PZP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20742,Pregnancy zone protein,PZP,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PZP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20742,Pregnancy zone protein,PZP,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PZP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20742,Pregnancy zone protein,PZP,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PZP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P20742,Pregnancy zone protein,PZP,Skin dermis,Homo sapiens,65,years,6.21995281541703,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PZP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q92954,Proteoglycan 4,PRG4,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG4,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q92954,Proteoglycan 4,PRG4,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG4,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q92954,Proteoglycan 4,PRG4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG4,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q92954,Proteoglycan 4,PRG4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG4,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q92954,Proteoglycan 4,PRG4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG4,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q92954,Proteoglycan 4,PRG4,Skin dermis,Homo sapiens,65,years,8.4677571302461,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG4,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q92954,Proteoglycan 4,PRG4,Skin dermis,Homo sapiens,65,years,3.00454614898184,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG4,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q92954,Proteoglycan 4,PRG4,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",PRG4,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q03692,Collagen alpha-1(X) chain,COL10A1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL10A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q03692,Collagen alpha-1(X) chain,COL10A1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL10A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q03692,Collagen alpha-1(X) chain,COL10A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL10A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q03692,Collagen alpha-1(X) chain,COL10A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL10A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q03692,Collagen alpha-1(X) chain,COL10A1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL10A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q03692,Collagen alpha-1(X) chain,COL10A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL10A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q03692,Collagen alpha-1(X) chain,COL10A1,Skin dermis,Homo sapiens,65,years,5.59486150223169,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL10A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q03692,Collagen alpha-1(X) chain,COL10A1,Skin dermis,Homo sapiens,65,years,4.86512469518843,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL10A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P49746,Thrombospondin-3,THBS3,Skin dermis,Homo sapiens,2,years,10.8465477833458,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P49746,Thrombospondin-3,THBS3,Skin dermis,Homo sapiens,2,years,10.2761426093875,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P49746,Thrombospondin-3,THBS3,Skin dermis,Homo sapiens,14,years,10.5964159034801,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P49746,Thrombospondin-3,THBS3,Skin dermis,Homo sapiens,14,years,9.95503650237682,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P49746,Thrombospondin-3,THBS3,Skin dermis,Homo sapiens,14,years,10.1726631637759,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P49746,Thrombospondin-3,THBS3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P49746,Thrombospondin-3,THBS3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P49746,Thrombospondin-3,THBS3,Skin dermis,Homo sapiens,65,years,16.8730831336963,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",THBS3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P09486,SPARC,SPARC,Skin dermis,Homo sapiens,2,years,9.34600763842407,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPARC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P09486,SPARC,SPARC,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPARC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P09486,SPARC,SPARC,Skin dermis,Homo sapiens,14,years,9.62570538274891,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPARC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P09486,SPARC,SPARC,Skin dermis,Homo sapiens,14,years,6.82020620320239,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPARC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P09486,SPARC,SPARC,Skin dermis,Homo sapiens,14,years,9.28412445182397,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPARC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P09486,SPARC,SPARC,Skin dermis,Homo sapiens,65,years,12.1543089280184,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPARC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P09486,SPARC,SPARC,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPARC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P09486,SPARC,SPARC,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SPARC,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55001,Microfibrillar-associated protein 2,MFAP2,Skin dermis,Homo sapiens,2,years,15.8582277339712,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55001,Microfibrillar-associated protein 2,MFAP2,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55001,Microfibrillar-associated protein 2,MFAP2,Skin dermis,Homo sapiens,14,years,15.4585896165662,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55001,Microfibrillar-associated protein 2,MFAP2,Skin dermis,Homo sapiens,14,years,15.6858610008571,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55001,Microfibrillar-associated protein 2,MFAP2,Skin dermis,Homo sapiens,14,years,15.3545383526616,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55001,Microfibrillar-associated protein 2,MFAP2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55001,Microfibrillar-associated protein 2,MFAP2,Skin dermis,Homo sapiens,65,years,16.5630583638884,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55001,Microfibrillar-associated protein 2,MFAP2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MFAP2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02452,Collagen alpha-1(I) chain,COL1A1,Skin dermis,Homo sapiens,2,years,17.2231574626972,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02452,Collagen alpha-1(I) chain,COL1A1,Skin dermis,Homo sapiens,2,years,17.4194086299532,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02452,Collagen alpha-1(I) chain,COL1A1,Skin dermis,Homo sapiens,14,years,18.0289449438224,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02452,Collagen alpha-1(I) chain,COL1A1,Skin dermis,Homo sapiens,14,years,18.2860337234925,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02452,Collagen alpha-1(I) chain,COL1A1,Skin dermis,Homo sapiens,14,years,18.0196702478594,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02452,Collagen alpha-1(I) chain,COL1A1,Skin dermis,Homo sapiens,65,years,21.2162010618225,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02452,Collagen alpha-1(I) chain,COL1A1,Skin dermis,Homo sapiens,65,years,18.861563639708,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02452,Collagen alpha-1(I) chain,COL1A1,Skin dermis,Homo sapiens,65,years,19.5979644782674,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08123,Collagen alpha-2(I) chain,COL1A2,Skin dermis,Homo sapiens,2,years,17.5105194308994,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08123,Collagen alpha-2(I) chain,COL1A2,Skin dermis,Homo sapiens,2,years,17.1496525615391,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08123,Collagen alpha-2(I) chain,COL1A2,Skin dermis,Homo sapiens,14,years,17.729878662009,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08123,Collagen alpha-2(I) chain,COL1A2,Skin dermis,Homo sapiens,14,years,18.0932546636247,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08123,Collagen alpha-2(I) chain,COL1A2,Skin dermis,Homo sapiens,14,years,17.6609619215103,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08123,Collagen alpha-2(I) chain,COL1A2,Skin dermis,Homo sapiens,65,years,18.9415717080622,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08123,Collagen alpha-2(I) chain,COL1A2,Skin dermis,Homo sapiens,65,years,18.3676777481977,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08123,Collagen alpha-2(I) chain,COL1A2,Skin dermis,Homo sapiens,65,years,18.8072478017902,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL1A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q8WU66,Thrombospondin-type laminin G domain and EAR repeat-containing protein,TSPEAR,Skin dermis,Homo sapiens,2,years,5.29256503142119,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TSPEAR,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8WU66,Thrombospondin-type laminin G domain and EAR repeat-containing protein,TSPEAR,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TSPEAR,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8WU66,Thrombospondin-type laminin G domain and EAR repeat-containing protein,TSPEAR,Skin dermis,Homo sapiens,14,years,5.07652865222363,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TSPEAR,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8WU66,Thrombospondin-type laminin G domain and EAR repeat-containing protein,TSPEAR,Skin dermis,Homo sapiens,14,years,5.39843292420356,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TSPEAR,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8WU66,Thrombospondin-type laminin G domain and EAR repeat-containing protein,TSPEAR,Skin dermis,Homo sapiens,14,years,6.13473673349874,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TSPEAR,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8WU66,Thrombospondin-type laminin G domain and EAR repeat-containing protein,TSPEAR,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TSPEAR,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8WU66,Thrombospondin-type laminin G domain and EAR repeat-containing protein,TSPEAR,Skin dermis,Homo sapiens,65,years,6.80716402437847,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TSPEAR,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8WU66,Thrombospondin-type laminin G domain and EAR repeat-containing protein,TSPEAR,Skin dermis,Homo sapiens,65,years,6.84950922036891,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TSPEAR,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P15502,Elastin,ELN,Skin dermis,Homo sapiens,2,years,10.3915932008532,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ELN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P15502,Elastin,ELN,Skin dermis,Homo sapiens,2,years,11.0574306964194,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ELN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P15502,Elastin,ELN,Skin dermis,Homo sapiens,14,years,8.10387215605454,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ELN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P15502,Elastin,ELN,Skin dermis,Homo sapiens,14,years,6.2049754035868,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ELN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P15502,Elastin,ELN,Skin dermis,Homo sapiens,14,years,5.40905257255403,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ELN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P15502,Elastin,ELN,Skin dermis,Homo sapiens,65,years,19.517948534426,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ELN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P15502,Elastin,ELN,Skin dermis,Homo sapiens,65,years,17.9605709859439,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ELN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P15502,Elastin,ELN,Skin dermis,Homo sapiens,65,years,14.6331811935485,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",ELN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35555,Fibrillin-1 {ECO:0000303|PubMed:15221638},FBN1,Skin dermis,Homo sapiens,2,years,15.2917438291372,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35555,Fibrillin-1 {ECO:0000303|PubMed:15221638},FBN1,Skin dermis,Homo sapiens,2,years,11.7534957081564,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35555,Fibrillin-1 {ECO:0000303|PubMed:15221638},FBN1,Skin dermis,Homo sapiens,14,years,14.4745375124641,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35555,Fibrillin-1 {ECO:0000303|PubMed:15221638},FBN1,Skin dermis,Homo sapiens,14,years,15.0230168237111,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35555,Fibrillin-1 {ECO:0000303|PubMed:15221638},FBN1,Skin dermis,Homo sapiens,14,years,14.7126105483067,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35555,Fibrillin-1 {ECO:0000303|PubMed:15221638},FBN1,Skin dermis,Homo sapiens,65,years,16.3893084427433,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35555,Fibrillin-1 {ECO:0000303|PubMed:15221638},FBN1,Skin dermis,Homo sapiens,65,years,17.8299215023014,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35555,Fibrillin-1 {ECO:0000303|PubMed:15221638},FBN1,Skin dermis,Homo sapiens,65,years,15.9941568570627,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P08572,Collagen alpha-2(IV) chain {ECO:0000305},COL4A2,Skin dermis,Homo sapiens,2,years,10.6183427019403,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08572,Collagen alpha-2(IV) chain {ECO:0000305},COL4A2,Skin dermis,Homo sapiens,2,years,10.5286976272248,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08572,Collagen alpha-2(IV) chain {ECO:0000305},COL4A2,Skin dermis,Homo sapiens,14,years,11.2372042776527,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08572,Collagen alpha-2(IV) chain {ECO:0000305},COL4A2,Skin dermis,Homo sapiens,14,years,11.5259889532512,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08572,Collagen alpha-2(IV) chain {ECO:0000305},COL4A2,Skin dermis,Homo sapiens,14,years,11.1848950628516,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08572,Collagen alpha-2(IV) chain {ECO:0000305},COL4A2,Skin dermis,Homo sapiens,65,years,14.097286291084,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08572,Collagen alpha-2(IV) chain {ECO:0000305},COL4A2,Skin dermis,Homo sapiens,65,years,11.6748284218411,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08572,Collagen alpha-2(IV) chain {ECO:0000305},COL4A2,Skin dermis,Homo sapiens,65,years,12.0454393369037,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A2,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P01011,Alpha-1-antichymotrypsin,SERPINA3,Skin dermis,Homo sapiens,2,years,10.8515144672573,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01011,Alpha-1-antichymotrypsin,SERPINA3,Skin dermis,Homo sapiens,2,years,11.1994173526778,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01011,Alpha-1-antichymotrypsin,SERPINA3,Skin dermis,Homo sapiens,14,years,9.98393340741228,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01011,Alpha-1-antichymotrypsin,SERPINA3,Skin dermis,Homo sapiens,14,years,10.9092961335469,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01011,Alpha-1-antichymotrypsin,SERPINA3,Skin dermis,Homo sapiens,14,years,10.8884121011557,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01011,Alpha-1-antichymotrypsin,SERPINA3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01011,Alpha-1-antichymotrypsin,SERPINA3,Skin dermis,Homo sapiens,65,years,12.2407712046169,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P01011,Alpha-1-antichymotrypsin,SERPINA3,Skin dermis,Homo sapiens,65,years,11.753086639625,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINA3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35625,Metalloproteinase inhibitor 3,TIMP3,Skin dermis,Homo sapiens,2,years,8.66287557376026,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TIMP3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35625,Metalloproteinase inhibitor 3,TIMP3,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TIMP3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35625,Metalloproteinase inhibitor 3,TIMP3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TIMP3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35625,Metalloproteinase inhibitor 3,TIMP3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TIMP3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35625,Metalloproteinase inhibitor 3,TIMP3,Skin dermis,Homo sapiens,14,years,5.74084749351772,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TIMP3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35625,Metalloproteinase inhibitor 3,TIMP3,Skin dermis,Homo sapiens,65,years,14.415814864577,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TIMP3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35625,Metalloproteinase inhibitor 3,TIMP3,Skin dermis,Homo sapiens,65,years,12.0422070230094,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TIMP3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P35625,Metalloproteinase inhibitor 3,TIMP3,Skin dermis,Homo sapiens,65,years,9.70105484732828,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TIMP3,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q96CG8,Collagen triple helix repeat-containing protein 1,CTHRC1,Skin dermis,Homo sapiens,2,years,9.51209602400146,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTHRC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96CG8,Collagen triple helix repeat-containing protein 1,CTHRC1,Skin dermis,Homo sapiens,2,years,8.65948480366011,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTHRC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96CG8,Collagen triple helix repeat-containing protein 1,CTHRC1,Skin dermis,Homo sapiens,14,years,9.08578297818532,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTHRC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96CG8,Collagen triple helix repeat-containing protein 1,CTHRC1,Skin dermis,Homo sapiens,14,years,7.48293850741166,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTHRC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96CG8,Collagen triple helix repeat-containing protein 1,CTHRC1,Skin dermis,Homo sapiens,14,years,9.64773808912624,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTHRC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96CG8,Collagen triple helix repeat-containing protein 1,CTHRC1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTHRC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96CG8,Collagen triple helix repeat-containing protein 1,CTHRC1,Skin dermis,Homo sapiens,65,years,11.8125749462723,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTHRC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q96CG8,Collagen triple helix repeat-containing protein 1,CTHRC1,Skin dermis,Homo sapiens,65,years,7.84933604501119,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTHRC1,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P00742,Coagulation factor X,F10,Skin dermis,Homo sapiens,2,years,4.76063103763707,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F10,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00742,Coagulation factor X,F10,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F10,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00742,Coagulation factor X,F10,Skin dermis,Homo sapiens,14,years,4.58674026563883,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F10,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00742,Coagulation factor X,F10,Skin dermis,Homo sapiens,14,years,5.50414622780001,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F10,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00742,Coagulation factor X,F10,Skin dermis,Homo sapiens,14,years,5.37374194031161,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F10,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00742,Coagulation factor X,F10,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F10,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00742,Coagulation factor X,F10,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F10,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P00742,Coagulation factor X,F10,Skin dermis,Homo sapiens,65,years,6.14640101693011,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",F10,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P12111,Collagen alpha-3(VI) chain,COL6A3,Skin dermis,Homo sapiens,2,years,16.9474581359068,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12111,Collagen alpha-3(VI) chain,COL6A3,Skin dermis,Homo sapiens,2,years,17.9522310622436,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12111,Collagen alpha-3(VI) chain,COL6A3,Skin dermis,Homo sapiens,14,years,17.4363714657856,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12111,Collagen alpha-3(VI) chain,COL6A3,Skin dermis,Homo sapiens,14,years,17.9797487021327,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12111,Collagen alpha-3(VI) chain,COL6A3,Skin dermis,Homo sapiens,14,years,17.8491168235274,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12111,Collagen alpha-3(VI) chain,COL6A3,Skin dermis,Homo sapiens,65,years,17.1747008857637,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12111,Collagen alpha-3(VI) chain,COL6A3,Skin dermis,Homo sapiens,65,years,18.6384238565608,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12111,Collagen alpha-3(VI) chain,COL6A3,Skin dermis,Homo sapiens,65,years,18.2294504804221,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A3,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P31151,Protein S100-A7,S100A7,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A7,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31151,Protein S100-A7,S100A7,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A7,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31151,Protein S100-A7,S100A7,Skin dermis,Homo sapiens,14,years,7.73904120759988,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A7,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31151,Protein S100-A7,S100A7,Skin dermis,Homo sapiens,14,years,7.17188885959665,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A7,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31151,Protein S100-A7,S100A7,Skin dermis,Homo sapiens,14,years,6.89503131917094,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A7,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31151,Protein S100-A7,S100A7,Skin dermis,Homo sapiens,65,years,11.8978643315449,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A7,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31151,Protein S100-A7,S100A7,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A7,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P31151,Protein S100-A7,S100A7,Skin dermis,Homo sapiens,65,years,11.4171575662405,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",S100A7,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P03973,Antileukoproteinase,SLPI,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLPI,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P03973,Antileukoproteinase,SLPI,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLPI,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P03973,Antileukoproteinase,SLPI,Skin dermis,Homo sapiens,14,years,8.98319883761999,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLPI,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P03973,Antileukoproteinase,SLPI,Skin dermis,Homo sapiens,14,years,9.31280578191625,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLPI,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P03973,Antileukoproteinase,SLPI,Skin dermis,Homo sapiens,14,years,10.5187783132837,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLPI,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P03973,Antileukoproteinase,SLPI,Skin dermis,Homo sapiens,65,years,13.8208582353373,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLPI,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P03973,Antileukoproteinase,SLPI,Skin dermis,Homo sapiens,65,years,13.0965675879592,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLPI,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P03973,Antileukoproteinase,SLPI,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SLPI,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P07585,Decorin,DCN,Skin dermis,Homo sapiens,2,years,15.7870346690093,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DCN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P07585,Decorin,DCN,Skin dermis,Homo sapiens,2,years,14.1406946650069,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DCN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P07585,Decorin,DCN,Skin dermis,Homo sapiens,14,years,17.3407777233352,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DCN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P07585,Decorin,DCN,Skin dermis,Homo sapiens,14,years,17.456104602215,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DCN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P07585,Decorin,DCN,Skin dermis,Homo sapiens,14,years,17.5486092949391,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DCN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P07585,Decorin,DCN,Skin dermis,Homo sapiens,65,years,18.3314338058197,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DCN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P07585,Decorin,DCN,Skin dermis,Homo sapiens,65,years,18.2371531365905,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DCN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P07585,Decorin,DCN,Skin dermis,Homo sapiens,65,years,19.8558308652354,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DCN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P28300,Protein-lysine 6-oxidase,LOX,Skin dermis,Homo sapiens,2,years,11.6521755672738,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOX,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P28300,Protein-lysine 6-oxidase,LOX,Skin dermis,Homo sapiens,2,years,11.7365096669327,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOX,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P28300,Protein-lysine 6-oxidase,LOX,Skin dermis,Homo sapiens,14,years,13.4534773381491,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOX,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P28300,Protein-lysine 6-oxidase,LOX,Skin dermis,Homo sapiens,14,years,13.4135389490554,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOX,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P28300,Protein-lysine 6-oxidase,LOX,Skin dermis,Homo sapiens,14,years,13.2898340236745,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOX,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P28300,Protein-lysine 6-oxidase,LOX,Skin dermis,Homo sapiens,65,years,12.8118527710039,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOX,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P28300,Protein-lysine 6-oxidase,LOX,Skin dermis,Homo sapiens,65,years,12.9862685775965,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOX,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P28300,Protein-lysine 6-oxidase,LOX,Skin dermis,Homo sapiens,65,years,15.6395847601108,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOX,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P12109,Collagen alpha-1(VI) chain,COL6A1,Skin dermis,Homo sapiens,2,years,17.563643434312,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12109,Collagen alpha-1(VI) chain,COL6A1,Skin dermis,Homo sapiens,2,years,18.3516350670626,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12109,Collagen alpha-1(VI) chain,COL6A1,Skin dermis,Homo sapiens,14,years,18.2597142701472,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12109,Collagen alpha-1(VI) chain,COL6A1,Skin dermis,Homo sapiens,14,years,18.7381430860215,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12109,Collagen alpha-1(VI) chain,COL6A1,Skin dermis,Homo sapiens,14,years,18.8283318423625,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12109,Collagen alpha-1(VI) chain,COL6A1,Skin dermis,Homo sapiens,65,years,19.5205185181744,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12109,Collagen alpha-1(VI) chain,COL6A1,Skin dermis,Homo sapiens,65,years,18.7739900221654,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P12109,Collagen alpha-1(VI) chain,COL6A1,Skin dermis,Homo sapiens,65,years,19.4423125460031,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL6A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02760,Protein AMBP {ECO:0000303|PubMed:1708673},AMBP,Skin dermis,Homo sapiens,2,years,9.44575228878177,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AMBP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02760,Protein AMBP {ECO:0000303|PubMed:1708673},AMBP,Skin dermis,Homo sapiens,2,years,9.72146003603697,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AMBP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02760,Protein AMBP {ECO:0000303|PubMed:1708673},AMBP,Skin dermis,Homo sapiens,14,years,12.9556130059481,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AMBP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02760,Protein AMBP {ECO:0000303|PubMed:1708673},AMBP,Skin dermis,Homo sapiens,14,years,13.4269378431299,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AMBP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02760,Protein AMBP {ECO:0000303|PubMed:1708673},AMBP,Skin dermis,Homo sapiens,14,years,13.9824437155034,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AMBP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02760,Protein AMBP {ECO:0000303|PubMed:1708673},AMBP,Skin dermis,Homo sapiens,65,years,15.1628095254156,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AMBP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02760,Protein AMBP {ECO:0000303|PubMed:1708673},AMBP,Skin dermis,Homo sapiens,65,years,15.3466031781903,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AMBP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02760,Protein AMBP {ECO:0000303|PubMed:1708673},AMBP,Skin dermis,Homo sapiens,65,years,16.0086166530454,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",AMBP,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q9UBX5,Fibulin-5,FBLN5,Skin dermis,Homo sapiens,2,years,12.2717611021011,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UBX5,Fibulin-5,FBLN5,Skin dermis,Homo sapiens,2,years,12.2177941855716,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UBX5,Fibulin-5,FBLN5,Skin dermis,Homo sapiens,14,years,12.4650655776073,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UBX5,Fibulin-5,FBLN5,Skin dermis,Homo sapiens,14,years,13.3821566645886,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UBX5,Fibulin-5,FBLN5,Skin dermis,Homo sapiens,14,years,12.3733739954574,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UBX5,Fibulin-5,FBLN5,Skin dermis,Homo sapiens,65,years,14.4557382587389,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UBX5,Fibulin-5,FBLN5,Skin dermis,Homo sapiens,65,years,14.7087123478713,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q9UBX5,Fibulin-5,FBLN5,Skin dermis,Homo sapiens,65,years,10.1045704767119,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBLN5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O15230,Laminin subunit alpha-5,LAMA5,Skin dermis,Homo sapiens,2,years,9.45137146856655,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O15230,Laminin subunit alpha-5,LAMA5,Skin dermis,Homo sapiens,2,years,10.4879123947036,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O15230,Laminin subunit alpha-5,LAMA5,Skin dermis,Homo sapiens,14,years,10.7720775286186,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O15230,Laminin subunit alpha-5,LAMA5,Skin dermis,Homo sapiens,14,years,10.761204515402,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O15230,Laminin subunit alpha-5,LAMA5,Skin dermis,Homo sapiens,14,years,10.6177210346326,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O15230,Laminin subunit alpha-5,LAMA5,Skin dermis,Homo sapiens,65,years,11.8326744605591,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O15230,Laminin subunit alpha-5,LAMA5,Skin dermis,Homo sapiens,65,years,10.2500371793957,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O15230,Laminin subunit alpha-5,LAMA5,Skin dermis,Homo sapiens,65,years,10.6254960750737,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMA5,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P13611,Versican core protein,VCAN,Skin dermis,Homo sapiens,2,years,12.4849166024136,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VCAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13611,Versican core protein,VCAN,Skin dermis,Homo sapiens,2,years,12.1466322274301,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VCAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13611,Versican core protein,VCAN,Skin dermis,Homo sapiens,14,years,11.526164666141,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VCAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13611,Versican core protein,VCAN,Skin dermis,Homo sapiens,14,years,12.3999682277826,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VCAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13611,Versican core protein,VCAN,Skin dermis,Homo sapiens,14,years,11.8166116240276,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VCAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13611,Versican core protein,VCAN,Skin dermis,Homo sapiens,65,years,13.1105964380465,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VCAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13611,Versican core protein,VCAN,Skin dermis,Homo sapiens,65,years,13.3547085616698,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VCAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P13611,Versican core protein,VCAN,Skin dermis,Homo sapiens,65,years,11.9350251892809,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VCAN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P04004,Vitronectin,VTN,Skin dermis,Homo sapiens,2,years,11.2646914632264,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04004,Vitronectin,VTN,Skin dermis,Homo sapiens,2,years,12.7876149721864,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04004,Vitronectin,VTN,Skin dermis,Homo sapiens,14,years,12.0841910433904,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04004,Vitronectin,VTN,Skin dermis,Homo sapiens,14,years,11.4893231953641,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04004,Vitronectin,VTN,Skin dermis,Homo sapiens,14,years,11.9004878597175,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04004,Vitronectin,VTN,Skin dermis,Homo sapiens,65,years,14.0191863952858,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04004,Vitronectin,VTN,Skin dermis,Homo sapiens,65,years,15.0967376602671,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P04004,Vitronectin,VTN,Skin dermis,Homo sapiens,65,years,15.0770382176197,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",VTN,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P20774,Mimecan,OGN,Skin dermis,Homo sapiens,2,years,14.5337540159748,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P20774,Mimecan,OGN,Skin dermis,Homo sapiens,2,years,15.200045421519,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P20774,Mimecan,OGN,Skin dermis,Homo sapiens,14,years,18.5191503885304,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P20774,Mimecan,OGN,Skin dermis,Homo sapiens,14,years,18.6416401352438,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P20774,Mimecan,OGN,Skin dermis,Homo sapiens,14,years,18.4673407253366,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P20774,Mimecan,OGN,Skin dermis,Homo sapiens,65,years,18.6026149298434,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P20774,Mimecan,OGN,Skin dermis,Homo sapiens,65,years,19.0662132389094,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P20774,Mimecan,OGN,Skin dermis,Homo sapiens,65,years,19.4040606138906,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",OGN,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
Q14031,Collagen alpha-6(IV) chain,COL4A6,Skin dermis,Homo sapiens,2,years,5.51804073457037,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q14031,Collagen alpha-6(IV) chain,COL4A6,Skin dermis,Homo sapiens,2,years,4.60061709413259,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q14031,Collagen alpha-6(IV) chain,COL4A6,Skin dermis,Homo sapiens,14,years,8.54283616148532,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q14031,Collagen alpha-6(IV) chain,COL4A6,Skin dermis,Homo sapiens,14,years,9.31610139912862,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q14031,Collagen alpha-6(IV) chain,COL4A6,Skin dermis,Homo sapiens,14,years,8.19485257048043,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q14031,Collagen alpha-6(IV) chain,COL4A6,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q14031,Collagen alpha-6(IV) chain,COL4A6,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
Q14031,Collagen alpha-6(IV) chain,COL4A6,Skin dermis,Homo sapiens,65,years,9.95653883231476,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A6,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P08311,Cathepsin G,CTSG,Skin dermis,Homo sapiens,2,years,13.0965576301315,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08311,Cathepsin G,CTSG,Skin dermis,Homo sapiens,2,years,13.1921790488989,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08311,Cathepsin G,CTSG,Skin dermis,Homo sapiens,14,years,12.9387100004044,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08311,Cathepsin G,CTSG,Skin dermis,Homo sapiens,14,years,12.8817059890537,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08311,Cathepsin G,CTSG,Skin dermis,Homo sapiens,14,years,12.6831744377537,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08311,Cathepsin G,CTSG,Skin dermis,Homo sapiens,65,years,12.7424580202108,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08311,Cathepsin G,CTSG,Skin dermis,Homo sapiens,65,years,14.8468344778453,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P08311,Cathepsin G,CTSG,Skin dermis,Homo sapiens,65,years,14.2556096679625,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CTSG,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P02675,Fibrinogen beta chain,FGB,Skin dermis,Homo sapiens,2,years,14.4779667612881,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02675,Fibrinogen beta chain,FGB,Skin dermis,Homo sapiens,2,years,13.9920512599341,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02675,Fibrinogen beta chain,FGB,Skin dermis,Homo sapiens,14,years,16.0266909280236,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02675,Fibrinogen beta chain,FGB,Skin dermis,Homo sapiens,14,years,14.7656163204125,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02675,Fibrinogen beta chain,FGB,Skin dermis,Homo sapiens,14,years,16.8563344850233,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02675,Fibrinogen beta chain,FGB,Skin dermis,Homo sapiens,65,years,15.0951311818,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02675,Fibrinogen beta chain,FGB,Skin dermis,Homo sapiens,65,years,16.5480038388356,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02675,Fibrinogen beta chain,FGB,Skin dermis,Homo sapiens,65,years,17.998077849122,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FGB,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P48061,Stromal cell-derived factor 1,CXCL12,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL12,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48061,Stromal cell-derived factor 1,CXCL12,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL12,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48061,Stromal cell-derived factor 1,CXCL12,Skin dermis,Homo sapiens,14,years,9.71654489147882,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL12,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48061,Stromal cell-derived factor 1,CXCL12,Skin dermis,Homo sapiens,14,years,9.22227596904974,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL12,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48061,Stromal cell-derived factor 1,CXCL12,Skin dermis,Homo sapiens,14,years,9.18422776192678,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL12,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48061,Stromal cell-derived factor 1,CXCL12,Skin dermis,Homo sapiens,65,years,14.7537180428657,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL12,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48061,Stromal cell-derived factor 1,CXCL12,Skin dermis,Homo sapiens,65,years,13.2177595770101,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL12,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48061,Stromal cell-derived factor 1,CXCL12,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CXCL12,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q07507,Dermatopontin,DPT,Skin dermis,Homo sapiens,2,years,16.2023274357377,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DPT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q07507,Dermatopontin,DPT,Skin dermis,Homo sapiens,2,years,16.3165495059963,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DPT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q07507,Dermatopontin,DPT,Skin dermis,Homo sapiens,14,years,17.9790138440502,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DPT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q07507,Dermatopontin,DPT,Skin dermis,Homo sapiens,14,years,18.2969182789088,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DPT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q07507,Dermatopontin,DPT,Skin dermis,Homo sapiens,14,years,18.1888603223194,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DPT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q07507,Dermatopontin,DPT,Skin dermis,Homo sapiens,65,years,18.8226995531477,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DPT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q07507,Dermatopontin,DPT,Skin dermis,Homo sapiens,65,years,17.2340479184773,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DPT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q07507,Dermatopontin,DPT,Skin dermis,Homo sapiens,65,years,19.1589907595976,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",DPT,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P02462,Collagen alpha-1(IV) chain {ECO:0000305},COL4A1,Skin dermis,Homo sapiens,2,years,11.1797452010869,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02462,Collagen alpha-1(IV) chain {ECO:0000305},COL4A1,Skin dermis,Homo sapiens,2,years,8.12214728201918,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02462,Collagen alpha-1(IV) chain {ECO:0000305},COL4A1,Skin dermis,Homo sapiens,14,years,11.9715797543532,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02462,Collagen alpha-1(IV) chain {ECO:0000305},COL4A1,Skin dermis,Homo sapiens,14,years,12.1809766304421,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02462,Collagen alpha-1(IV) chain {ECO:0000305},COL4A1,Skin dermis,Homo sapiens,14,years,11.9029233758599,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02462,Collagen alpha-1(IV) chain {ECO:0000305},COL4A1,Skin dermis,Homo sapiens,65,years,12.9596625669543,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02462,Collagen alpha-1(IV) chain {ECO:0000305},COL4A1,Skin dermis,Homo sapiens,65,years,12.2974099794747,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P02462,Collagen alpha-1(IV) chain {ECO:0000305},COL4A1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",COL4A1,Collagens,Core matrisome,Gene_Symbol_or_UniProt,1
P55268,Laminin subunit beta-2,LAMB2,Skin dermis,Homo sapiens,2,years,10.5119115041213,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55268,Laminin subunit beta-2,LAMB2,Skin dermis,Homo sapiens,2,years,11.1544996336704,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55268,Laminin subunit beta-2,LAMB2,Skin dermis,Homo sapiens,14,years,12.2284749243824,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55268,Laminin subunit beta-2,LAMB2,Skin dermis,Homo sapiens,14,years,11.9646682168558,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55268,Laminin subunit beta-2,LAMB2,Skin dermis,Homo sapiens,14,years,11.8856705146207,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55268,Laminin subunit beta-2,LAMB2,Skin dermis,Homo sapiens,65,years,13.2452371212813,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55268,Laminin subunit beta-2,LAMB2,Skin dermis,Homo sapiens,65,years,11.4095078067248,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P55268,Laminin subunit beta-2,LAMB2,Skin dermis,Homo sapiens,65,years,12.8474640641113,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LAMB2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35556,Fibrillin-2 {ECO:0000303|PubMed:32329225},FBN2,Skin dermis,Homo sapiens,2,years,12.1451683685562,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35556,Fibrillin-2 {ECO:0000303|PubMed:32329225},FBN2,Skin dermis,Homo sapiens,2,years,6.81084085600628,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35556,Fibrillin-2 {ECO:0000303|PubMed:32329225},FBN2,Skin dermis,Homo sapiens,14,years,8.17301232477922,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35556,Fibrillin-2 {ECO:0000303|PubMed:32329225},FBN2,Skin dermis,Homo sapiens,14,years,8.39809234638399,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35556,Fibrillin-2 {ECO:0000303|PubMed:32329225},FBN2,Skin dermis,Homo sapiens,14,years,8.48765409972446,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35556,Fibrillin-2 {ECO:0000303|PubMed:32329225},FBN2,Skin dermis,Homo sapiens,65,years,8.97240122350145,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35556,Fibrillin-2 {ECO:0000303|PubMed:32329225},FBN2,Skin dermis,Homo sapiens,65,years,11.1683088417226,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P35556,Fibrillin-2 {ECO:0000303|PubMed:32329225},FBN2,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN2,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75339,Cartilage intermediate layer protein 1,CILP,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CILP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75339,Cartilage intermediate layer protein 1,CILP,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CILP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75339,Cartilage intermediate layer protein 1,CILP,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CILP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75339,Cartilage intermediate layer protein 1,CILP,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CILP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75339,Cartilage intermediate layer protein 1,CILP,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CILP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75339,Cartilage intermediate layer protein 1,CILP,Skin dermis,Homo sapiens,65,years,9.24516841557668,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CILP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75339,Cartilage intermediate layer protein 1,CILP,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CILP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75339,Cartilage intermediate layer protein 1,CILP,Skin dermis,Homo sapiens,65,years,6.21548086415687,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",CILP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
O75888,Tumor necrosis factor ligand superfamily member 13,TNFSF13,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNFSF13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75888,Tumor necrosis factor ligand superfamily member 13,TNFSF13,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNFSF13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75888,Tumor necrosis factor ligand superfamily member 13,TNFSF13,Skin dermis,Homo sapiens,14,years,7.55696439131887,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNFSF13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75888,Tumor necrosis factor ligand superfamily member 13,TNFSF13,Skin dermis,Homo sapiens,14,years,8.01776690313941,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNFSF13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75888,Tumor necrosis factor ligand superfamily member 13,TNFSF13,Skin dermis,Homo sapiens,14,years,7.47548776705935,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNFSF13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75888,Tumor necrosis factor ligand superfamily member 13,TNFSF13,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNFSF13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75888,Tumor necrosis factor ligand superfamily member 13,TNFSF13,Skin dermis,Homo sapiens,65,years,11.9248839976879,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNFSF13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
O75888,Tumor necrosis factor ligand superfamily member 13,TNFSF13,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",TNFSF13,Secreted Factors,Matrisome-associated,Gene_Symbol_or_UniProt,1
P10915,Hyaluronan and proteoglycan link protein 1,HAPLN1,Skin dermis,Homo sapiens,2,years,4.48320032935283,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN1,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P10915,Hyaluronan and proteoglycan link protein 1,HAPLN1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN1,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P10915,Hyaluronan and proteoglycan link protein 1,HAPLN1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN1,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P10915,Hyaluronan and proteoglycan link protein 1,HAPLN1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN1,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P10915,Hyaluronan and proteoglycan link protein 1,HAPLN1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN1,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P10915,Hyaluronan and proteoglycan link protein 1,HAPLN1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN1,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P10915,Hyaluronan and proteoglycan link protein 1,HAPLN1,Skin dermis,Homo sapiens,65,years,7.13035094592171,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN1,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P10915,Hyaluronan and proteoglycan link protein 1,HAPLN1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",HAPLN1,Proteoglycans,Core matrisome,Gene_Symbol_or_UniProt,1
P48594,Serpin B4,SERPINB4,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48594,Serpin B4,SERPINB4,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48594,Serpin B4,SERPINB4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48594,Serpin B4,SERPINB4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48594,Serpin B4,SERPINB4,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48594,Serpin B4,SERPINB4,Skin dermis,Homo sapiens,65,years,9.22657772168049,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48594,Serpin B4,SERPINB4,Skin dermis,Homo sapiens,65,years,6.30018536428482,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
P48594,Serpin B4,SERPINB4,Skin dermis,Homo sapiens,65,years,6.79618213309276,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SERPINB4,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08397,Lysyl oxidase homolog 1,LOXL1,Skin dermis,Homo sapiens,2,years,8.29746715995998,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOXL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08397,Lysyl oxidase homolog 1,LOXL1,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOXL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08397,Lysyl oxidase homolog 1,LOXL1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOXL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08397,Lysyl oxidase homolog 1,LOXL1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOXL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08397,Lysyl oxidase homolog 1,LOXL1,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOXL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08397,Lysyl oxidase homolog 1,LOXL1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOXL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08397,Lysyl oxidase homolog 1,LOXL1,Skin dermis,Homo sapiens,65,years,9.87488178013233,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOXL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q08397,Lysyl oxidase homolog 1,LOXL1,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",LOXL1,ECM Regulators,Matrisome-associated,Gene_Symbol_or_UniProt,1
Q75N90,Fibrillin-3,FBN3,Skin dermis,Homo sapiens,2,years,4.32244304743274,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q75N90,Fibrillin-3,FBN3,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q75N90,Fibrillin-3,FBN3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q75N90,Fibrillin-3,FBN3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q75N90,Fibrillin-3,FBN3,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q75N90,Fibrillin-3,FBN3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q75N90,Fibrillin-3,FBN3,Skin dermis,Homo sapiens,65,years,5.60183155222109,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q75N90,Fibrillin-3,FBN3,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",FBN3,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IVN8,Somatomedin-B and thrombospondin type-1 domain-containing protein,SBSPON,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SBSPON,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IVN8,Somatomedin-B and thrombospondin type-1 domain-containing protein,SBSPON,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SBSPON,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IVN8,Somatomedin-B and thrombospondin type-1 domain-containing protein,SBSPON,Skin dermis,Homo sapiens,14,years,6.898574873473,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SBSPON,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IVN8,Somatomedin-B and thrombospondin type-1 domain-containing protein,SBSPON,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SBSPON,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IVN8,Somatomedin-B and thrombospondin type-1 domain-containing protein,SBSPON,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SBSPON,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IVN8,Somatomedin-B and thrombospondin type-1 domain-containing protein,SBSPON,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SBSPON,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IVN8,Somatomedin-B and thrombospondin type-1 domain-containing protein,SBSPON,Skin dermis,Homo sapiens,65,years,7.43763732832721,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SBSPON,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
Q8IVN8,Somatomedin-B and thrombospondin type-1 domain-containing protein,SBSPON,Skin dermis,Homo sapiens,65,years,8.27445517096581,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",SBSPON,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P08493,Matrix Gla protein,MGP,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_1,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MGP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P08493,Matrix Gla protein,MGP,Skin dermis,Homo sapiens,2,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Toddler_2,"Age=2yr (midpoint of Toddler group, range varies); Column 'Toddler-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MGP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P08493,Matrix Gla protein,MGP,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_1,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MGP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P08493,Matrix Gla protein,MGP,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_2,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MGP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P08493,Matrix Gla protein,MGP,Skin dermis,Homo sapiens,14,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Teenager_3,"Age=14yr (midpoint of Teenager group, range varies); Column 'Teenager-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MGP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P08493,Matrix Gla protein,MGP,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_1,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample1' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MGP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P08493,Matrix Gla protein,MGP,Skin dermis,Homo sapiens,65,years,10.4480194258527,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_2,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample2' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MGP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
P08493,Matrix Gla protein,MGP,Skin dermis,Homo sapiens,65,years,0.0,log2_normalized_intensity,Label-free LC-MS/MS,LiDermis_2021,Dermis_Elderly_3,"Age=65yr (midpoint of Elderly group, >60yr); Column 'Elderly-Sample3' in Table 2 sheet 'Table S2'; Abundance: log2-normalized intensity (FOT fraction of total); Method: LC-MS/MS on decellularized dermal scaffold; Adult group (40yr, n=2) excluded as middle-aged (30<40<55); Retained 57.1% samples",MGP,ECM Glycoproteins,Core matrisome,Gene_Symbol_or_UniProt,1
